



ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA

DELIBERAZIONE DEL DIRETTORE GENERALE

(Nominato con D.P.G.R.T. n. 233 del 13/12/2010)

N° 72 del 26/06/2013

Oggetto: Progetto "Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors", finanziato dalla Regione Toscana-ITT. Approvazione dello schema di convenzione, recepimento del finanziamento ed approvazione del piano economico finanziario.

Struttura	S.C. Epidemiologia Molecolare e Nutrizionale
Proponente	
	Coordinatore Amministrativo
	Contabilità e Controllo di Gestione
Proposta n.	Responsabile del procedimento
	Estensore
	Monica Di Stasio

IMMEDIATAMENTE ESEGUIBILE



Conto Economico n. 3A01010201

Eseguibile a norma di Legge dal 31 LUG. 2013

Pubblicato a norma di Legge il 26 GIU. 2013

Inviato al Collegio Sindacale il 26 GIU. 2013

L'anno 2013, il giorno 26 del mese di giugno
Il sottoscritto prof. Gianni Amunni, nella sua qualità di

DIRETTORE GENERALE

di questo Istituto per lo Studio e la Prevenzione Oncologica, con sede in Via Cosimo Il Vecchio 2 – 50139 Firenze, in forza del Decreto del Presidente della Giunta Regionale Toscana n. 233 del 13/12/2010.

Visto il D. Lgs. n. 502 del 30/12/1992 e sue successive modifiche ed integrazioni e la L. R. Toscana n. 40 del 24/02/2005 di disciplina del Servizio Sanitario Regionale e successive modificazioni ed integrazioni;

vista la legge regionale 4 febbraio 2008, n. 3, così come modificata dalla Legge R.T. 32/12, ai sensi della quale è stato istituito ISPO – Istituto per lo Studio e la Prevenzione Oncologica - "ente del servizio sanitario regionale, dotato di personalità giuridica pubblica e di autonomia organizzativa, amministrativa e contabile" (art.1);

vista la delibera del Direttore Generale n. 4 del 12.01.2012 con la quale è stato approvato il regolamento dei progetti finalizzati;

visti:

- La Delibera della Giunta Regione Toscana n. 1148 del 28.12.2010 con la quale viene dato mandato alla Struttura della Direzione Generale Diritto di Cittadinanza e Coesione Sociale di indire un nuovo Bando per l'assegnazione di fondi per il finanziamento di progetti annuali, biennali e triennali di ricerca in campo oncologico;
- Il Decreto della Direzione Generale Diritto di Cittadinanza e Coesione Sociale n. 6709 del 31.12.2010 con il quale viene approvato il Bando per l'assegnazione di fondi per il finanziamento di progetti di ricerca in campo oncologico – anno 2010 - e la relativa modulistica prevedendo anche che i progetti ammissibili al finanziamento dovranno essere sottoposti alla valutazione di revisori qualificati e dell'International Scientific Advisory Board (ISAB) dell'ITT in modo da garantire un livello qualitativamente alto dei progetti da finanziare;
- Il Decreto della Direzione Generale Diritto di Cittadinanza e Coesione Sociale n. 4102 del 06.09.2012 con il quale viene approvato lo schema di convenzione per la disciplina dell'erogazione dei finanziamenti per i progetti di ricerca in campo oncologico;

preso atto che con Decreto della Direzione Generale Diritto di Cittadinanza e Coesione Sociale n. 6204 del 19.12.2012 a seguito dell'iter valutativo previsto, sono stati approvati dall'Ufficio di Direzione dell'ITT 26 progetti di ricerca tra cui 4 presentati da ISPO come sotto riportato:

1. *"Comparative risk assessment of social, behavioural and environmental risk factors"*, Resp. Prof. Annibale Biggeri, Euro 100.000,00, durata del progetto 2 anni;
2. *"Cancer clusters and citizens' alarms: epidemiological and statistical approaches"*, Resp. Dr.ssa Lucia Miligi, Euro 64.000,00, durata due anni;
3. *"Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors"*, Resp. Dr. Domenico Palli, Euro 150.000,00, durata tre anni;
4. *"Targeting oxidative DNA damage at genomic and sequence level in a breast cancer case-control study and in vitro experiments"*, Resp. Dr. Marco Peluso, Euro 120.000,00, durata tre anni;

Preso atto che con email del 24.04.2013 l'Istituto Toscano Tumori ha inviato ad ISPO, per la sottoscrizione, il testo di convenzione (allegato alla presente sotto lettera "A" quale parte integrante e sostanziale) per regolare lo svolgimento dell'attività relativa al progetto di ricerca *"Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors"*, il cui Responsabile per ISPO è il Dr. Domenico Palli; per il sopra citato progetto, la cui durata è di tre anni a decorrere dalla data di comunicazione avvio progetto da parte del responsabile ed è previsto un finanziamento totale di € 150.000,00 che sarà erogato secondo le modalità previste in convenzione;

dato atto che il progetto su citato, così come approvato dall'ITT, prevede che una quota del finanziamento totale previsto per ISPO, venga destinata, attraverso l'attivazione di apposite convenzioni, alle seguenti Additional Unit:

- Gruppo di Ricerca Oncologica dell'Università di Pisa (GROUP), Referente Dr.ssa Maria Adelaide Caligo, per un importo totale pari ad Euro 45.000,00 (quarantacinquemila/00);
- Università degli Studi di Firenze – Dipartimento di Chirurgia e Medicina Traslazionale - Sezione di Anatomia Patologica, Referente Prof.ssa Simonetta Bianchi, per un importo totale pari ad Euro 18.000,00 (diciottomila/00);

Vista la nota prot. 0065530/50.2.4.3 del 09.05.2006, agli atti, con la quale il comitato Etico dell'Azienda USL 10 di Firenze ha espresso parere favorevole allo svolgimento dello studio;

rilevato che per le attività oggetto della convenzione che ISPO dovrà garantire, il Responsabile del progetto, Dr. Domenico Palli, Medico Dirigente presso la SC Epidemiologia Molecolare e Nutrizionale di ISPO, ha presentato una relazione progettuale per la realizzazione degli obiettivi previsti dal progetto, allegata alla presente sotto lettera "B" quale parte integrante e sostanziale;

ritenuto pertanto opportuno approvare il progetto, il relativo piano economico-finanziario (allegato alla presente sotto lettera "C" quale parte integrante e sostanziale) e lo schema di convenzione recependo il finanziamento totale pari ad Euro 150.000,00 (centocinquantamila/00);

vista la delibera del Direttore Generale n. 5 del 14.07.2008 con la quale è stato approvato il regolamento dell'ISPO;

con il visto di conformità giuridico amministrativa del Coordinatore Amministrativo;

con il parere favorevole del Direttore Sanitario

DELIBERA


Per quanto esposto in narrativa, formante parte integrante e sostanziale del presente atto:

1. di approvare lo schema di convenzione per il progetto *"Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors"*, allegato alla presente sotto lettera "A" quale parte integrale e sostanziale, finanziato dalla Regione Toscana- ITT autorizzandone al contempo la stipula e di recepire il relativo finanziamento pari ad Euro 150.000,00 (centocinquantamila/00);
2. di prendere atto che il progetto su citato, così come approvato dall'ITT, prevede che una quota del finanziamento totale previsto per ISPO, venga destinata, attraverso l'attivazione di apposite convenzioni, alle seguenti Additional Unit:
 - Gruppo di Ricerca Oncologica dell'Università di Pisa (GROUP), Referente Dr.ssa Maria Adelaide Caligo, per un importo totale pari ad Euro 45.000,00 (quarantacinquemila/00);
 - Università degli Studi di Firenze – Dipartimento di Chirurgia e Medicina Traslazionale - Sezione di Anatomia Patologica, Referente Prof.ssa Simonetta Bianchi, per un importo totale pari ad Euro 18.000,00 (diciottomila/00);
3. di prendere atto ed approvare la relazione progettuale ed il relativo piano economico finanziario, redatti dal Dr. Domenico Palli, Responsabile del Progetto per ISPO, documenti allegati rispettivamente sotto le lettere "B" e "C" quali parti integranti e sostanziali;
4. di prendere atto che ISPO, per l'effettuazione delle attività connesse al progetto, riceverà dalla Regione Toscana-ITT la somma complessiva di Euro 150.000,00 (centocinquantamila/00), a valere dei ricavi registrati nel bilancio d'esercizio dell'Istituto per il periodo di competenza relativo, conto economico 3A01010201 "contributi da Regione Toscana-vincolati", aut. n. 83/13, cdc 696;
5. di trasmettere il presente atto all'albo di pubblicità degli atti di questo Istituto e al Collegio Sindacale.

IL DIRETTORE GENERALE
Gianni Amunni



IL DIRETTORE SANITARIO
Chiara Neri



Elenco degli allegati

Allegato A	Schema di convenzione tra ITT e ISPO	pag. 79
Allegato B	relazione progettuale del Responsabile del progetto	pag. 02
Allegato C	piano economico finanziario	pag. 01

Strutture aziendali da partecipare:

S.C. Epidemiologia Molecolare e Nutrizionale ISPO;

S.S. Contabilità e Controllo di Gestione ISPO;

Gestione Contabile Progetti ISPO;

Supporto Amministrativo Attività Scientifica e di Ricerca ISPO;

Dipartimento Amministrazione e Finanza ASF.

REGIONE TOSCANA



Giunta Regionale

Progetti di ricerca ITT

CONVENZIONE

tra la Regione Toscana e l' ISPO - Istituto per lo Studio e la Prevenzione Oncologica- per la realizzazione del progetto : ""Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors"".

La REGIONE TOSCANA, (di seguito chiamata Regione), Codice Fiscale 013866030488 rappresentata dal dirigente regionale Dr.ssa Simona Carli, nominata con decreto del Direttore Generale n. 220 del 04/02/2013 autorizzata, ai sensi della L.R. 1/2009, a sottoscrivere la presente convenzione approvata in schema con decreto n. 4102 del 06/09/2012;

E

ISPO - Istituto per lo Studio e la Prevenzione Oncologica - Codice Fiscale 94158910482 in persona del Prof. Gianni Amunni , nato a Firenze il 6/08/1954;

PREMESSO

- che la Regione con Decreto Dirigenziale n. 6709 del 31.12.2010 avente per oggetto "ITT - Approvazione del Bando per l'assegnazione di fondi per il finanziamento di progetti per la ricerca in campo oncologico - anno 2010 - e della relativa modulistica" ha approvato e di seguito diffuso un avviso pubblico;
- che la Regione in attuazione del suddetto Bando, con Decreto Dirigenziale n. 6204 del 19/12/2012 ha approvato il progetto, denominato "Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors".
- che l'ISPO è in possesso dei titoli e dei requisiti richiesti dal Bando in oggetto per svolgere correttamente il progetto di ricerca;
- che il responsabile del progetto di ricerca è il Dr. Domenico Palli , nato a Portico e San Benedetto (FC) il 31 Maggio 1953;

- che il responsabile del progetto di ricerca condivide il contenuto della presente convenzione;

TUTTO CIÒ PREMESSO SI CONVIENE E SI STIPULA QUANTO SEGUE:

Art. 1

Premessa

La premessa costituisce parte integrante ed essenziale della presente convenzione.

Art. 2

Soggetto attuatore

L' ISPO, successivamente indicato anche come "soggetto attuatore", si impegna verso la Regione, a curare l'organizzazione e l'effettuazione delle attività indicate nel progetto di ricerca come sopra denominato, successivamente indicato semplicemente progetto, di cui si allega copia sotto la lettera A), quale parte integrante ed essenziale della presente convenzione.

Il soggetto attuatore, per la realizzazione delle attività progettuali, dovrà avvalersi di personale in possesso delle necessarie caratteristiche professionali specifiche; e si impegna al pieno rispetto della normativa in vigore, in particolare quella relativa alla sicurezza sui luoghi di lavoro. La Regione resta comunque estranea a qualsiasi rapporto di lavoro e collaborazione a qualunque titolo instaurato dal soggetto attuatore nello svolgimento e per le necessità del programma.

Art. 3

Finanziamento del progetto

Il progetto è finanziato dalla Regione per un costo complessivo di €. 150.000 (centocinquantamila/00), secondo le modalità di erogazione previste al successivo art. 4, così ripartite, 1° anno €. 50.000, 2° anno €. 50.000, 3°anno €. 50.000.

Il soggetto attuatore dichiara altresì che non esistono co-finanziamenti.

In particolare il soggetto attuatore dichiara di non cumulare il finanziamento approvato con altri ulteriori finanziamenti pubblici o privati già ottenuti per realizzare le stesse azioni e che non verranno chiesti in futuro altri finanziamenti pubblici per la realizzazione delle stesse azioni.

Il finanziamento previsto a carico della Regione si deve intendere al lordo di qualsiasi spesa e costituisce il tetto massimo di spesa rimborsabile. L'erogazione del saldo, al termine del progetto di ricerca, sarà subordinato all'obbligo di documentare le spese effettivamente sostenute, come meglio precisato anche nei successivi articoli della presente convenzione. La mancata presentazione, senza giustificato motivo della documentazione suddetta, entro i termini previsti dai successivi articoli, comporterà la decadenza del diritto al rimborso, nonché il recupero degli acconti già erogati, fatte salve eventuali altre azioni per la tutela degli interessi della Pubblica Amministrazione nelle sedi opportune.

Poiché trattasi di un contributo di ricerca, il finanziamento è fuori campo di applicazione IVA e non è oggetto alla ritenuta di acconto del 4% ai sensi dell'art. 28 del DPR 600/73.

Art. 4
Erogazione del Finanziamento

La Regione, in conformità del Bando Regionale in oggetto, si impegna ad erogare le somme di cui al precedente art. 3, al ricevimento della documentazione richiesta e con le seguenti modalità:

Il finanziamento relativo ai **progetti triennali** verrà erogato, salvo eccezioni, come segue:

- la prima erogazione, pari al 100% dell'importo finanziato per il primo anno, dopo la comunicazione di inizio del progetto di ricerca, firmata dal responsabile del progetto, contenente l'indicazione puntuale della data di avvio, non antecedente alla data del decreto di approvazione dei progetti.

- la seconda erogazione, pari al 100% dell'importo finanziato per il secondo anno, alla fine del primo anno dalla data dichiarata di inizio, inviando i seguenti documenti:

- Relazione scientifica sullo stato di avanzamento del progetto;
- Rendiconto delle spese effettivamente sostenute nell'intero primo anno di ricerca, da predisporre con gli stessi criteri utilizzati per la definizione del preventivo (vedi tab. 16 allegata al progetto). Il rendiconto dovrà essere redatto in relazione alle spese effettivamente sostenute per ogni singola voce del progetto, sulla base dei costi ammissibili previsti dalla normativa vigente;
- Dichiarazione sostitutiva resa ai sensi del DPR 28 Dicembre 2000, n. 445, con la quale il responsabile del progetto di ricerca attesta la veridicità ed esattezza dei dati esposti e dei documenti prodotti.

- la terza erogazione, pari al 70% dell'importo finanziato per il terzo anno, alla fine del secondo anno, seguito presentazione della medesima documentazione richiesta al termine del primo anno;

Si intende quindi che il 30% del finanziamento del terzo anno sarà anticipato dal soggetto attuatore; l'erogazione del saldo avverrà al termine della verifica dei documenti, nella misura delle spese effettivamente sostenute e documentate nel triennio, come dal successivo articolo 6.

Eventuali spostamenti di somme tra voci di spesa o da un anno all'altro, dovranno essere preventivamente autorizzati dalla Regione Toscana.

Tutti i documenti relativi al primo e al secondo anno del progetto dovranno essere trasmessi entro 30 giorni dal termine di ciascun anno.

L'esame della documentazione richiesta dovrà essere effettuato dagli organismi competenti entro 60 giorni dalla ricezione, in particolare la relazione scientifica sarà sottoposta a valutazione del Direttore Scientifico dell'ITT; entro tale termine dovrà essere inoltre data comunicazione al responsabile del progetto sull'esito della verifica effettuata.

L'ultima rata del finanziamento verrà erogata a saldo delle spese effettivamente sostenute nella durata dell'intero progetto, rispettando il tetto massimo di spesa rimborsabile.

Entro 60 giorni dal termine del progetto, dovranno essere inviati:

- la relazione scientifica conclusiva stilata dal responsabile del progetto, corredata di eventuali pubblicazioni che dovranno citare il supporto della Regione Toscana -ITT,
- il rendiconto economico finale complessivo secondo quanto indicato al successivo art. 6.
- la dichiarazione sostitutiva resa ai sensi del DPR 28 Dicembre 2000, n. 445.

La documentazione finale dovrà essere approvata dall'Ufficio di Direzione dell'ITT entro 60 giorni dal ricevimento.

Ritardi o mancanza nel sottoporre questa documentazione potranno avere effetti negativi su successive richieste di finanziamento.

La Regione attuerà delle verifiche a campione sui documenti giustificativi di spesa utilizzando anche le strutture regionali competenti in materia. Il soggetto attuatore si impegna a restituire alla Regione gli importi da questa ricevuti, ma non riconosciuti ammissibili dall'Amministrazione stessa in sede di verifica finale del progetto, relativamente all'attività svolta. Il soggetto attuatore si impegna a restituire tali importi nelle forme e tempi indicati dalla Regione, fatto salvo il proprio diritto a prendere visione e controllare il verbale di accertamento finale delle spese, redatto in sede di verifica finale. L'eventuale recupero dei finanziamenti indebitamente ricevuti dal beneficiario finale sarà incrementato dagli interessi calcolati in base alla normativa vigente.

Art. 5

Durata del Progetto

Il progetto ha la durata di 3 anni. Il non avvio del progetto e la conseguente mancata comunicazione entro 30 (trenta) giorni dalla firma del presente atto comporterà la risoluzione della convenzione e non potrà essere rimborsata nessun tipo di spesa

Il progetto non potrà subire né modifiche né proroghe salvo in casi del tutto eccezionali per i quali saranno definite apposite procedure. Il soggetto attuatore ed il responsabile del progetto di ricerca invieranno motivata e ben documentata richiesta scritta alla Regione che, acquisito il parere del Direttore Scientifico dell'ITT, accorderà o meno tale richiesta. La concessione della eventuale proroga, che sarà subordinata alla riconosciuta sussistenza di ragioni di necessità e d'opportunità, non costituisce motivo di maggiorazione del corrispettivo accordato.

Qualora sia accertata la mancata o irregolare attuazione del programma la Regione potrà sospendere l'erogazione del finanziamento.

Art. 6

Rendiconto finale

Il soggetto attuatore si impegna a presentare alla Regione, entro 60 (sessanta) giorni dal termine delle attività, il rendiconto finale relativo alle spese effettivamente sostenute nella durata dell'intero progetto. Tale rendiconto verrà presentato utilizzando la tabella 16 e specificando all'interno di ogni macrovoce le singole voci di spesa, anno per anno, sulla base dei costi ammissibili previsti dalla normativa vigente.

Questo dovrà essere corredato dalla relazione illustrativa delle attività svolte e da una dichiarazione sostitutiva resa ai sensi del DPR 28 Dicembre 2000, n. 445, con la quale il responsabile del progetto di ricerca attesti la veridicità ed esattezza dei dati esposti e dei documenti prodotti.

Per quanto concerne l'I.V.A. e le altre imposte dirette o indirette che possono essere recuperate, rimborsate o compensate in qualsiasi modo e che pertanto non restano definitivamente a carico del soggetto attuatore, beneficiario finale del finanziamento, non possono essere ammesse a rimborso.

I documenti giustificativi di tutte le spese sostenute nel corso dell'attuazione del progetto, dovranno essere conservati secondo le norme di legge ed esibiti in originale, su richiesta della Regione, per le verifiche previste dall'art. 4.

Art. 7

Responsabile del progetto di ricerca

Se nel corso della durata del progetto termina il rapporto di lavoro tra il responsabile del progetto ed il soggetto attuatore, il finanziamento si intende sospeso.

Se ne esistono i presupposti, il soggetto attuatore o il responsabile del progetto possono far richiesta alla Regione Toscana affinché il finanziamento venga corrisposto ad altro soggetto attuatore o ad altro responsabile.

Art. 8

Parere Comitato Etico

Se il progetto prevede la sperimentazione umana, l'utilizzo di campioni biologici umani o la sperimentazione su animali o loro campioni biologici, è richiesto il parere positivo del Comitato Etico locale prima dell'avvio della ricerca. Per quanto riguarda la sperimentazione umana e l'utilizzo di campioni biologici umani deve essere prestata particolare attenzione alla sussistenza dei requisiti in materia di consenso informato.

Art. 9

Proprietà dei risultati e pubblicazione

Qualora il responsabile del progetto intenda procedere alla pubblicazione scientifica o divulgazione in forma orale e/o scritta di risultati, concernenti l'attività di ricerca relativa al progetto, potenzialmente suscettibili di tutela brevettuale, il responsabile del progetto dovrà farne richiesta attraverso comunicazione scritta all'ITT, allegando bozza della proposta di pubblicazione o della divulgazione. La richiesta si considera accolta qualora l'ITT, entro 30 (trenta) giorni dal ricevimento della predetta richiesta da parte del responsabile del progetto, non comunichi il proprio diniego.

L'ITT si avvarrà della collaborazione dell'Ufficio per la Valorizzazione della Ricerca Biomedica e Farmaceutica (UVaR), istituito presso la Direzione Generale Diritti di cittadinanza e coesione sociale, per la valutazione dei requisiti di brevettabilità dei risultati oggetto della suddetta pubblicazione e per eventuali azioni, concordate fra le parti, a tutela e valorizzazione della proprietà intellettuale relativa ai risultati derivanti dal progetto.

In caso di pubblicazione anche parziale dei risultati, è obbligatorio citare che la ricerca è stata fatta con il contributo della Regione Toscana-ITT.

La proprietà dei risultati eventualmente brevettabili sarà definita in ottemperanza a quanto stabilito dal "Codice della Proprietà Industriale" emanato con D. Lgs. 10 febbraio 2005, n. 30 a norma dell'art. 15 della L. 12.12.2002, n. 273 salvo particolari accordi che potranno essere stipulati anche successivamente tra le parti firmatarie del presente atto.

I proprietari dei risultati concedono l'uso degli studi, dei prodotti e delle metodologie sopra descritti per le finalità che le sono proprie, ferma restando la loro disponibilità in favore del Servizio Sanitario Regionale.

Art. 10

Foro Competente

Per ogni controversia che dovesse insorgere con riferimento alla presente convenzione è competente il Foro di Firenze.

Art. 11

Trattamento dati personali

Il trattamento dei dati personali viene effettuato ai sensi dell'art. 18 comma 2 del Decreto Legislativo n. 196 del 30 giugno 2003, per l'esclusivo svolgimento delle funzioni istituzionali dell'ente.

Art.12

Oneri Fiscali

La presente convenzione è redatta in due originali. In caso d'uso verrà registrata a tassa fissa, ai sensi del II comma dell'art. 5 (caso d'uso) e dell'art. 38 (tassa fissa) del DPR 26.10.72, n. 634 e successive modifiche ed integrazioni, a cura e spese del richiedente la registrazione.

E' inoltre esente da bollo, ai sensi dell'art. 16, tab. B del DPR 26.10.72, n. 642, come modificato dall'art. 28 del DPR 30.12.82, n. 955.

Letto, approvato e sottoscritto

Per Regione Toscana

Simona Carli

Per ISPO

Gianni Amunni



ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA



SC Epidemiologia Molecolare e Nutrizionale
Direttore: Dott. Domenico Palli

Allegato "A"

6. FINANCIAL REQUEST

16.1 PRINCIPAL INVESTIGATOR'S UNIT (S)

	Year 1	Year 2	Year 3	Total
A) NON-STAFF PERSONNEL (CONTRACTS, FELLOWSHIPS, ETC). SPECIFY: CONTRACT	25500	25500	25500	76500
B) CONSUMABLES SUPPLIES: (TIPS, DISPOSABLE MATERIALS)	500	500	500	1500
C) SMALL EQUIPMENT(S) SPECIFY:				
D) TRAVEL EXPENSES (MEETINGS, COURSES, ETC.)	364	364	364	1092
E) PUBLICATION COSTS. SPECIFY:				
F) OVERHEAD	2636	2636	2636	7908
TOTAL COSTS	29.000	29.000	29.000	87.000

16.2 JUSTIFICATION OF EACH ITEM BUDGET (except for overhead)

A) NON-STAFF PERSONNEL

1 PhD part-time contract for 3 years (identification of male breast cancer cases, personal interviews; family history data collection; collection of snap-frozen tissue samples, medical records, diagnostic confirmation, collection of blood samples, retrieval of histological specimens)
1 nurse part-time contract for 3 years (blood drawing, dietary and life-style data collection)

B) CONSUMABLE SUPPLIES

Questionnaires, Tips, Disposable materials,

c) Small Equipment(s)

d) Travel Expenses (Meetings, Courses, etc.)

Dissemination of results (meetings/workshops etc.)

e) Publication Costs

SC Epidemiologia Molecolare e Nutrizionale
Direttore: Dott. Domenico Palli

16.3 ADDITIONAL UNIT(S) WITHIN REGIONE TOSCANA Dr.ssa MARIA ADELAIDE CALIGO

	Year 1	Year 2	Year 3	Total
A) NON-STAFF PERSONNEL (CONTRACTS, FELLOWSHIPS, ETC). SPECIFY: CONTRACT	5000	5000	5000	15000
B) CONSUMABLES SUPPLIES: (REAGENTS, ENZYMES, TAQ, TIPS, PRIMERS ETC)	9000	9000	9000	27000
C) SMALL EQUIPMENT(S) (MAX 20.000 EUROS). SPECIFY:				
D) TRAVEL EXPENSES (MEETINGS, COURSES, ETC.)	1000	1000	1000	3000
E) PUBLICATION COSTS. SPECIFY:				
F) OVERHEAD.				
TOTAL COSTS	15000	15000	15000	45000

16.4 ADDITIONAL UNIT(S) - JUSTIFICATION OF EACH ITEM BUDGET (except for overhead)

A) NON-STAFF PERSONNEL

1 PhD contract for 3 years (DETECTION OF GERMLINE MUTATIONS IN BRCA GENES AND MODERATE GENES, GENOTYPING OF SNPs)

B) CONSUMABLE SUPPLIES

REAGENTS, ENZYMES, TAQ, TIPS, PRIMERS ETC

c) Small Equipment(s)

d) Travel Expenses (Meetings, Courses, etc.)

Dissemination of results (meetings/workshops etc.)

e) Publication Costs

SC Epidemiologia Molecolare e Nutrizionale
Direttore: Dott. Domenico Palli

16.3 ADDITIONAL UNIT(S) WITHIN REGIONE TOSCANA Prof.ssa SIMONETTA BIANCHI

	Year 1	Year 2	Year 3	Total
A) NON-STAFF PERSONNEL (CONTRACTS, FELLOWSHIPS, ETC). SPECIFY:				
B) CONSUMABLES SUPPLIES: ANTIBODIES AND DISPOSABLE MATERIAL FOR TISSUE MICROARRAY	4655	4655	4655	13965
C) SMALL EQUIPMENT(S) (MAX 20.000 EUROS). SPECIFY:				
D) TRAVEL EXPENSES (MEETINGS, COURSES, ETC.)	800	800	800	2400
E) PUBLICATION COSTS. SPECIFY:				
F) OVERHEAD.	545	545	545	1635
TOTAL COSTS	6000	6000	6000	18000

16.4 ADDITIONAL UNIT(S) - JUSTIFICATION OF EACH ITEM BUDGET (except for overhead)

A) NON-STAFF PERSONNEL

B) CONSUMABLE SUPPLIES

ANTIBODIES AND DISPOSABLE MATERIAL FOR TISSUE MICROARRAY

C) Small Equipment(s)

D) Travel Expenses (Meetings, Courses, etc.)

Dissemination of results (meetings/workshops etc.)

E) Publication Costs

**ISTITUTO TOSCANO TUMORI (ITT) – REGIONE TOSCANA
GRANT PROPOSAL 2010**

REGIONE TOSCANA

16 MAR. 2011

AOO-GRT Prot. 68825/Q. 080.11

1. PRINCIPAL INVESTIGATOR (PI)

FIRST AND LAST NAME	DOMENICO PALLI
POSITION TITLE	MD Head, Molecular and Nutritional Epidemiology Unit
INSTITUTION	ISPO (Cancer Prevention and Research Institute)
ADDRESS	Via Cosimo il vecchio n. 2
CITY	FLORENCE
PHONE	055-32697828
E-MAIL	d.palli@ispo.toscana.it
LEGAL REPRESENTATIVE	Gianni Amunni
ADDRESS	VIA COSIMO IL VECCHIO 2 - 50139 FIRENZE
E-MAIL	g.amunni@ispo.toscana.it

2. PROJECT TITLE (Max 150 Characters)

Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors
--

2.1 KEY-WORDS

Male Breast Cancer	
BRCA susceptibility genes	
Low penetrance genes	
Gene-gene interaction	
Gene-environment interaction	

3. ESTIMATED COMPREHENSIVE COSTS OF THE PROPOSED RESEARCH

Grant Requested to ITT (see n.16.5)	240.000	Euros
Available Grant(s) co-financing the Proposal (see n. 17/17.1)		Euros


4. PROJECT TIME-FRAME

Annual	
Biennial	
Triennial	X

5. EXTERNAL COLLABORATORS INVOLVED IN THE PROJECT (ADDITIONAL RESEARCH UNITS)

FIRST AND LAST NAME OF THE COLLABORATOR	INSTITUTION (FULL NAME AND ADDRESS)
Maria Adelaide Caligo	Division of Surgical, Molecular and Ultrastructural Pathology, University of Pisa
Simonetta Bianchi	Department of Pathology, University of Florence,

6. SIGNATURES


Principal Investigator	Legal Representative (o soggetto delegato alla firma)
	

6.1 DICHIARAZIONE DEL LEGALE RAPPRESENTANTE o DEL SOGGETTO DELEGATO ALLA FIRMA (obbligatoria)

Il Sottoscritto GIANNI ARUNNI, in qualità di DIRETTORE GENERALE ISPO

DICHIARA:

- a) che il P.I. che presenta il progetto fa parte del personale "strutturato", dipendente con contratto a tempo indeterminato o determinato, dell'Istituzione proponente;
- b) che sul progetto presentato non esiste altra fonte di finanziamento se non quello dichiarato al punto 3. e specificato nel punto 17 e seguenti;
- c) di approvare quanto dichiarato al punto 16 e seguenti ed in particolare la tabella "justification on budget"

Firma del Legale Rappresentante (o Soggetto Delegato).....

6.2 DICHIARAZIONE DEL SOGGETTO DELEGATO


Se il progetto non è firmato dal Legale Rappresentante è necessario sottoscrivere anche la seguente dichiarazione:

Il Sottoscritto..... **DICHIARA** di essere legittimato a firmare essendo in possesso di delega del Legale Rappresentante.

Firma

6.3 DICHIARAZIONE DEL P.I.

Il P.I. nell'inoltare la domanda, **DICHIARA** specificatamente, che sarà presente a tempo pieno nell'istituzione in cui si svolge il progetto.

Firma del P.I.

7. ABSTRACT (Max 2500 Characters)

Male breast cancer (MBC) is an uncommon disease but its incidence is rising. Because of its rarity, MBC has been so far the focus of very limited research and little is known about its aetiology.

Hormonal, genetic and environmental factors are involved in the pathogenesis of BC in men as well as in women. However, at the population level, gender-unrelated BC risk factors can be better investigated in MBC, which is unaffected by the strong confounding effects of reproductive-history related variables.

In MBC, the strongest genetic risk factor is represented by inherited high-penetrance mutations involving primarily *BRCA2*, but also *BRCA1* and possibly other genes. Environmental and life style factors, particularly occupational and dietary carcinogen exposures, should importantly contribute to MBC risk, probably interacting with low-penetrance polymorphic variants in genes controlling DNA repair, steroid hormones and carcinogen metabolism.

The project will expand an epidemiologically well-characterized population-based series of 125 MBCs, diagnosed in the period 1991-2008, all residing in North-Eastern Tuscany, for which blood samples and paraffin-embedded tumor sections have been already collected together with extensive epidemiological information and an appropriate control series of about 270 men. We aim -to expand the series to include all incident MBCs residing in North Eastern Tuscany diagnosed in the period 2009-2011 and to cover all other areas in Tuscany with the cases diagnosed in the period 1996-2007; -to use MBC as a model to study interactions between genetic (constitutional mutations in high-, moderate-penetrance genes and genetic polymorphisms), and carcinogen exposures in the pathogenesis of BC. The aim is to reach a total of about 220 MBCs. All new MBC cases will be analyzed for *BRCA1/2* mutations to identify the subset accounted for by dominant heredity. *BRCA1/2* mutation negative MBCs will be further screened for germ-line alterations in set of moderate-risk genes in order to assess their impact on MBC predisposition. A multigenic approach to MBC susceptibility will be carried out on a series of relevant genes involved in DNA repair, steroid/carcinogens metabolism, cell cycle, apoptosis and mitotic control by using a population-based case-control. Gene-gene interactions analyses will be performed to evaluate the combined effects of the different polymorphisms. The use of a population-based series will allow the generalization of the results.

The role of interactions between genetic and environmental factors in mammary carcinogenesis will be analyzed by integrating the germ-line and somatic mutational status and the immunohistochemical expression patterns with the epidemiological, occupational, dietary, and clinico-pathological information

8. SPECIFIC AIMS (Max 2500 Characters)

A. RECRUITMENT OF A LARGE POPULATION-BASED SERIES OF MBCs

A1. Recruitment of new cases

- A1.1 To expand the available population-based series of 125 MBC by recruiting all incident cases residing in North Eastern Tuscany diagnosed in the period 2009-2011.
- A1.2 To recovery additional cases diagnosed in the period 1996-2007 in all the other areas of Tuscany.
 - Based on MBC incidence and population size, the aim is to collect a total of about 220 MBCs in Tuscany. For each study participant we will obtain detailed information on his personal and familial history for cancer at any site and exposure(s) of interest.

A2. Detection of germline mutations

- A2.1 To assess germ-line *BRCA1/2* mutational status in the new recruited MBCs and in carriers relatives.
- A2.2 To investigate genomic *BRCA1/2* rearrangements in MBCs negative for germ-line mutations.
 - Each case index will be screened for germ-line point mutations and rearrangements by protein truncation test (PTT), Single Strand conformation polymorphism (SSCP) and/or direct sequencing, and Multiplex Ligation-dependent Probe Amplification (MLPA).
- A2.3 To characterize founder mutations typical of the local population.
- A2.4 To Identify MBC cases with germ-line mutations in moderate-risk genes.
 - The entire coding sequences of *BRIP1* (NC_000017) and *PALB2* (NC_000017), will be screened for germ-line mutations by automatic sequencing.

A3. Detection of expression profile

- A3.1 To verify whether distinct molecular subsets may be identified in MBC based on tissue specimen.
 - Expression and co-expression of a range of different biomarkers will be evaluated by tissue microarray (TMA).

B. TO CARRY OUT A POPULATION-BASED CASE CONTROL STUDY

B.1 To genotype SNPs within genes involved in DNA repair, steroid hormone and carcinogens metabolism, cell cycle, apoptosis and mitotic control in cases and controls.

- Analyses of selected SNPs in p53, SULT1A1, XPA, XPD, XRCC1, CYP17, CYP1B1, ErbB2, BRCA2 will be performed by Taqman technology
- To avoid bias due to "population stratification" we intend to expand the available series of controls including an additional series of healthy male subjects residing in the same area where additional cases will be collected (western Tuscany).

B.2 To evaluate the association between MBC risk and each SNPs

- to estimate odds ratio (OR) and its corresponding 95% confidence interval unconditional logistic regression will be used with four inheritance models (co-dominant, dominant, recessive and multiplicative codominant effect).

B.3 To analyze interactions between gene-gene and gene-environment in MBC.

- Two-way and three-way statistical interaction between selected SNPs and between selected SNPs and exposures of interest will be evaluated (Millstein 2006) with a case-control design.
- In a case-case design a crude analysis of 2X2 tables and multivariate logistic analyses taking into account different individual characteristics of MBCs will be performed. The estimated Case-only Odds Ratios (CORs) will provide an evaluation of the departure from a multiplicative effect.

9. BACKGROUND AND RATIONALE (Max 4000 Characters)

Male breast cancer (MBC) accounts for less than 1% of all cancers in males, however its incidence is rising 1.1% annually (NCI, SEER 2007). In Italy MBC accounts for 0.2% of all cancers in males and incidence rates (standardized on European population) are approximately 1 new case x 100,000 male residents per year [1], while some variations are evident between different areas of the country, no clear pattern emerges. Because of its rarity, MBC has been the focus of very limited research and little is known about its etiology. MBC is similar to female breast cancer (FBC), with the main differences represented by a lower incidence and older age of occurrence of MBC [2-4]. The complex effects of genetic predisposition, environmental and lifestyle factors affect breast cancer (BC) risk in both sexes. However, at the population level, gender-unrelated BC risk factors can be better investigated in MBC, which is unaffected by the strong confounding effects of reproduction-related variables.

BRCA2 and, to lesser extent, BRCA1 germline mutations are associated with MBC but their frequencies are different in ethnically diverse series. In Italy, we reported a frequency of 7.4% and 2.0% for BRCA2 and BRCA1 germline mutations, respectively [5-7], with no evidence of large genomic rearrangements for both genes [8].

Our results indicate that the majority of MBCs are not accounted for by BRCA1/2 alterations. MBCs unaccounted for by BRCA1/2 can be explained by a polygenic model in which many genes that confer low risk individually act in combination to confer much larger risk in the population. Indeed, low-penetrance alleles are reported to account for FBC risk at the population level, and this could also apply to MBC [9]. The list of genes associated with low BC risk is enlarging significantly including genes that interact with BRCA1/2 to preserve genomic integrity (Walsh and King 2007). Accumulating evidence supports that single polymorphisms (SNPs) in genes involved in DNA repair, steroid/carcinogens metabolism, cell cycle, apoptosis and mitotic control may also contribute to genetic susceptibility to BC. Intriguingly, putative high risk SNPs in these genes are associated with estrogen-dependent FBC risk [10-13], a finding that could be relevant to MBC because hyperestrogenism is a major MBC risk factor. SNPs in DNA repair and metabolic genes may modify the effect of environmental exposure on BC risk and, on the other hand, subtle genetic effects may be magnified by environmental exposure as it has been reported that occupational exposure may activate DNA repair, inflammatory and apoptotic mechanisms [14, 15]. Indeed, there are intriguing relationships between MBC and occupational exposures [16, 17].

An increased MBC risk has been reported in occupational groups exposed to gasoline and gasoline combustion products and we found a strong association between a specific occupation (truck driving) and BC risk in male carriers of BRCA1/2 mutations [6]. Thus, gene-environment interactions may contribute to inter-individual differences in susceptibility to environmental carcinogens and BC risk. Overall, variants in many genes along related biological pathways may combine to influence BC risk and gene-gene and gene-environment interactions may modulate BC risk at population level. Polymorphisms in genes involved in DNA repair, steroid and carcinogens metabolism, cell cycle and apoptosis may represent good candidates for evaluating gene-gene and gene-environment interactions when a population-based series of MBC well characterized for working history and lifestyle habits is available for the study. BC is a heterogeneous disease and distinct morphologic and molecular phenotypes have been reported for FBC [18, 19]. MBCs are most frequently invasive ductal carcinoma and show higher rates of ER and PR positivity and lesser rate of HER-2 over-expression compared with FBC [17, 20]. Intriguingly, we observed that BRCA2-related MBCs showed a significant association with HER-2 over-expression [5, 7]. Considering that EGFR has recently received attention as target for therapy and that the expression of ErbB family members has prognostic significance in BC [21], the elucidation of new molecular markers in MBC might have prognostic and therapeutic implications.

A. RECRUITMENT OF A LARGE POPULATION-BASED SERIES OF MBCs

A1. Recruitment of new cases

Study population and data collection.

In the past years we have already accrued an epidemiologically well-characterized population-based series of 125 MBCs diagnosed in the period 1991-2008 all residing in North-Eastern Tuscany.

The recruitment of the MBC cases was carried out according to the following protocol : For each study participant we obtained: 1) signed informed consent form with a detailed description of the study protocol, including the information about the mutational analysis of the *BRCA1* and *BRCA2* genes; 2) one or more blood sample(s); 3) detailed information on his personal history of cancer at any site; 4) detailed information on his family history for cancer at any sites, including all first-, second- and third-degree relatives of both genders (all of this information was validated by available sources, mainly local Cancer and Mortality Registries); 5) information on life style habits; 6) a detailed working history. In particular, for each job listed in a chronological order starting from the first job the following data were collected: starting and ending year, the main activity of the company where the subject worked, a brief description of the tasks done at the workplace. The information obtained were utilised to have an accurate definition of the jobs done by each patient and to code each occupation in order to allow comparisons with other studies according to an international classification system (*i.e* International Labour Office Classification).

Pathological reports and histological slides for all of the MBC cases were identified and retrieved from the archival files of Pathology Departments of the area for diagnostic confirmation. Step sections from formalin-fixed, paraffin-embedded primary mammary tumor blocks were also obtained to perform *ad hoc* immuno-histochemical and bio-molecular analyses. Procedures to maintain confidentiality for all the information collected were developed and are strictly applied. The study has been originally approved by the Florence Ethical Research Committee.

Methods. MBC patients. The currently available population-based series of 108 MBCs will be expanded to include all incident MBC cases residing in the area of North-Eastern Tuscany diagnosed in the period 2009-2011. Moreover, using the Tuscany Region Discharge System data-base and the contacts with Pathology Departments we intend to extend the series including MBC cases residing in the whole Tuscany diagnosed in the period 1996-2007. Patients diagnosed in the previous period and not traced or contacted in the initial phase of the study will be also included in a new contact protocol. Considering that the local Cancer Registry RTT has estimated the average incidence rate of MBCs in the provinces of Florence and Prato to be 1,1 per 100,000 male residents/year in the period 1985-2003, and considering that the male population of Tuscany is about 1,800,000, it can be anticipated that we will be able to expand the series to include an additional series of 30 cases/year with a final goal of about 220 MBCs. The recruitment of the new cases will be continued according to the same protocol as described above for the current series of 125 MBC.

Population controls. The Molecular and Nutritional Epidemiology Unit, has already collected two series of healthy adults randomly selected from the municipality lists of two areas in North-Eastern Tuscany (the city of Florence and one nearby rural area) in the frame of a multi-site cancer epidemiology project. All participants, after signature of an informed consent form, were

requested to provide a blood sample and detailed individual information on dietary and life-style habits.

Out of 700 randomly selected subjects, 553 subjects (79%) accepted to participate into the study and provided a blood sample. Males were 48.6% (269/553) and were all in the age group 35-65 years. The blood samples collected from population were processed at the study laboratory, in the same day of collection and divided in specific aliquots (RBC, buffy coat, serum, plasma). The aliquots have been stored in -80°C freezer at the Biological Bank of the Molecular Epidemiology Unit. To avoid bias due to "population stratification" we intend to expand the series of controls including an additional series of healthy male subjects residing in the same areas where additional cases will be collected.

A2. Detection of germline mutations

Identification of *BRCA1*- and *BRCA2*- associated MBC cases.

BRCA1 and *BRCA2* germ-line mutations are the strongest known genetic risk factor associated with MBC. However, the frequency of *BRCA1* and *BRCA2* mutations are quite different in ethnically diverse population- and clinic-based MBC series, ranging between 4% and 40% for *BRCA2* and up to 10% for *BRCA1* being higher in the presence of a founder effect. We have screened the currently available population-based series of 108 MBCs for *BRCA1/2* germ-line alterations reporting a frequency of about 7.4% and 2.0% for *BRCA2* and *BRCA1* germ-line mutations, respectively, [5, 6].

BRCA1/2 inactivation may also occur by large genomic rearrangements and a significant contribution of *BRCA2* rearrangements has been reported in MBC families. By analysing a large series of Italian MBC cases, all tested negative for *BRCA1/2* mutations, we showed that *BRCA1/2* rearrangements are very rare in population-based MBC cases, supporting the idea that the presence of MBC is the strongest predictor for the occurrence of *BRCA2* rearrangement specifically in high-risk families [8]. Interestingly, in this series we observed the recurrence of the same *BRCA1* mutation in two unrelated MBCs and preliminary results show a common haplotype suggesting a founder effect [22].

Here, we plan to extend the mutational screening to include all new recruited MBC cases in order to assess the prevalence and spectrum of *BRCA1/2* alterations in this series of Italian MBCs and to search for the presence of recurrent mutations due to a possible founder effect [23].

Methods: The entire *BRCA1* and *BRCA2* coding sequences will be screened for germ-line mutations, by automatic sequencing with the ABI 3100 Genetic Analyzer (Applied Biosystems Foster City, CA, USA), and for large genomic rearrangements, by Multiplex Ligation-dependent Probe Amplification (MLPA, MCR Holland, Amsterdam, the Netherlands) as described [5, 6, 8].

BRCA1/2 intronic variants will be evaluated by using the SpliceSiteFinder software (<http://www.genet.sickkids.on.ca/~ali/splicesitefinder.html>) and the Splice Site prediction software (http://www.fruitfly.org/cgi-bin/seq_tools/splice.pl). Intronic variants predicted to affect RNA splicing will be further analysed by RT-PCR. Other variants of unknown significance will be recorded as they might modulate the penetrance of mutations elsewhere in the gene or represent markers of susceptibility. To characterize the haplotype associated with recurrent mutations nine microsatellite markers linked to *BRCA1* or *BRCA2* will be used. Alleles will be numbered according to the size of each microsatellite marker. All these analyses will be performed by Dr.ssa Caligo (University of Pisa)

The disease-associated haplotypes will be deduced by inspection of segregating genotypes in the analyzed individuals and will be constructed using dedicated software (PHASE and

HaploStats programs.). Age of mutation estimates will be calculated by DMLE +2.0 software program (www.dmle.org).

Identification of MBC cases with germ-line mutations in moderate-risk genes.

The list of genes associated with BC risk is enlarging significantly including genes that encode proteins interacting with *BRCA1* and *BRCA2* in the maintenance of genomic integrity such as *CHEK2*, *BRIP1* and *PALB2* genes [24].

Germ-line mutations of *CHEK2* gene have been implicated in inherited MBC predisposition, in particular the *CHEK2 1100delC* mutation has been shown to increase the risk of BC in men lacking *BRCA1/2* mutations. We recently investigated the contribution of *CHEK2* alterations to MBC by analysing our series of MBCs negative for *BRCA1/2* mutations and showed that common *CHEK2* mutations play an irrelevant role in Italy [8].

Compared to *BRCA1/2*, *BRIP1* and *PALB2* cause a much more modest (2-4 fold) BC risk, thus studies with large sample size are needed to evaluate their impact. However, large sample size can be greatly reduced when cases are drawn from high-risk families [25]. In this respect, the MBC families negative for *BRCA1/2* mutations in our series may be useful in identifying alterations in genes predisposing to moderate BC risk.

Our preliminary results indicate that *PALB2* and *BRIP1* germ-line alterations may not play a relevant role in MBC predisposition. [26, 27]

Here, plan to extend the mutational screening to include all new recruited MBC cases, negative for *BRCA1/2* mutations, in order to assess the prevalence and spectrum of mutations in moderate BC risk genes in Italy.

Methods: The entire coding sequences and exon-intron boundaries of *BRIP1* (NC_000017), and *PALB2* (NC_000017), will be screened for germ-line mutations by automatic sequencing with ABI 3100 Genetic Analyzer (Applied Biosystems Foster City, CA, USA) as previously described [28, 29].

All these analyses will be performed in collaboration with Dr.ssa Caligo (University of Pisa) and Prof.ssa Ottini (University of Roma).

A3. Detection of expression profile

Characterization of molecular subtypes in MBC

MBCs are most frequently ER/PR-positive and HER-2 -negative compared to FBC [30].

Intriguingly, we observed that *BRCA2*-related MBCs showed a significant association with HER-2 over-expression [5,7].

Here, we intend to verify whether distinct molecular subsets may be identified in MBC. A wide range of morpho-pathological prognostic factors, including tumor size, lymph-node status, histological tumor type according to WHO, histologic grade, and biological markers, including ER, PR, proliferative activity and HER-2 expression, are already available for the whole MBC series. In collaboration with Prof. Simonetta Bianchi (University of Florence), additional markers will be evaluated by tissue microarray (TMA) to assess the expression and co-expression of a range of different biomarkers.

Methods: TMA construction. Representative areas of different lesions will be carefully selected on H-E sections. Two tissue cores (1 mm in diameter) will be obtained from each specimen and two cores of normal breast tissue will be included as controls. The tissue cores will be arrayed onto new paraffin block using a tissue microarray (TMA) workstation (Beecher Instruments, Silver Spring, MD, USA). TMA will be performed to efficiently examine the four ErbB receptors as a whole panel and to test tumors for additional markers including hormones receptors (AR, PRLR), DNA repair proteins (p53, *BRCA1/2*, *CHEK2*, *RAD50*, *ATM*, *MRE11*, *NBS1* and *RAD51*) and cytocheratins (*CK5*, *CK8/18*, *CK14*). Well-characterized, commercially

available antibodies will be used. Immunohistochemical procedures and scoring methods will be as previously described [7, 21].

B. POPULATION-BASED CASE CONTROL STUDY

Genotyping of SNPs within genes involved in DNA repair, steroid hormone and carcinogens metabolism, cell cycle, apoptosis and mitotic control.

Accumulating evidence supports that SNPs in genes involved in DNA repair, steroid/carcinogens metabolism, cell cycle, apoptosis and mitotic control may contribute to genetic susceptibility to BC.

Intriguingly, putative high-risk SNPs in these genes are associated with estrogen-dependent FBC risk, a finding that is relevant to MBC because hyperestrogenism is a major MBC risk factor. Indeed, estrogen is known to promote BC development via its mitogenic effect, leading to malignant proliferation of the breast epithelium and estrogen metabolites could cause DNA damage. Subtle genetic effects, such as those exerted by low penetrant but widespread cancer predisposing genes, may be magnified by environmental exposure. Environmental and occupational carcinogens probably play a major role in causing sporadic MBC. There are intriguing relationships between MBC and occupational exposures and we found a strong association between a specific occupation and BC risk in male carriers of *BRCA1/2* mutations [6]. Overall, variants in many genes along related biological pathways may combine to influence BC risk and gene-gene and gene-environment interactions may modulate BC risk at population level. Polymorphisms in genes involved in DNA repair, steroid and carcinogens metabolism, cell cycle, apoptosis and mitotic control may represent good candidates for evaluating gene-gene and gene-environment interactions when a population-based series of MBC well characterized for working history and lifestyle habits is available for the study. The screening of quite large number of SNPs selected in a series of DNA repair and metabolism genes (p53, SULT1A1, XPA, XPD, XRCC1, CYP17, CYP1B1, ErbB2, BRCA2), performed in about 100 MBC cases and 270 controls, let us identify at risk genotypes and very promising MBC susceptibility alleles.

Here, in order to investigate MBC predisposition by a multigenic approach we plan to extend the analysis to all new MBC cases (for a total of about 200 population-based MBCs) in collaboration with Dr.ssa Caligo (University of Pisa) and Prof.ssa Ottini (University of Roma) and to include the genotyping of other relevant genes involved in DNA repair, steroid/carcinogens metabolism, cell cycle, apoptosis and mitotic checkpoint.

To mimic the situation *in vivo*, where the different gene products do not act as single entities, the concomitant effect of different polymorphisms in different genes will be evaluated by analyzing gene-gene interactions. Gene-environment interactions will be also investigated since they may contribute to interindividual differences in susceptibility to environmental carcinogens and BC risk.

Methods: A **population-based case-control study** will be performed to test the association between variants of DNA repair, steroid/carcinogens metabolism, cell cycle, apoptosis and mitotic genes and MBC susceptibility using MBCs and population controls previously described. A candidate gene approach will be performed and SNPs will be selected on the basis of possible functional relevance, evidence of potentially association with BC risk and an expected minor allele frequency greater than 5%. Genotyping will be performed by PCR-RFLP or by TaqMan assay as previously described [9]. Subjects with each of the three possible genotypes for each SNPs will be confirmed by sequencing and included on each genotyping tray.

Statistical analyses will be performed as already described [9]. Allele and genotype frequencies will be calculated in cases and controls. The genotype distribution is evaluated for

the Hardy-Weinberg equilibrium in controls. The association between MBC risk and each SNPs will be measured by the odds ratio (OR) and its corresponding 95% confidence interval and will be estimated using unconditional logistic regression after adjustment for age. The analysis will be performed with four logistic regression models based on a co-dominant, dominant, recessive and multiplicative codominant effect (inheritance model).

Considering a minor allele frequency of 10%, and a dominant model, with 180 cases and about 360 controls, we will be able to put in evidence an OR of 1.72 with a power of 80%. As far as the evaluation of statistical interactions (gene-gene or gene-environment) is considered, although this series will be the largest ever assembled in a single country, the statistical power will be limited and we have already established contacts with a consortium of prospective studies (including EPIC-Europe) for a possible collaborative effort, including a genome wide association study (GWAS). All the analyses will be carried out using Statistical Analysis System (Ver. 9.0, SAS Institute, Cary, NC).

Analysis of interactions between gene-gene and gene- environment in MBC.

We intend to analyze at the population level gene-gene and gene-environment interactions between environmental carcinogen exposures and genetic factors in MBC.

Methods: Two-way and three-way statistical interaction between selected SNPs and between selected SNPs and protein will be firstly evaluated using the procedure suggested by Millstein [31].

An evaluation of the interaction between the genetic backgrounds, determined by carrier status for *BRCA1/BRCA2* mutations, at risk genotypes for genes involved in DNA damage repair, steroid hormones and carcinogens metabolism, immunohistochemical expression patterns and exposure to environmental carcinogens will be carried out using a case-case design. The prevalence of a series of occupations associated with exposure to carcinogens of interest, will be estimated according to mutational carrier status [6]. A crude analysis of 2X2 tables and multivariate logistic analyses taking into account different individual characteristics will be performed. The estimated Case-only Odds Ratios (CORs) will provide an evaluation of the departure from a multiplicative effect. The assumption of independence between exposure and genotype, that must be satisfied to apply this method, seems reasonable in this case. The use of a population-based case series could ensure further validity and could allow to maximize the generalization of the results, particularly with analyses focused on age-groups well represented among controls.

MANAGMENT and REPORTING of project

The project could be managed in partnership with the "Inter-Institutional Integrated Department University of Florence/AOUC-Careggi/Meyer (DIPINT)". ISPO delegates DIPINT at the organizational and accounting support, transferring funding share to it. The scientific activity will be guaranteed by ISPO.

11. PRELIMINARY RESULTS AND FEASIBILITY (Max 6000 Characters)

This research project will have the advantage of utilizing information, materials, cases and specific molecular and epidemiological expertise developed in the course of past investigations [5, 6, 8, 9, 21, 22].

We have already analyzed a population-based series of 125 MBCs diagnosed in the period 1991-2008, all residing in North-Eastern Tuscany, for which blood samples and paraffin-embedded tumor sections have been already collected together with extensive epidemiological information and an appropriate control series of 250 men, residing in the same area.

Our results indicate that about 10% of MBCs are accounted for by *BRCA1/2* mutations and that *BRCA1/2* rearrangements are very rare in MBCs unselected for family history [8]. We identified a recurrent *BRCA1* mutation [5] and demonstrated that it represents a founder mutation in Tuscany [22]. Our findings also suggest that the *BRCA2* N372H variant (HH genotype) might be positively associated with an increased risk of BC in men younger than 60 years [9] and we found a strong association between a specific occupation (truck driving) and BC risk in male carriers of *BRCA1/2* mutations [6].

The existing framework of collaborations, expertise, storage facilities, samples and data ensure the feasibility of the proposed project.

Dr. Domenico Palli. The specific expertise of the PI in molecular epidemiology is documented by his relevant publications in the field, as a first or last author. The P.I. has received AIRC Investigator Grants concerning the molecular epidemiology of cancer for over 15 years. All involved investigators collaborate in the frame of the "High-risk family project in Tuscany"

List of PI's publications pertinent to the proposed research:

1. Ottini L, Masala G, D'Amico C, Mancini B, Saieva C, Aceto G, Gestri D, Vezzosi V, Falchetti M, De Marco M, Paglierani M, Cama A, Bianchi S, Mariani-Costantini R, **Palli D.** *BRCA1* and *BRCA2* Mutation Status and Tumor Characteristics in Male Breast Cancer: A Population-based Study in Italy. *Cancer Res.* 2003 Jan 15;63(2):342-7. (I.F. 7.7).
2. **Palli D**, Masala G, Mariani-Costantini R, Zanna I, Saieva C, Sera F, Decarli A, Ottini L. A gene-environment interaction between occupation and *BRCA1/BRCA2* mutations in male breast cancer? *Eur J Cancer.* 40:2474-9, 2004 (I.F. 4.5).
3. Bianchi S, **Palli D**, Falchetti M, Saieva C, Masala G, Mancini B, Lupi R, Noviello C, Omerovic J, Paglierini M, Vezzosi V, Alimandi M, Mariani-Costantini R, Ottini L. ErbB-receptors expression and survival in breast carcinoma: A 15-year follow-up study. *J Cell Physiol.* 206 (3): 702-8, 2006 (I.F. 3.6).
4. **Palli D**, Falchetti M, Masala G, Lupi R, Sera F, Saieva C, D'Amico C, Ceroti M, Rizzolo P, Caligo MA, Zanna I, Ottini L. Association between the *BRCA2* N372H variant and male breast cancer risk: a population based case-control study in Tuscany, Central Italy. *BMC Cancer* 7:170-4, 2007 (I.F. 2,7).
5. Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, **Palli D**, Ottini L. *BRCA1/BRCA2* rearrangements and *CHEK2* common mutations are infrequent in Italian male breast cancer cases. *Breast Cancer Res Treat* DOI 10.1007/Jul 28, 2007 (I.F. 4,5).
6. Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, Sera F, **Palli D.** *BRCA1/BRCA2* mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central

Italy. Breast Cancer Res Treat (2009) 116:577–586. (I.F. 4,5).

7. Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Turco MR, Ottini L, Palli D, Genuardi M. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. Breast Cancer Res Treat (2009) 117:497–504. (I.F. 4,5).

8. Papi L., Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, **Palli D.** A PALB2 germline mutation associated with hereditary breast cancer in Italy. Fam Cancer. 2010 Jun;9(2):181-5. Epub 2009 Sep 18.

9. Papi L, **Palli D**, Masi L, Putignano AL, Congregati C, Zanna I, Marini F, Giusti F, Luzi E, Tonelli F, Genuardi M, Brandi ML, Falchetti A. Germline mutations in MEN1 and BRCA1 genes in a female subject with familial Multiple Endocrine Neoplasia type 1 and inherited breast/ovarian cancer syndromes: a case report. Cancer Genetics and Cytogenetics 195 (2009) 75-79.

10. Silvestri V, Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, Papi L, Giannini G, **Palli D**, Ottini L. PALB2 mutations in male breast cancer: a population-based study in Central Italy. Breast Cancer Res Treat. 2010 Jul;122(1):299-301. Epub 2010 Feb 24. (I.F. 4,5).

11. Zanna I, Rizzolo P, Sera F, Falchetti M, Aretini P, Giannini G, Masala G, Gulino A, **Palli D**, Ottini L. The BRCAPRO 5.0 model is a useful tool in genetic counseling and clinical management of male breast cancer cases. Eur J Hum Genet. 2010 Jul;18(7):856-8. Epub 2010 Mar 17.

12. Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, **Palli D**, Ottini L. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy. Breast Cancer Res Treat. 2010 Dec 17. [Epub ahead of print]

Dr. Maria Adelaide Caligo (Pisa) Dr. Maria Adelaide Caligo is working in the field of hereditary breast cancer since 1990. She took her PhD in Experimental Oncology and Tumor Morphology in 1993. She specialized in Biochemistry and Clinical Chemistry in 1994; She specialized in Medical Genetics in 1997. Since 2002 she is the Head of the Genetic Oncology Section of the Division of Pathology of the Azienda Ospedaliera-Universitaria Pisana. Research interests: Tumor suppressor genes involved in the metastatic process. Genetic basis of hereditary cancer in particular breast and ovarian cancer. Identification of new major breast cancer susceptibility genes and low penetrance alleles; molecular basis of BRCA1/2-driven carcinogenesis; definition of BRCA1&2 mutational spectrum in the Italian population. She also participated to the European Breast Cancer Linkage Consortium and to the European Concerted actions funded in BIOMED I and II.

The laboratory of Dr. Caligo is fully equipped with the facilities and equipment needed to carry out the analyses outlined in this proposal. These include:

- Instruments for DNA, RNA, protein analysis
- PCR thermocyclers
- 3100 ABI PRISM genetic analyzer
- Flow Cytometry, CAS 200 (Image analysis system)
- Cultures hoods and CO2 incubators for human cells

- Immunohistochemistry and in situ hybridisation

Prof.ssa Simonetta Bianchi is Ordinary Professor at Department of Pathology, University of Florence. She is working in the field of breast cancer since 1987.

Research interests: pathology of the breast and in addition molecular biology.

She is member of the "European Working Group for Breast Screening Pathology", and she has participated to the drafting of the 4th (2006) "European guidelines for quality assurance in breast cancer screening and diagnosis" published by European Commission.

She has contributed to "Raccomandazioni cliniche per i principali tumori solidi" of ITT, published in 2005, coordinating the panel of pathologists involved in the drafting of clinical guidelines for breast cancer.

12. REFERENCES

1. Zanetti, R., F. Falcini, L. Simonato, et al., *Survival of cancer patients in Italy in the nineties: the importance of population based data*. Epidemiol Prev, 2001. **25**(3 Suppl): p. 1-8.
2. Giordano, S.H., D.S. Cohen, A.U. Buzdar, et al., *Breast carcinoma in men: a population-based study*. Cancer, 2004. **101**(1): p. 51-7.
3. Brinton, L.A., D.A. Richesson, G.L. Gierach, et al., *Prospective evaluation of risk factors for male breast cancer*. J Natl Cancer Inst, 2008. **100**(20): p. 1477-81.
4. Marchal, F., M. Salou, C. Marchal, et al., *Men With Breast Cancer Have Same Disease-Specific and Event-Free Survival as Women*. Ann Surg Oncol, 2009.
5. Ottini, L., P. Rizzolo, I. Zanna, et al., *BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy*. Breast Cancer Res Treat, 2008.
6. Palli, D., G. Masala, R. Mariani-Costantini, et al., *A gene-environment interaction between occupation and BRCA1/BRCA2 mutations in male breast cancer?* Eur J Cancer, 2004. **40**(16): p. 2474-9.
7. Ottini, L., G. Masala, C. D'Amico, et al., *BRCA1 and BRCA2 mutation status and tumor characteristics in male breast cancer: a population-based study in Italy*. Cancer Res, 2003. **63**(2): p. 342-7.
8. Falchetti, M., R. Lupi, P. Rizzolo, et al., *BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases*. Breast Cancer Res Treat, 2008. **110**(1): p. 161-7.
9. Palli, D., M. Falchetti, G. Masala, et al., *Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy*. BMC Cancer, 2007. **7**: p. 170.
10. Hsu, H.M., H.C. Wang, S.T. Chen, et al., *Breast cancer risk is associated with the genes encoding the DNA double-strand break repair Mre11/Rad50/Nbs1 complex*. Cancer Epidemiol Biomarkers Prev, 2007. **16**(10): p. 2024-32.
11. Crew, K.D., M.D. Gammon, M.B. Terry, et al., *Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk*. Carcinogenesis, 2007. **28**(12): p. 2548-51.
12. Lo, Y.L., J.C. Yu, S.T. Chen, et al., *Breast cancer risk associated with genotypic polymorphism of the mitotic checkpoint genes: a multigenic study on cancer susceptibility*. Carcinogenesis, 2007. **28**(5): p. 1079-86.
13. Ding, S.L., J.C. Yu, S.T. Chen, et al., *Genetic variation in the premature aging gene WRN: a case-control study on breast cancer susceptibility*. Cancer Epidemiol Biomarkers Prev, 2007. **16**(2): p. 263-9.
14. Sigurdson, A.J., P. Bhatti, M.M. Doody, et al., *Polymorphisms in apoptosis- and proliferation-related genes, ionizing radiation exposure, and risk of breast cancer among U.S. Radiologic Technologists*. Cancer Epidemiol Biomarkers Prev, 2007. **16**(10): p. 2000-7.
15. Kotnis, A., S. Kannan, R. Sarin, et al., *Case-control study and meta-analysis of SUL1A1 Arg213His polymorphism for gene, ethnicity and environment interaction for cancer risk*. Br J Cancer, 2008. **99**(8): p. 1340-7.
16. Weiss, J.R., K.B. Moysich, and H. Swede, *Epidemiology of male breast cancer*. Cancer Epidemiol Biomarkers Prev, 2005. **14**(1): p. 20-6.
17. Fentiman, I.S., A. Fourquet, and G.N. Hortobagyi, *Male breast cancer*. Lancet, 2006. **367**(9510): p. 595-604.
18. Bane, A.L., J.C. Beck, I. Bleiweiss, et al., *BRCA2 mutation-associated breast cancers exhibit a distinguishing phenotype based on morphology and molecular profiles from*

- tissue microarrays. *Am J Surg Pathol*, 2007. **31**(1): p. 121-8.
19. Brekelmans, C.T., M.M. Tilanus-Linthorst, C. Seynaeve, et al., *Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases*. *Eur J Cancer*, 2007. **43**(5): p. 867-76.
 20. Akbulut, S., I. Arer, A. Kochiyik, et al., *Male breast cancer: thirteen years experience of a single center*. *Int Semin Surg Oncol*, 2009. **6**(1): p. 4.
 21. Bianchi, S., D. Palli, M. Falchetti, et al., *ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study*. *J Cell Physiol*, 2006. **206**(3): p. 702-8.
 22. Papi, L., A.L. Putignano, C. Congregati, et al., *Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy*. *Breast Cancer Res Treat*, 2008.
 23. Russo, A., V. Calo, L. Bruno, et al., *Is BRCA1-5083del19, identified in breast cancer patients of Sicilian origin, a Calabrian founder mutation?* *Breast Cancer Res Treat*, 2009. **113**(1): p. 67-70.
 24. Walsh, T. and M.C. King, *Ten genes for inherited breast cancer*. *Cancer Cell*, 2007. **11**(2): p. 103-5.
 25. Antoniou, A.C. and D.F. Easton, *Polygenic inheritance of breast cancer: Implications for design of association studies*. *Genet Epidemiol*, 2003. **25**(3): p. 190-202.
 26. Silvestri V, Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, Papi L, Giannini G, Palli D, Ottini L. *PALB2 mutations in male breast cancer: a population-based study in Central Italy*. *Breast Cancer Res Treat*. 2010 Jul;**122**(1):299-301. Epub 2010 Feb 24.
 27. Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, Palli D, Ottini L. *Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in Central Italy*. *Breast Cancer Res Treat*. 2010 Dec 17. [Epub ahead of print]
 28. Tischkowitz, M., B. Xia, N. Sabbaghian, et al., *Analysis of PALB2/FANCN-associated breast cancer families*. *Proc Natl Acad Sci U S A*, 2007. **104**(16): p. 6788-93.
 29. Lose, F., J. Arnold, D.B. Young, et al., *BCoR-L1 variation and breast cancer*. *Breast Cancer Res*, 2007. **9**(4): p. R54.
 30. Abdel-Rehim, M., *New trend in sample preparation: on-line microextraction in packed syringe for liquid and gas chromatography applications. I. Determination of local anaesthetics in human plasma samples using gas chromatography-mass spectrometry*. *J Chromatogr B Analyt Technol Biomed Life Sci*, 2004. **801**(2): p. 317-21.
 31. Millstein, J., D.V. Conti, F.D. Gilliland, et al., *A testing framework for identifying susceptibility genes in the presence of epistasis*. *Am J Hum Genet*, 2006. **78**(1): p. 15-27.

13. PERSONEL INVOLVED IN THE RESEARCH PROJECT - P.I.'s UNIT AND ADDITIONAL UNITS (IF ANY)

FIRST AND LAST NAME	Position	Project Role	Dedicated Time (%)
Domenico Palli	MD	Investigator/Epidemiologist	20
Giovanna Masala	MD	Investigator/Epidemiologist	10
Calogero Saieva	MD	Investigator/Epidemiologist	10
Ines Zanna	Phd/ Fellow	Investigator/Genetician	80
Marco Ceroti	Statistician	Statistician	30
Maria Martinez	Nurse	Technician	20
Simonetta Bianchi	MD, Ordinary Professor	Investigator/Pathologist	20
Maria Adelaide Caligo	Phd	Investigator/Genetician	50
Paolo Aretini	Phd/Fellow	Investigator/Biologist	50
Manuela Roncella	MD	Investigator/Surgeon	20
Laura Ottini	MD, Associate Professor	Investigator/Oncologist	30

14. CURRICULUM VITAE (Principal Investigator) (Max 4000 Characters)

Domenico Palli, MD, MPH, Head, Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Florence, Italy, has authored about 400 peer-reviewed publications listed on Medline-PubMed. After an initial experience in the field of the evaluation of population-based cancer screening programmes (particularly breast and cervical cancer), he has been involved, as principal or co-investigator, in several projects in the field of nutritional and molecular epidemiology, including a multi-centre study on 'Diet and Gastric Cancer' funded by the National Cancer Institute (Bethesda-USA), and the European multi-centre study EUROGAST. Since 1992, he has co-ordinated the Florence section of the European prospective study **EPIC** (European Prospective Investigation on nutrition and Cancer, with 23 centres in 10 countries, including the International Agency for Research on Cancer, Lyon), funded by the European Union and by the Italian Association for Cancer Research-AIRC, Milan (with a series of grants 1991-2008 to the 5 Italian cohorts coordinated by dr. Palli); he is member of the central Steering Committee of the Project. In the period 1993-98, 13,597 volunteers have been enrolled by the Florence centre, each with two questionnaires on dietary and life-style habits and a blood sample collected (aliquots are stored in a local bio-bank in liquid nitrogen); since the start he collaborated to the project 'The Food Composition Database for Epidemiological Studies in Italy', that has been of key importance for the analysis of the EPIC study. Dr.Palli has coordinated the Project "Mammographic Patterns and Breast Cancer Risk" supported by a grant of the World Cancer Research Fund-WCRF London. He is currently involved in several nutritional and molecular epidemiology projects, among which 'Diet, lifestyle and geno-toxic damage (endogenous DNA adducts from lipid peroxidation)', EUR-GAST (*Helicobacter pylori*, diet and Gastric Cancer risk), EPIC-Elderly, EPIC-Heart and the European 6FP projects "**DiOGenes**" on the dietary, lifestyle and genetic determinants of obesity, "INTERACT" on the dietary, lifestyle and genetic determinants of diabetes, EUROFIR (food composition tables), PANACEA (Physical Activity, Nutrition, Alcohol, Cessation of Smoking, Eating out of home and Anthropometry) and IDAMES (Innovative Dietary Assessment Methods in Epidemiological Studies and Public Health). He set up the Tuscany Cancer Family Archive and is involved in a cancer risk reduction program in women at high-risk of breast cancer. He has run randomised intervention trials based on dietary modifications. Member of the Editorial Boards of the journals *Carcinogenesis* and *European Journal of Nutrition*.

15. SELF EVALUATION FORM (Principal Investigator)

Total Papers and Reviews with IF (from January 2005 or last available)	233
Total IF (from January 2005 or last available)	1222.536
Average IF	5.247

Total Papers First/Last Author with IF (from January 2005 or last available)	19
Total IF (from January 2005 or last available)	65.125
Average IF	3.428

15.1 LIST OF PAPERS WITH IF (FROM JANUARY 2005) OF THE PRINCIPAL INVESTIGATOR

1. Airolidi L, Vineis P, Colombi A, Olgiati L, Dell'Osta C, Fanelli R, Manzi L, Veglia F, Autrup H, Dunning A, Garte S, Hainaut P, Hoek G, Krzyzanowski M, Malaveille C, Matullo G, Overvad K, Tjonneland A, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, **Palli D**, Peluso M, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Agudo A, Martinez C, Dorronsoro M, Barricarte A, Chirlaque MD, Quiros JR, Berglund G, Jarvholm B, Hallmans G, Day NE, Allen N, Saracci R, Kaaks R, Riboli E. 4-Aminobiphenyl-hemoglobin adducts and risk of smoking-related disease in never smokers and former smokers in the European Prospective Investigation into Cancer and Nutrition prospective study. *Cancer Epidemiol Biomarkers Prev.* 2005 Sep;14(9):2118-24. IF: **4,642**
2. Al-Delaimy WK, Ferrari P, Slimani N, Pala V, Johansson I, Nilsson S, Mattisson I, Wirfalt E, Galasso R, **Palli D**, Vineis P, Tumino R, Dorronsoro M, Pera G, Ocke MC, Bueno-de-Mesquita HB, Overvad K, Chirlaque M, Trichopoulou A, Naska A, Tjonneland A, Olsen A, Lund E, Alsaker EH, Barricarte A, Kesse E, Boutron-Ruault MC, Clavel-Chapelon F, Key TJ, Spencer E, Bingham S, Welch AA, Sanchez-Perez MJ, Nagel G, Linseisen J, Quiros JR, Peeters PH, van Gils CH, Boeing H, van Kappel AL, Steghens JP, Riboli E. Plasma carotenoids as biomarkers of intake of fruits and vegetables: individual-level correlations in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Eur J Clin Nutr.* 2005 Dec;59(12):1387-96. IF: **2,326**
3. Al-Delaimy WK, Slimani N, Ferrari P, Key T, Spencer E, Johansson I, Johansson G, Mattisson I, Wirfalt E, Sieri S, Agudo A, Celentano E, **Palli D**, Sacerdote C, Tumino R, Dorronsoro M, Ocke MC, Bueno-De-Mesquita HB, Overvad K, Chirlaque MD, Trichopoulou A, Naska A, Tjonneland A, Olsen A, Lund E, Skeie G, Ardanaz E, Kesse E, Boutron-Ruault MC, Clavel-Chapelon F, Bingham S, Welch AA, Martinez-Garcia C, Nagel G, Linseisen J, Quiros JR, Peeters PH, van Gils CH, Boeing H, van Kappel AL, Steghens JP, Riboli E. Plasma carotenoids as biomarkers of intake of fruits and vegetables: ecological-level correlations in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Eur J Clin Nutr.* 2005 Dec;59(12):1397-408. IF: **2,326**
4. Bamia C, Orfanos P, Ferrari P, Overvad K, Hundborg HH, Tjonneland A, Olsen A, Kesse E, Boutron-Ruault MC, Clavel-Chapelon F, Nagel G, Boffetta P, Boeing H, Hoffmann K, Trichopoulos D, Baibas N, Psaltopoulou T, Norat T, Slimani N, **Palli D**, Krogh V, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, van Rossum CT, Quiros JR, Sanchez MJ, Navarro C, Barricarte A, Dorronsoro M,

- Berglund G, Wirfalt E, Hallmans G, Johansson I, Bingham S, Khaw KT, Spencer EA, Roddam AW, Riboli E, Trichopoulou A. Dietary patterns among older Europeans: the EPIC-Elderly study. *Br J Nutr.* 2005 Jul;94(1):100-13. IF: **2,339**
5. Bezemer ID, Rinaldi S, Dossus L, Gils CH, Peeters PH, Noord PA, Bueno-de-Mesquita HB, Johnsen SP, Overvad K, Olsen A, Tjonneland A, Boeing H, Lahmann PH, Linseisen J, Nagel G, Allen N, Roddam A, Bingham S, Khaw KT, Kesse E, Tehard B, Clavel-Chapelon F, Agudo A, Ardanaz E, Quiros JR, Amiano P, C MG, Tormo MJ, Pala V, Panico S, Vineis P, **Palli D**, Tumino R, Trichopoulou A, Baibas N, Zilis D, Hemon B, Norat T, Riboli E, Kaaks R. C-peptide, IGF-I, sex-steroid hormones and adiposity: a cross-sectional study in healthy women within the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes Control.* 2005 Jun;16(5):561-72. IF: **3,279**
 6. Bingham SA, Norat T, Moskal A, Ferrari P, Slimani N, Clavel-Chapelon F, Kesse E, Nieters A, Boeing H, Tjonneland A, Overvad K, Martinez C, Dorronsoro M, Gonzalez CA, Ardanaz E, Navarro C, Quiros JR, Key TJ, Day NE, Trichopoulou A, Naska A, Krogh V, Tumino R, **Palli D**, Panico S, Vineis P, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, Berglund G, Hallmans G, Lund E, Skeie G, Kaaks R, Riboli E. Is the association with fiber from foods in colorectal cancer confounded by folate intake? *Cancer Epidemiol Biomarkers Prev.* 2005 Jun;14(6):1552-6. IF: **4,642**
 7. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Bollot C, Rinaldi S, Llewellyn M, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, **Palli D**, Tumino R, Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Barricarte A, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R. Genetic variation in the growth hormone synthesis pathway in relation to circulating insulin-like growth factor-I, insulin-like growth factor binding protein-3, and breast cancer risk: results from the European prospective investigation into cancer and nutrition study. *Cancer Epidemiol Biomarkers Prev.* 2005 Oct;14(10):2316-25. IF: **4,642**
 8. Ferrari P, Al-Delaimy WK, Slimani N, Boshuizen HC, Roddam A, Orfanos P, Skeie G, Rodriguez-Barranco M, Thiebaut A, Johansson G, **Palli D**, Boeing H, Overvad K, Riboli E. An Approach to Estimate Between- and Within-Group Correlation Coefficients in Multicenter Studies: Plasma Carotenoids as Biomarkers of Intake of Fruits and Vegetables. *Am J Epidemiol.* 2005 Sep 15;162(6):591-8. IF: **5,285**
 9. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C, Secreto G, Amiano P, Bingham S, Boeing H, Bueno de Mesquita HB, Chang-Claude J, Clavel-Chapelon F, Fournier A, van Gils CH, Gonzalez CA, Gurrea AB, Critselis E, Khaw KT, Krogh V, Lahmann PH, Nagel G, Olsen A, Onland-Moret NC, Overvad K, **Palli D**, Panico S, Peeters P, Quiros JR, Roddam A, Thiebaut A, Tjonneland A, Chirlaque MD, Trichopoulou A, Trichopoulos D, Tumino R, Vineis P, Norat T, Ferrari P, Slimani N, Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). *J Natl Cancer Inst.* 2005 May 18;97(10):755-65. IF: **15,678**
 10. Kaaks R, Rinaldi S, Key TJ, Berrino F, Peeters PH, Biessy C, Dossus L, Lukanova A, Bingham S, Khaw KT, Allen NE, Bueno-de-Mesquita HB, van Gils CH, Grobbee D,

- Boeing H, Lahmann PH, Nagel G, Chang-Claude J, Clavel-Chapelon F, Fournier A, Thiebaut A, Gonzalez CA, Quiros JR, Tormo MJ, Ardanaz E, Amiano P, Krogh V, **Palli D**, Panico S, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Ferrari P, Norat T, Saracci R, Riboli E. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. *Endocr Relat Cancer*. 2005 Dec;12(4):1071-82. IF: **5,193**
11. Kraft P, Pharoah P, Chanock SJ, Albanes D, Kolonel LN, Hayes RB, Altshuler D, Andriole G, Berg C, Boeing H, Burt NP, Bueno-de-Mesquita B, Calle EE, Cann H, Canzian F, Chen YC, Crawford DE, Dunning AM, Feigelson HS, Freedman ML, Gaziano JM, Giovannucci E, Gonzalez CA, Haiman CA, Hallmans G, Henderson BE, Hirschhorn JN, Hunter DJ, Kaaks R, Key T, Marchand LL, Ma J, Overvad K, **Palli D**, Pike MC, Riboli E, Rodriguez C, Setiawan WV, Stampfer MJ, Stram DO, Thomas G, Thun MJ, Travis R, Trichopoulou A, Virtamo J, Wacholder S. Genetic Variation in the HSD17B1 Gene and Risk of Prostate Cancer. *PLoS Genet*. 2005 Nov 25;1(5):e68. IF: **8,721**
 12. Mondaini N, **Palli D**, Saieva C, Nesi G, Franchi A, Ponchietti R, Tripodi S, Miracco C, Meliani E, Carini M, Livi L, Zanna I, Trovarelli S, Marino V, Vignolini G, Pomara G, Orlando V, Giubilei G, Selli C, Rizzo M. Clinical characteristics and overall survival in genitourinary sarcomas treated with curative intent: a multicenter study. *Eur Urol*. 2005 Apr;47(4):468-73. IF: **5,634**
 13. Norat T, Bingham S, Ferrari P, Slimani N, Jenab M, Mazuir M, Overvad K, Olsen A, Tjonneland A, Clavel F, Boutron-Ruault MC, Kesse E, Boeing H, Bergmann MM, Nieters A, Linseisen J, Trichopoulou A, Trichopoulos D, Tountas Y, Berrino F, **Palli D**, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Engeset D, Lund E, Skeie G, Ardanaz E, Gonzalez C, Navarro C, Quiros JR, Sanchez MJ, Berglund G, Mattisson I, Hallmans G, Palmqvist R, Day NE, Khaw KT, Key TJ, San Joaquin M, Hemon B, Saracci R, Kaaks R, Riboli E. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. *J Natl Cancer Inst*. 2005 Jun 15;97(12):906-16. IF: **15,678**
 14. Onland-Moret NC, Peeters PH, van Gils CH, Clavel-Chapelon F, Key T, Tjonneland A, Trichopoulou A, Kaaks R, Manjer J, Panico S, **Palli D**, Tehard B, Stoikidou M, Bueno-De-Mesquita HB, Boeing H, Overvad K, Lenner P, Quiros JR, Chirlaque MD, Miller AB, Khaw KT, Riboli E. Age at Menarche in Relation to Adult Height. *Am J Epidemiol*. 2005 Oct 1;162(7):623-32. IF: **5,285**
 15. **Palli D**, Saieva C, Gemma S, Masala G, Gomez-Miguel MJ, Luzzi I, D'Errico M, Matullo G, Ozzola G, Manetti R, Nesi G, Sera F, Zanna I, Dogliotti E, Testai E. GSTT1 and GSTM1 gene polymorphisms and gastric cancer in a high-risk Italian population. *Int J Cancer*. 2005 Feb 1;115(2):284-9. IF: **4,555**
 16. **Palli D**, Saieva C, Luzzi I, Masala G, Topa S, Sera F, Gemma S, Zanna I, D'Errico M, Zini E, Guidotti S, Valeri A, Fabbucci P, Moretti R, Testai E, del Giudice G, Ottini L, Matullo G, Dogliotti E, Gomez-Miguel MJ. Interleukin-1 gene polymorphisms and gastric cancer risk in a high-risk Italian population. *Am J Gastroenterol*. 2005 Sep;100(9):1941-8. IF: **6,101**
 17. Peluso M, Munnia A, Hoek G, Krzyzanowski M, Veglia F, Airoldi L, Autrup H, Dunning

- A, Garte S, Hainaut P, Malaveille C, Gormally E, Matullo G, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, Trichopoulos D, Kaladidi A, **Palli D**, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Kumle M, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Berglund G, Janzon L, Jarvholm B, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Vineis P. DNA adducts and lung cancer risk: a prospective study. *Cancer Res.* 2005 Sep 1;65(17):8042-8. IF: **7,672**
18. Schulz M, Lahmann PH, Boeing H, Hoffmann K, Allen N, Key TJ, Bingham S, Wirfalt E, Berglund G, Lundin E, Hallmans G, Lukanova A, Martinez Garcia C, Gonzalez CA, Tormo MJ, Quiros JR, Ardanaz E, Larranaga N, Lund E, Gram IT, Skeie G, Peeters PH, van Gils CH, Bueno-de-Mesquita HB, Buchner FL, Pasanisi P, Galasso R, **Palli D**, Tumino R, Vineis P, Trichopoulou A, Kalapothaki V, Trichopoulos D, Chang-Claude J, Linseisen J, Boutron-Ruault MC, Touillaud M, Clavel-Chapelon F, Olsen A, Tjonneland A, Overvad K, Tetsche M, Jenab M, Norat T, Kaaks R, Riboli E. Fruit and vegetable consumption and risk of epithelial ovarian cancer: the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev.* 2005 Nov;14(11):2531-5. IF: **4,642**
 19. van Gils CH, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Lahmann PH, Clavel-Chapelon F, Thiebaut A, Kesse E, Sieri S, **Palli D**, Tumino R, Panico S, Vineis P, Gonzalez CA, Ardanaz E, Sanchez MJ, Amiano P, Navarro C, Quiros JR, Key TJ, Allen N, Khaw KT, Bingham SA, Psaltopoulou T, Koliva M, Trichopoulou A, Nagel G, Linseisen J, Boeing H, Berglund G, Wirfalt E, Hallmans G, Lenner P, Overvad K, Tjonneland A, Olsen A, Lund E, Engeset D, Alsaker E, Norat T, Kaaks R, Slimani N, Riboli E. Consumption of vegetables and fruits and risk of breast cancer. *JAMA.* 2005 Jan 12;293(2):183-93. IF: **25,547**
 20. Vineis P, Airolidi L, Veglia P, Olgiati L, Pastorelli R, Autrup H, Dunning A, Garte S, Gormally E, Hainaut P, Malaveille C, Matullo G, Peluso M, Overvad K, Tjonneland A, Clavel-Chapelon F, Boeing H, Krogh V, **Palli D**, Panico S, Tumino R, Bueno-De-Mesquita B, Peeters P, Berglund G, Hallmans G, Saracci R, Riboli E. Environmental tobacco smoke and risk of respiratory cancer and chronic obstructive pulmonary disease in former smokers and never smokers in the EPIC prospective study. *BMJ.* 2005 Feb 5;330(7486):277. IF: **9,723**
 21. Agudo A, Sala N, Pera G, Capella G, Berenguer A, Garcia N, **Palli D**, Boeing H, Del Giudice G, Saleva C, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Siman H, Stenling R, Hallmans G, Martinez C, Amiano P, Barricarte A, Navarro C, Quiros JR, Allen N, Key T, Bingham S, Khaw KT, Linseisen J, Nagel G, Overvad K, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Boshuizen HC, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Blaker H, Jenab M, Ferrari P, Norat T, Riboli E, Gonzalez CA. No Association between Polymorphisms in CYP2E1, GSTM1, NAT1, NAT2 and the Risk of Gastric Adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev.* 2006 May;15(5):1043-5. IF: **4,642**
 22. Agudo A, Sala N, Pera G, Capella G, Berenguer A, Garcia N, **Palli D**, Boeing H, Del Giudice G, Saleva C, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Siman H, Stenling R, Hallmans G, Martinez C, Bilbao R, Barricarte A, Navarro C, Quiros JR, Allen N, Key T, Bingham S, Khaw KT, Linseisen J, Nagel G,

- Overvad K, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Boshuizen HC, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Offerhaus J, Jenab M, Ferrari P, Norat T, Riboli E, Gonzalez CA. Polymorphisms in metabolic genes related to tobacco smoke and the risk of gastric cancer in the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev.* 2006 Dec;15(12):2427-34. IF: **4,642**
23. Berrington de Gonzalez A, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjaer J, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Boeing H, Pischon T, Linseisen J, Rohrmann S, Trichopoulou A, Benetou V, Papadimitriou A, Pala V, **Palli D**, Panico S, Tumino R, Vineis P, Boshuizen HC, Ocke MC, Peeters PH, Lund E, Gonzalez CA, Larranaga N, Martinez-Garcia C, Mendez M, Navarro C, Quiros JR, Tormo MJ, Hallmans G, Ye W, Bingham SA, Khaw KT, Allen N, Key TJ, Jenab M, Norat T, Ferrari P, Riboli E. Anthropometry, Physical Activity, and the Risk of Pancreatic Cancer in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev.* 2006 May;15(5):879-885. IF: **4,642**
24. Bianchi S, **Palli D**, Falchetti M, Saieva C, Masala G, Mancini B, Lupi R, Noviello C, Omerovic J, Paglierani M, Vezzosi V, Alimandi M, Mariani-Costantini R, Ottini L. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. *J Cell Physiol.* 2006 Mar;206(3):702-8. IF: **3,907**
25. Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, Frederiksen K, Christensen J, Tjonneland A, Overvad K, Chapelon FC, Nagel G, Chang-Claude J, Bergmann MM, Boeing H, Trichopoulos D, Trichopoulou A, Oikonomou E, Berrino F, **Palli D**, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Kiemeneij L, Gram IT, Braaten T, Lund E, Gonzalez CA, Berglund G, Allen N, Roddam A, Bingham S, Riboli E. Tobacco smoke and bladder cancer--in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 2006 Nov 15;119(10):2412-6. IF: **4,555**
26. Bjerregaard BK, Raaschou-Nielsen O, Sorensen M, Frederiksen K, Tjonneland A, Rohrmann S, Linseisen J, Bergman MM, Boeing H, Sieri S, **Palli D**, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Buchner FL, Gram IT, Braaten T, Lund E, Hallmans G, Agren A, Riboli E. The effect of occasional smoking on smoking-related cancers : In the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes Control.* 2006 Dec;17(10):1305-9. IF: **3,279**
27. Boeing H, Dietrich T, Hoffmann K, Pischon T, Ferrari P, Lahmann PH, Boutron-Ruault MC, Clavel-Chapelon F, Allen N, Key T, Skeie G, Lund E, Olsen A, Tjonneland A, Overvad K, Jensen MK, Rohrmann S, Linseisen J, Trichopoulou A, Bamia C, Psaltopoulou T, Weinehall L, Johansson I, Sanchez MJ, Jakszyn P, Ardanaz E, Amiano P, Chirlaque MD, Quiros JR, Wirfalt E, Berglund G, Peeters PH, van Gils CH, Bueno-de-Mesquita HB, Buchner FL, Berrino F, **Palli D**, Sacerdote C, Tumino R, Panico S, Bingham S, Khaw KT, Slimani N, Norat T, Jenab M, Riboli E. Intake of fruits and vegetables and risk of cancer of the upper aero-digestive tract: the prospective EPIC-study. *Cancer Causes Control.* 2006 Sep;17(7):957-69. IF: **3,279**
28. Canzian F, McKay JD, Cleveland RJ, Dossus L, Biessy C, Rinaldi S, Landi S, Boillot C, Monnier S, Chajes V, Clavel-Chapelon F, Tehard B, Chang-Claude J, Linseisen J, Lahmann PH, Pischon T, Trichopoulos D, Trichopoulou A, Zilis D, **Palli D**, Tumino R,

- Vineis P, Berrino F, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Pera G, Ardanaz E, Chirlaque MD, Quiros JR, Larranaga N, Martinez-Garcia C, Allen NE, Key TJ, Bingham SA, Khaw KT, Slimani N, Norat T, Riboli E, Kaaks R. Polymorphisms of genes coding for insulin-like growth factor 1 and its major binding proteins, circulating levels of IGF-I and IGFBP-3 and breast cancer risk: results from the EPIC study. *Br J Cancer*. 2006 Jan 30;94(2):299-307. IF: **4,635**
29. Cox DG, Blanche H, Pearce CL, Calle EE, Colditz GA, Pike MC, Albanes D, Allen NE, Amiano P, Berglund G, Boeing H, Buring J, Burt N, Canzian F, Chanock S, Clavel-Chapelon F, Spencer Feigelson H, Freedman M, Hankinson SE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, Kraft P, Lemarchand L, Lund E, **Palli D**, Peeters PH, Riboli E, Thun M, Tjonneland A, Trichopoulos D, Yeager M, Haiman CA, Stram DO, Henderson BE. A comprehensive analysis of the AR gene and risk of breast cancer: results from the NCI Breast and Prostate Cancer Cohort Consortium (BPC3). *Breast Cancer Res*. 2006 Sep 20;8(5):R54. IF: **4,371**
30. Decarli A, Calza S, Masala G, Specchia C, **Palli D**, Gail MH. Gail model for prediction of absolute risk of invasive breast cancer: independent evaluation in the Florence-European Prospective Investigation Into Cancer and Nutrition cohort. *J Natl Cancer Inst*. 2006 Dec 6;98(23):1686-93. IF: **15,678**
31. Engeset D, Alsaker E, Lund E, Welch A, Khaw KT, Clavel-Chapelon F, Thiebaut A, Chajes V, Key TJ, Allen NE, Amiano P, Dorronsoro M, Tjonneland A, Stripp C, Peeters PH, van Gils CH, Chirlaque MD, Nagel G, Linseisen J, Ocke MC, Bueno-de-Mesquita HB, Sacerdote C, Tumino R, Ardanaz E, Sanchez MJ, Panico S, **Palli D**, Trichopoulou A, Kalapothaki V, Benetou V, Quiros JR, Agudo A, Overvad K, Bjerregaard L, Wirfalt E, Schulz M, Boeing H, Slimani N, Riboli E. Fish consumption and breast cancer risk. The European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer*. 2006 Jul 1;119(1):175-82. IF: **4,555**
32. Feigelson HS, Cox DG, Cann HM, Wacholder S, Kaaks R, Henderson BE, Albanes D, Altshuler D, Berglund G, Berrino F, Bingham S, Buring JE, Burt NP, Calle EE, Chanock SJ, Clavel-Chapelon F, Colditz G, Diver WR, Freedman ML, Haiman CA, Hankinson SE, Hayes RB, Hirschhorn JN, Hunter D, Kolonel LN, Kraft P, LeMarchand L, Linseisen J, Modi W, Navarro C, Peeters PH, Pike MC, Riboli E, Setiawan VW, Stram DO, Thomas G, Thun MJ, Tjonneland A, Trichopoulos D (Contributing authors: **Palli D**, Panico S, Tumino R, Vineis P). Haplotype analysis of the HSD17B1 gene and risk of breast cancer: a comprehensive approach to multicenter analyses of prospective cohort studies. *Cancer Res*. 2006 Feb 15;66(4):2468-75. IF: **7,672**
33. Friedenreich C, Norat T, Steindorf K, Boutron-Ruault MC, Pischon T, Mazuir M, Clavel-Chapelon F, Linseisen J, Boeing H, Bergman M, Johnsen NF, Tjonneland A, Overvad K, Mendez M, Quiros JR, Martinez C, Dorronsoro M, Navarro C, Gurrea AB, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Trichopoulos D, Orfanou N, Krogh V, **Palli D**, Tumino R, Panico S, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Monninkhof E, Berglund G, Manjer J, Ferrari P, Slimani N, Kaaks R, Riboli E. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev*. 2006 Dec;15(12):2398-407. IF: **4,642**
34. Gonzalez CA, Jakszyn P, Pera G, Agudo A, Bingham S, **Palli D**, Ferrari P, Boeing H, del Giudice G, Plebani M, Carneiro F, Nesi G, Berrino F, Sacerdote C, Tumino R,

- Panico S, Berglund G, Siman H, Nyren O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Allen N, Key TJ, Day NE, Linseisen J, Nagel G, Bergmann MM, Overvad K, Jensen MK, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Ocke M, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Psaltopoulou T, Roukos D, Lund E, Hemon B, Kaaks R, Norat T, Riboli E. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). *J Natl Cancer Inst.* 2006 Mar 1;98(5):345-54. IF: **15,678**
35. Gonzalez CA, Pera G, Agudo A, **Palli D**, Linseisen J, Boeing H, Jenab M, Bueno-de-Mesquita HB, Numans ME, Riboli E. Reply to the letter to the editor. *Int J Cancer.* 2006 Dec 15;119(12):2992. IF: **4,555**
36. Gormally E, Vineis P, Matullo G, Veglia F, Caboux E, Le Roux E, Peluso M, Garte S, Guarrera S, Munnia A, Airoldi L, Autrup H, Malaveille C, Dunning A, Overvad K, Tjonneland A, Lund E, Clavel-Chapelon F, Boeing H, Trichopoulou A, **Palli D**, Krogh V, Tumino R, Panico S, Bueno-de-Mesquita HB, Peeters PH, Pera G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Hallmans G, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Hainaut P. TP53 and KRAS2 mutations in plasma DNA of healthy subjects and subsequent cancer occurrence: a prospective study. *Cancer Res.* 2006 Jul 1;66(13):6871-6. IF: **7,672**
37. Gram IT, Norat T, Rinaldi S, Dossus L, Lukanova A, Tehard B, Clavel-Chapelon F, van Gils CH, van Noord PA, Peeters PH, Bueno-de-Mesquita HB, Nagel G, Linseisen J, Lahmann PH, Boeing H, **Palli D**, Sacerdote C, Panico S, Tumino R, Sieri S, Dorronsoro M, Quiros JR, Navarro CA, Barricarte A, Tormo MJ, Gonzalez CA, Overvad K, Paaske Johnsen S, Olsen A, Tjonneland A, Travis R, Allen N, Bingham S, Khaw KT, Stattin P, Trichopoulou A, Kalapothaki V, Psaltopoulou T, Casagrande C, Riboli E, Kaaks R. Body mass index, waist circumference and waist-hip ratio and serum levels of IGF-I and IGFBP-3 in European women. *Int J Obes (Lond).* 2006 Nov;30(11):1623-31. IF: **3,56**
38. Jakszyn P, Bingham S, Pera G, Agudo A, Luben R, Welch A, Boeing H, Del Giudice G, **Palli D**, Saieva C, Krogh V, Sacerdote C, Tumino R, Panico S, Berglund G, Siman H, Hallmans G, Sanchez MJ, Larranaga N, Barricarte A, Chirlaque MD, Quiros JR, Key TJ, Allen N, Lund E, Carneiro F, Linseisen J, Nagel G, Overvad K, Tjonneland A, Olsen A, Bueno-de-Mesquita HB, Ocke MO, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Fenger C, Stenling R, Ferrari P, Jenab M, Norat T, Riboli E, Gonzalez CA. Endogenous versus exogenous exposure to N-nitroso compounds and gastric cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST) study. *Carcinogenesis.* 2006 Jul;27(7):1497-501. IF: **5,406**
39. Jenab M, Riboli E, Ferrari P, Friesen M, Sabate J, Norat T, Slimani N, Tjonneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Boeing H, Schulz M, Linseisen J, Nagel G, Trichopoulou A, Naska A, Oikonomou E, Berrino F, Panico S, **Palli D**, Sacerdote C, Tumino R, Peeters PH, Numans ME, Bueno-de-Mesquita HB, Buchner FL, Lund E, Pera G, Chirlaque MD, Sanchez MJ, Arriola L, Barricarte A, Quiros JR, Johansson I, Johansson A, Berglund G, Bingham S, Khaw KT, Allen N, Key T, Carneiro F, Save V, Del Giudice G, Plebani M, Kaaks R, Gonzalez CA. Plasma and dietary carotenoid, retinol and tocopherol levels and the risk of gastric adenocarcinomas in the European prospective investigation into cancer and nutrition. *Br J Cancer.* 2006 Aug 7;95(3):406-15. IF: **4,635**

40. Jenab M, Riboli E, Ferrari P, Sabate J, Slimani N, Norat T, Friesen M, Tjonneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Touvier M, Boeing H, Schulz M, Linseisen J, Nagel G, Trichopoulou A, Naska A, Oikonomou E, Krogh V, Panico S, Masala G, Sacerdote C, Tumino R, Peeters PH, Numans ME, Bueno-de-Mesquita HB, Buchner FL, Lund E, Pera G, Sanchez CN, Sanchez MJ, Arriola L, Barricarte A, Quiros JR, Hallmans G, Stenling R, Berglund G, Bingham S, Khaw KT, Key T, Allen N, Carneiro F, Mahlke U, Del Giudice G, **Palli D**, Kaaks R, Gonzalez CA. Plasma and dietary vitamin C levels and risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Carcinogenesis*. 2006 Nov;27(11):2250-7. IF: **5,406**
41. Jenab M, Sabate J, Slimani N, Ferrari P, Mazuir M, Casagrande C, Deharveng G, Tjonneland A, Olsen A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Boeing H, Weikert C, Linseisen J, Rohrmann S, Trichopoulou A, Naska A, **Palli D**, Sacerdote C, Tumino R, Mattiello A, Pala V, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, Engeset D, Skeie G, Jakszyn P, Ardanaz E, Quiros JR, Chirlaque MD, Martinez C, Amiano P, Berglund G, Palmqvist R, Guelpen B, Bingham S, Key T, Riboli E. Consumption and portion sizes of tree nuts, peanuts and seeds in the European Prospective Investigation into Cancer and Nutrition (EPIC) cohorts from 10 European countries. *Br J Nutr*. 2006 Nov;96 Suppl 2:S12-23. IF: **2,339**
42. Masala G, Ambrogetti D, Assedi M, Giorgi D, Del Turco MR, **Palli D**. Dietary and lifestyle determinants of mammographic breast density. A longitudinal study in a Mediterranean population. *Int J Cancer*. 2006 Apr 1;118(7):1782-9. IF: **4,555**
43. Matullo G, Dunning AM, Guarrera S, Baynes C, Polidoro S, Garte S, Autrup H, Malaveille C, Peluso M, Airoldi L, Veglia F, Gormally E, Hoek G, Krzyzanowski M, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, **Palli D**, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Pera G, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Vineis P. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. *Carcinogenesis*. 2006 May;27(5):997-1007. IF: **5,406**
44. Pala V, Sieri S, Masala G, **Palli D**, Panico S, Vineis P, Sacerdote C, Mattiello A, Galasso R, Salvini S, Ceroti M, Berrino F, Fusconi E, Tumino R, Frasca G, Riboli E, Trichopoulou A, Baibas N, Krogh V. Associations between dietary pattern and lifestyle, anthropometry and other health indicators in the elderly participants of the EPIC-Italy cohort. *Nutr Metab Cardiovasc Dis*. 2006 Apr;16(3):186-201. IF: **3,279**
45. **Palli D**, Masala G, Sera F, Bagnoli S, d'Albasio G. Colorectal cancer risk in patients affected with Crohn's disease. *Am J Gastroenterol*. 2006 Jun;101(6):1400-1. IF: **6,101**
46. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A, Halkjaer J, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Guernec G, Bergmann MM, Linseisen J, Becker N, Trichopoulou A, Trichopoulos D, Sieri S, **Palli D**, Tumino R, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Boshuizen HC, Van Guelpen B, Palmqvist R, Berglund G, Gonzalez CA, Dorronsoro M, Barricarte A, Navarro C, Martinez C, Quiros JR, Roddam A, Allen N, Bingham S, Khaw KT, Ferrari P, Kaaks R, Slimani N, Riboli E. Body size and risk of colon and rectal cancer in the European

Prospective Investigation Into Cancer and Nutrition (EPIC). *J Natl Cancer Inst.* 2006 Jul 5;98(13):920-31. IF: **15,678**

47. Pischon T, Lahmann PH, Boeing H, Tjonneland A, Halkjaer J, Overvad K, Klipstein-Grobusch K, Linseisen J, Becker N, Trichopoulou A, Benetou V, Trichopoulos D, Sieri S, **Palli D**, Tumino R, Vineis P, Panico S, Monninkhof E, Peeters PH, Bueno-de-Mesquita HB, Buchner FL, Ljungberg B, Hallmans G, Berglund G, Gonzalez CA, Dorronsoro M, Gurrea AB, Navarro C, Martinez C, Quiros JR, Roddam A, Allen N, Bingham S, Khaw KT, Kaaks R, Norat T, Slimani N, Riboli E. Body size and risk of renal cell carcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer.* 2006 Feb 1;118(3):728-738. IF: **4,555**
48. Reeves GK, Kan SW, Key T, Tjonneland A, Olsen A, Overvad K, Peeters PH, Clavel-Chapelon F, Paoletti X, Berrino F, Krogh V, **Palli D**, Tumino R, Panico S, Vineis P, Gonzalez CA, Ardanaz E, Martinez C, Amiano P, Quiros JR, Tormo MR, Khaw KT, Trichopoulou A, Psaltopoulou T, Kalapothaki V, Nagel G, Chang-Claude J, Boeing H, Lahmann PH, Wirfalt E, Kaaks R, Riboli E. Breast cancer risk in relation to abortion: Results from the EPIC study. *Int J Cancer.* 2006 Oct 1;119(7):1741-5. IF: **4,555**
49. Rinaldi S, Key TJ, Peeters PH, Lahmann PH, Lukanova A, Dossus L, Biessy C, Vineis P, Sacerdote C, Berrino F, Panico S, Tumino R, **Palli D**, Nagel G, Linseisen J, Boeing H, Roddam A, Bingham S, Khaw KT, Chloutios J, Trichopoulou A, Trichopoulos D, Tehard B, Clavel-Chapelon F, Gonzalez CA, Larranaga N, Barricarte A, Quiros JR, Chirlaque MD, Martinez C, Monninkhof E, Grobbee DE, Bueno-de-Mesquita HB, Ferrari P, Slimani N, Riboli E, Kaaks R. Anthropometric measures, endogenous sex steroids and breast cancer risk in postmenopausal women: A study within the EPIC cohort. *Int J Cancer.* 2006 Jun 1;118(11):2832-9. IF: **4,555**
50. Rinaldi S, Peeters PH, Berrino F, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Tehard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Trichopoulou A, Trichopoulos D, Koliva M, **Palli D**, Panico S, Tumino R, Sacerdote C, van Gils CH, van Noord P, Grobbee DE, Bueno-de-Mesquita HB, Gonzalez CA, Agudo A, Chirlaque MD, Barricarte A, Larranaga N, Quiros JR, Bingham S, Khaw KT, Key T, Allen NE, Lukanova A, Slimani N, Saracci R, Riboli E, Kaaks R. IGF-I, IGFBP-3 and breast cancer risk in women: The European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocr Relat Cancer.* 2006 Jun;13(2):593-605. IF: **5,193**
51. Rinaldi S, Peeters PH, Bezemer ID, Dossus L, Biessy C, Sacerdote C, Berrino F, Panico S, **Palli D**, Tumino R, Khaw KT, Bingham S, Allen NE, Key T, Jensen MK, Overvad K, Olsen A, Tjonneland A, Amiano P, Ardanaz E, Agudo A, Martinez-Garcia C, Quiros JR, Tormo MJ, Nagel G, Linseisen J, Boeing H, Schulz M, Grobbee DE, Bueno-de-Mesquita HB, Koliva M, Kyriazi G, Trichopoulou A, Boutron-Ruault MC, Clavel-Chapelon F, Ferrari P, Slimani N, Saracci R, Riboli E, Kaaks R. Relationship of alcohol intake and sex steroid concentrations in blood in pre- and post-menopausal women: the European Prospective Investigation into Cancer and Nutrition. *Cancer Causes Control.* 2006 Oct;17(8):1033-43. IF: **3,279**
52. Rohrmann S, Linseisen J, Boshuizen HC, Whittaker J, Agudo A, Vineis P, Boffetta P, Jensen MK, Olsen A, Overvad K, Tjonneland A, Boutron-Ruault MC, Clavel-Chapelon F, Bergmann MM, Boeing H, Allen N, Key T, Bingham S, Khaw KT, Kyriazi G, Soukara

- S, Trichopoulou A, Panico S, **Palli D**, Sieri S, Tumino R, Peeters PH, Bueno-de-Mesquita HB, Buchner FL, Gram IT, Lund E, Ardanaz E, Chirlaque MD, Dorronsoro M, Perez MJ, Quiros JR, Berglund G, Janzon L, Rasmuson T, Weinehall L, Ferrari P, Jenab M, Norat T, Riboli E. Ethanol intake and risk of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Epidemiol*. 2006 Dec 1;164(11):1103-14. IF: **5,285**
53. Salvini S, Sera F, Caruso D, Giovannelli L, Visioli F, Saieva C, Masala G, Ceroti M, Giovacchini V, Pitozzi V, Galli C, Romani A, Mulinacci N, Bortolomeazzi R, Dolara P, **Palli D**. Daily consumption of a high-phenol extra-virgin olive oil reduces oxidative DNA damage in postmenopausal women. *Br J Nutr*. 2006 Apr;95(4):742-51. IF: **2,339**
54. Steindorf K, Friedenreich C, Linseisen J, Rohrmann S, Rundle A, Veglia F, Vineis P, Johnsen NF, Tjonneland A, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Schulz M, Boeing H, Trichopoulou A, Kalapothaki V, Koliva M, Krogh V, **Palli D**, Tumino R, Panico S, Monninkhof E, Peeters PH, Boshuizen HC, Bueno-de-Mesquita HB, Chirlaque MD, Agudo A, Larranaga N, Quiros JR, Martinez C, Barricarte A, Janzon L, Berglund G, Bingham S, Khaw KT, Key TJ, Norat T, Jenab M, Cust A, Riboli E. Physical activity and lung cancer risk in the European Prospective Investigation into Cancer and Nutrition Cohort. *Int J Cancer*. 2006 Nov 15;119(10):2389-97. IF: **4,555**
55. Verheus M, Peeters PH, Rinaldi S, Dossus L, Biessy C, Olsen A, Tjonneland A, Overvad K, Jeppesen M, Clavel-Chapelon F, Tehard B, Nagel G, Linseisen J, Boeing H, Lahmann PH, Arvaniti A, Psaltopoulou T, Trichopoulou A, **Palli D**, Tumino R, Panico S, Sacerdote C, Sieri S, van Gils CH, Bueno-de-Mesquita BH, Gonzalez CA, Ardanaz E, Larranaga N, Garcia CM, Navarro C, Quiros JR, Key T, Allen N, Bingham S, Khaw KT, Slimani N, Riboli E, Kaaks R. Serum C-peptide levels and breast cancer risk: Results from the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer*. 2006 Aug 1;119(3):659-67. IF: **4,555**
56. Vineis P, Hoek G, Krzyzanowski M, Vigna-Taglianti F, Veglia F, Airoldi L, Autrup H, Dunning A, Garte S, Hainaut P, Malaveille C, Matullo G, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, **Palli D**, Peluso M, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund EE, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Cirera L, Quiros JR, Berglund G, Forsberg B, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E. Air pollution and risk of lung cancer in a prospective study in Europe. *Int J Cancer*. 2006 Jul 1;119(1):169-74. IF: **4,555**
57. Weikert S, Boeing H, Pischon T, Olsen A, Tjonneland A, Overvad K, Becker N, Linseisen J, Lahmann PH, Arvaniti A, Kassapa C, Trichopoulou A, Sieri S, **Palli D**, Tumino R, Vineis P, Panico S, van Gils CH, Peeters PH, Bueno-de-Mesquita HB, Buchner FL, Ljungberg B, Hallmans G, Berglund G, Wirfalt E, Pera G, Dorronsoro M, Gurrea AB, Navarro C, Martinez C, Quiros JR, Allen N, Roddam A, Bingham S, Jenab M, Slimani N, Norat T, Riboli E. Fruits and vegetables and renal cell carcinoma: findings from the European prospective investigation into cancer and nutrition (EPIC). *Int J Cancer*. 2006 Jun 15;118(12):3133-9. IF: **4,555**
58. Achilli A, Olivieri A, Pala M, Metspalu E, Fornarino S, Battaglia V, Accetturo M, Kutuev I, Khusnutdinova E, Pennarun E, Cerutti N, Di Gaetano C, Crobu F, **Palli D**, Matullo G, Santachiara-Benerecetti AS, Cavalli-Sforza LL, Semino O, Villems R, Bandelt HJ,

Piazza A, Torroni A. Mitochondrial DNA variation of modern Tuscans supports the near eastern origin of Etruscans. *Am J Hum Genet.* 2007 Apr;80(4):759-68. IF: **11,092**

59. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Rinaldi S, Egevad L, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjønneland A, Gronbaek H, Overvad K, Kiemeny L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Berrino F, Mattiello A, Sacerdote C, **Palli D**, Quiros JR, Ardanaz E, Navarro C, Larranaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Travezea C, Trichopoulos D, Jenab M, Ferrari P, Riboli E, Kaaks R. Serum Insulin-like Growth Factor (IGF)-I and IGF-Binding Protein-3 Concentrations and Prostate Cancer Risk: Results from the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev.* 2007 Jun;16(6):1121-1127. IF: **4,642**
60. Al-Zoughool M, Dossus L, Kaaks R, Clavel-Chapelon F, Tjønneland A, Olsen A, Overvad K, Boutron-Ruault MC, Gauthier E, Linseisen J, Chang-Claude J, Boeing H, Schulz M, Trichopoulou A, Chryssa T, Trichopoulos D, Berrino F, **Palli D**, Mattiello A, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Boshuizen HC, Peeters PH, Gram IT, Braaten T, Lund E, Chirlaque MD, Ardanaz E, Agudo A, Larrañaga N, Quirós JR, Berglund G, Manjer J, Lundin E, Hallmans G, Khaw KT, Bingham S, Allen N, Key T, Jenab M, Cust AE, Rinaldi S, Riboli E. Risk of endometrial cancer in relationship to cigarette smoking: Results from the EPIC study. *Int J Cancer.* 2007 Dec 15;121(12):2741-7. IF: **4,555**
61. Bamia C, Trichopoulos D, Ferrari P, Overvad K, Bjerregaard L, Tjønneland A, Halkjaer J, Clavel-Chapelon F, Kesse E, Boutron-Ruault MC, Boffetta P, Nagel G, Linseisen J, Boeing H, Hoffmann K, Kasapa C, Orfanou A, Travezea C, Slimani N, Norat T, **Palli D**, Pala V, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Waijers PM, Peeters PH, van der Schouw YT, Berenguer A, Martinez-Garcia C, Navarro C, Barricarte A, Dorronsoro M, Berglund G, Wirfalt E, Johansson I, Johansson G, Bingham S, Khaw KT, Spencer EA, Key T, Riboli E, Trichopoulou A. Dietary patterns and survival of older Europeans: the EPIC-Elderly Study (European Prospective Investigation into Cancer and Nutrition). *Public Health Nutr.* 2007 Jun;10(6):590-8. IF: **1,858**
62. Cammarota G, Masala G, Cianci R, **Palli D**, Capaccio P, Schindler A, Cuoco L, Galli J, Ierardi E, Cannizzaro O, Caselli M, Dore MP, Bendinelli B, Gasbarrini G. Reflux symptoms in professional opera choristers. *Gastroenterology.* 2007 Mar;132(3):890-8. IF: **11,673**
63. Carneiro F, Moutinho C, Pera G, Caldas C, Fenger C, Offerhaus J, Save V, Stenling R, Nesi G, Mahlke U, Blaker H, Torrado J, Roukos DH, Sabourin JC, Boeing H, **Palli D**, Bueno-de-Mesquita HB, Overvad K, Bingham S, Clavel-Chapelon F, Lund E, Trichopoulou A, Manjer J, Riboli E, Gonzalez CA. Pathology findings and validation of gastric and esophageal cancer cases in a European cohort (EPIC/EUR-GAST). *Scand J Gastroenterol.* 2007 May;42(5):618-27. IF: **1,758**
64. Chen YC, Kraft P, Bretsky P, Ketkar S, Hunter DJ, Albanes D, Altshuler D, Andriole G, Berg CD, Boeing H, Burt N, Bueno-de-Mesquita B, Cann H, Canzian F, Chanock S, Dunning A, Feigelson HS, Freedman M, Gaziano JM, Giovannucci E, Sánchez MJ, Haiman CA, Hallmans G, Hayes RB, Henderson BE, Hirschhorn J, Kaaks R, Key TJ, Kolonel LN, LeMarchand L, Ma J, Overvad K, **Palli D**, Pharaoh P, Pike M, Riboli E, Rodriguez C, Setiawan VW, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC,

Virtamo J, Trichopoulou A, Wacholder S, Weinstein SJ. Sequence variants of estrogen receptor beta and risk of prostate cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium. *Cancer Epidemiol Biomarkers Prev*. 2007 Oct;16(10):1973-81. IF: **4,642**

65. Cust AE, Allen NE, Rinaldi S, Dossus L, Friedenreich C, Olsen A, Tjønneland A, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Chang-Claude J, Boeing H, Schulz M, Benetou V, Trichopoulou A, Trichopoulos D, **Palli D**, Berrino F, Tumino R, Mattiello A, Vineis P, Quiros JR, Agudo A, Sanchez MJ, Larranaga N, Navarro C, Ardanaz E, Bueno-de-Mesquita HB, Peeters PH, van Gils CH, Bingham S, Khaw KT, Key T, Slimani N, Riboli E, Kaaks R. Serum levels of C-peptide, IGFBP-1 and IGFBP-2 and endometrial cancer risk; results from the European prospective investigation into cancer and nutrition. *Int J Cancer*. 2007 Jun 15;120(12):2656-64. IF: **4,555**
66. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, Rinaldi S, Dossus L, Slimani N, Lundin E, Tjønneland A, Olsen A, Overvad K, Clavel-Chapelon F, Mesrine S, Joulin V, Linseisen J, Rohrmann S, Pischon T, Boeing H, Trichopoulos D, Trichopoulou A, Benetou V, **Palli D**, Berrino F, Tumino R, Sacerdote C, Mattiello A, Quiros JR, Mendez MA, Sanchez MJ, Larranaga N, Tormo MJ, Ardanaz E, Bueno-de-Mesquita HB, Peeters PH, van Gils CH, Khaw KT, Bingham S, Allen N, Key T, Jenab M, Riboli E. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. *J Clin Endocrinol Metab*. 2007 Jan;92(1):255-63. IF: **5,493**
67. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Tjønneland A, Olsen A, Overvad K, Jakobsen MU, Chajès V, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Lukanova A, Boeing H, Pischon T, Trichopoulou A, Christina B, Trichopoulos D, **Palli D**, Berrino F, Panico S, Tumino R, Sacerdote C, Gram IT, Lund E, Quirós JR, Travier N, Martínez-García C, Larrañaga N, Chirlaque MD, Ardanaz E, Berglund G, Lundin E, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, Bingham S, Khaw KT, Allen N, Key T, Ferrari P, Rinaldi S, Slimani N, Riboli E. Metabolic syndrome, plasma lipid, lipoprotein and glucose levels, and endometrial cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocr Relat Cancer*. 2007 Sep;14(3):755-67. IF: **5,193**
68. Cust AE, Slimani N, Kaaks R, van Bakel M, Biessy C, Ferrari P, Laville M, Tjønneland A, Olsen A, Overvad K, Lajous M, Clavel-Chapelon F, Boutron-Ruault MC, Linseisen J, Rohrmann S, Nöthlings U, Boeing H, **Palli D**, Sieri S, Panico S, Tumino R, Sacerdote C, Skeie G, Engeset D, Gram IT, Quirós JR, Jakszyn P, Sánchez MJ, Larrañaga N, Navarro C, Ardanaz E, Wirfält E, Berglund G, Lundin E, Hallmans G, Bueno-de-Mesquita HB, Du H, Peeters PH, Bingham S, Khaw KT, Allen NE, Key TJ, Jenab M, Riboli E. Dietary carbohydrates, glycemic index, glycemic load, and endometrial cancer risk within the European Prospective Investigation into Cancer and Nutrition cohort. *Am J Epidemiol*. 2007 Oct 15;166(8):912-23. IF: **5,285**
69. Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S, Linseisen J, Rohrmann S, Boeing H, Pischon T, Tjønneland A, Halkjaer J, Overvad K, Mendez M, Redondo ML, Garcia CM, Larranaga N, Tormo MJ, Gurreea AB, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Vasilopoulou E, Trichopoulos D, Pala V, **Palli D**, Tumino R, Mattiello A, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Berglund G, Manjer J, Lundin E, Lukanova A, Slimani N, Jenab M,

- Kaaks R, Riboli E. Anthropometric factors and risk of endometrial cancer: the European prospective investigation into cancer and nutrition. *Cancer Causes Control*. 2007 May;18(4):399-413. IF: 3,279
70. Friedenreich C, Cust A, Lahmann PH, Steindorf K, Boutron-Ruault MC, Clavel-Chapelon F, Mesrine S, Linseisen J, Rohrmann S, Pischon T, Schulz M, Tjønneland A, Johnsen NF, Overvad K, Mendez M, Arguelles MV, Garcia CM, Larranaga N, Chirlaque MD, Ardanaz E, Bingham S, Khaw KT, Allen N, Key T, Trichopoulou A, Dilis V, Trichopoulos D, Pala V, **Palli D**, Tumino R, Panico S, Vineis P, Bueno-de-Mesquita HB, Peeters PH, Monninkhof E, Berglund G, Manjer J, Slimani N, Ferrari P, Kaaks R, Riboli E. Physical activity and risk of endometrial cancer: The European prospective investigation into cancer and nutrition. *Int J Cancer*. 2007 Jul 15;121(2):347-55. IF: 4,555
 71. Gacci M, Del Popolo G, Artibani W, Tubaro A, **Palli D**, Vittori G, Lapini A, Serni S, Carini M. Visual assessment of uroflowmetry curves: description and interpretation by urodynamicists. *World J Urol*. 2007 Jun;25(3):333-7. IF: 2,217
 72. Gensini F, Sestini R, Piazzini M, Vignoli M, Chiarugi A, Brandani P, Ghiorzo P, Salvini C, Borgognoni L, **Palli D**, Bianchi-Scarrà G, Carli P, Genuardi M. The p.G23S CDKN2A founder mutation in high-risk melanoma families from Central Italy. *Melanoma Res*. 2007 Dec;17(6):387-392. IF: 2,225
 73. Gerlini G, Urso C, Mariotti G, Di Gennaro P, **Palli D**, Brandani P, Salvadori A, Pimpinelli N, Reali UM, Borgognoni L. Plasmacytoid dendritic cells represent a major dendritic cell subset in sentinel lymph nodes of melanoma patients and accumulate in metastatic nodes. *Clin Immunol*. 2007 Nov;125(2):184-93. IF: 3,551
 74. Key TJ, Appleby PN, Allen NE, Travis RC, Roddam AW, Jenab M, Egevad L, Tjønneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, **Palli D**, Vineis P, Tumino R, Berrino F, Psaltopoulou T, Trichopoulou A, Trichopoulos D, **Palli D**, Vineis P, Tumino R, Berrino F, Kiemeny L, Bueno-de-Mesquita HB, Quirós JR, González CA, Martínez C, Larrañaga N, Chirlaque MD, Ardanaz E, Stattin P, Hallmans G, Khaw KT, Bingham S, Slimani N, Ferrari P, Rinaldi S, Riboli E. Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. *Am J Clin Nutr*. 2007 Sep;86(3):672-81. IF: 6,603
 75. Lahmann PH, Friedenreich C, Schuit AJ, Salvini S, Allen NE, Key TJ, Khaw KT, Bingham S, Peeters PH, Monninkhof E, Bueno-de-Mesquita HB, Wirfalt E, Manjer J, Gonzales CA, Ardanaz E, Amiano P, Quiros JR, Navarro C, Martinez C, Berrino F, **Palli D**, Tumino R, Panico S, Vineis P, Trichopoulou A, Bamia C, Trichopoulos D, Boeing H, Schulz M, Linseisen J, Chang-Claude J, Chapelon FC, Fournier A, Boutron-Ruault MC, Tjønneland A, Fons Johnson N, Overvad K, Kaaks R, Riboli E. Physical activity and breast cancer risk: the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev*. 2007 Jan;16(1):36-42. IF: 4,642
 76. Linseisen J, Rohrmann S, Miller AB, Bueno-de-Mesquita HB, Büchner FL, Vineis P, Agudo A, Gram IT, Janson L, Krogh V, Overvad K, Rasmuson T, Schulz M, Pischon T, Kaaks R, Nieters A, Allen NE, Key TJ, Bingham S, Khaw KT, Amiano P, Barricarte A, Martinez C, Navarro C, Quirós R, Clavel-Chapelon F, Boutron-Ruault MC, Touvier M, Peeters PH, Berglund G, Hallmans G, Lund E, **Palli D**, Panico S, Tumino R, Tjønneland

- A, Olsen A, Trichopoulou A, Trichopoulos D, Autier P, Boffetta P, Slimani N, Riboli E. Fruit and vegetable consumption and lung cancer risk: updated information from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Int J Cancer*. 2007 Sep 1;121(5):1103-14. IF: **4,555**
77. M A M, Pera G, Agudo A, Bueno-de-Mesquita HB, **Palli D**, Boeing H, Carneiro F, Berrino F, Sacerdote C, Tumino R, Panico S, Berglund G, Manjer J, Johansson I, Stenling R, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Allen N, Key TJ, Bingham S, Linseisen J, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Slimani N, Jenab M, Ferrari P, Riboli E, González CA. Cereal fiber intake may reduce risk of gastric adenocarcinomas: the EPIC-EURGAST study. *Int J Cancer*. 2007 Oct 1;121(7):1618-23. IF: **4,555**
 78. Manuguerra M, Matullo G, Veglia F, Autrup H, Dunning AM, Garte S, Gormally E, Malaveille C, Guarrera S, Polidoro S, Saletta F, Peluso M, Airoldi L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulos D, Kalandidi A, **Palli D**, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Pera G, Martinez C, Amiano P, Barricarte A, Tormo MJ, Quiros JR, Berglund G, Janzon L, Jarvholm B, Day NE, Allen NE, Saracci R, Kaaks R, Ferrari P, Riboli E, Vineis P. Multi-factor dimensionality reduction applied to a large prospective investigation on gene-gene and gene-environment interactions. *Carcinogenesis*. 2007 Feb;28(2):414-22. IF: **5,406**
 79. Masala G, Ceroti M, Pala V, Krogh V, Vineis P, Sacerdote C, Saieva C, Salvini S, Sieri S, Berrino F, Panico S, Mattiello A, Tumino R, Giurdanella MC, Bamia C, Trichopoulou A, Riboli E, **Palli D**. A dietary pattern rich in olive oil and raw vegetables is associated with lower mortality in Italian elderly subjects. *Br J Nutr*. 2007 Aug;98(2):406-15. IF: **2,339**
 80. Nagel G, Linseisen J, Boshuizen HC, Pera G, Del Giudice G, Westert GP, Bueno-de-Mesquita HB, Allen NE, Key TJ, Numans ME, Peeters PH, Sieri S, Siman H, Berglund G, Hallmans G, Stenling R, Martinez C, Arriola L, Barricarte A, Chirlaque MD, Quiros JR, Vineis P, Masala G, **Palli D**, Panico S, Tumino R, Bingham S, Boeing H, Bergmann MM, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Olsen A, Tjønneland A, Trichopoulou A, Bamia C, Soukara S, Sabourin JC, Carneiro F, Slimani N, Jenab M, Norat T, Riboli E, Gonzalez CA. Socioeconomic position and the risk of gastric and oesophageal cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Int J Epidemiol*. 2007 Feb;36(1):66-76. IF: **5,151**
 81. Nesi G, Bruno L, Saieva C, Caldini A, Girardi LR, Zanna I, Rapi S, Bechi P, Cortesini C, **Palli D**. DNA ploidy and S-phase fraction as prognostic factors in surgically resected gastric carcinoma: a 7-year prospective study. *Anticancer Res*. 2007 Nov-Dec;27(6C):4435-41. IF: **1,414**
 82. Norat T, Dossus L, Rinaldi S, Overvad K, Gronbaek H, Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Boeing H, Lahmann PH, Linseisen J, Nagel G, Trichopoulou A, Trichopoulos D, Kalapothaki V, Sieri S, **Palli D**, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Peeters PH, van Gils CH, Agudo A, Amiano P, Ardanoz E, Martinez C, Quiros R, Tormo MJ, Bingham S, Key TJ, Allen NE, Ferrari P, Slimani N, Riboli E, Kaaks R. Diet, serum insulin-like growth factor-I and IGF-binding

protein-3 in European women. *Eur J Clin Nutr.* 2007 Jan;61(1):91-98. IF: **2,326**

83. **Palli D**, Falchetti M, Masala G, Lupi R, Sera F, Saieva C, D'Amico C, Ceroti M, Rizzolo P, Caligo MA, Zanna I, Ottini L. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. *BMC Cancer.* 2007 Sep 3;7:170. IF: **2,709**
84. **Palli D**, Masala G, Del Giudice G, Plebani M, Basso D, Berti D, E Numans M, Ceroti M, Peeters PH, de Mesquita HB, Buchner FL, Clavel-Chapelon F, Boutron-Ruault MC, Krogh V, Saieva C, Vineis P, Panico S, Tumino R, Nyren O, Siman H, Berglund G, Hallmans G, Sanchez MJ, Larranaga N, Barricarte A, Navarro C, Quiros JR, Key T, Allen N, Bingham S, Khaw KT, Boeing H, Weikert C, Linseisen J, Nagel G, Overvad K, Thomsen RW, Tjonneland A, Olsen A, Trichoupoulou A, Trichopoulos D, Arvaniti A, Pera G, Kaaks R, Jenab M, Ferrari P, Nesi G, Carneiro F, Riboli E, Gonzalez CA. CagA+ *Helicobacter pylori* infection and gastric cancer risk in the EPIC-EURGAST study. *Int J Cancer.* 2007 Feb 15;120(4):859-67. IF: **4,555**
85. Peeters PH, Lukanova A, Allen N, Berrino F, Key T, Dossus L, Rinaldi S, van Gils CH, Bueno-de-Mesquita HB, Boeing H, Schulz M, Chang-Claude J, Linseisen J, Panico S, Sacerdote C, **Palli D**, Tumino R, Trichopoulou A, Trichopoulos D, Bamia C, Larranaga N, Ardanaz E, Pera G, Quiros JR, Martinez-Garcia C, Navarro C, Bingham SA, Khaw KT, Clavel F, Tjonneland A, Olsen A, Overvad K, Tetsche MS, Lund E, Lundin E, Berglund G, Riboli E, Kaaks R. Serum IGF-I, its major binding protein (IGFBP-3) and epithelial ovarian cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocr Relat Cancer.* 2007 Mar;14(1):81-90. IF: **5,193**
86. Peeters PH, Slimani N, van der Schouw YT, Grace PB, Navarro C, Tjonneland A, Olsen A, Clavel-Chapelon F, Touillaud M, Boutron-Ruault MC, Jenab M, Kaaks R, Linseisen J, Trichopoulou A, Trichopoulos D, Dilis V, Boeing H, Weikert C, Overvad K, Pala V, **Palli D**, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, van Gils CH, Skeie G, Jakszyn P, Hallmans G, Berglund G, Key TJ, Travis R, Riboli E, Bingham SA. Variations in plasma phytoestrogen concentrations in European adults. *J Nutr.* 2007 May;137(5):1294-300. IF: **3,771**
87. Rinaldi S, Dossus L, Lukanova A, Peeters PH, Allen NE, Key T, Bingham S, Khaw KT, Trichopoulos D, Trichopoulou A, Oikonomou E, Pera G, Larranaga N, Martinez-Garcia C, Ardanaz E, Quiros JR, Tormo MJ, Tjonneland A, Olsen A, Overvad K, Chang-Claude J, Linseisen J, Schulz M, Boeing H, van Gils CH, Bueno-de-Mesquita BH, Pala V, **Palli D**, Panico S, Tumino R, Vineis P, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC, Lundin E, Agren A, Berglund G, Manjer J, Kumle M, Lund E, Slimani N, Saracci R, Riboli E, Kaaks R. Endogenous Androgens and Risk of Epithelial Ovarian Cancer: Results from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Epidemiol Biomarkers Prev.* 2007 Jan;16(1):23-9. IF: **4,642**
88. Sacerdote C, Guarrera S, Smith GD, Grioni S, Krogh V, Masala G, Mattiello A, **Palli D**, Panico S, Tumino R, Veglia F, Matullo G, Vineis P. Lactase persistence and bitter taste response: instrumental variables and mendelian randomization in epidemiologic studies of dietary factors and cancer risk. *Am J Epidemiol.* 2007 Sep 1;166(5):576-81. IF: **5,285**
89. Schulz M, Nothlings U, Allen N, Onland-Moret NC, Agnoli C, Engeset D, Galasso R, Wirfalt E, Tjonneland A, Olsen A, Overvad K, Boutron-Ruault MC, Chajes V, Clavel-

- Chapelon F, Ray J, Hoffmann K, Chang-Claude J, Kaaks R, Trichopoulos D, Georgila C, Zourna P, **Palli D**, Berrino F, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita HB, Ocke MC, Peeters PH, Lund E, Gram IT, Skeie G, Berglund G, Lundin E, Hallmans G, Gonzalez CA, Quiros JR, Dorronsoro M, Martinez C, Tormo MJ, Barricarte A, Bingham S, Khaw KT, Key TJ, Jenab M, Rinaldi S, Slimani N, Riboli E. No association of consumption of animal foods with risk of ovarian cancer. *Cancer Epidemiol Biomarkers Prev.* 2007 Apr;16(4):852-5. IF: **4,642**
90. Setiawan VW, Schumacher FR, Haiman CA, Stram DO, Albanes D, Altshuler D, Berglund G, Buring J, Calle EE, Clavel-Chapelon F, Cox DG, Gaziano JM, Hankinson SE, Hayes RB, Henderson BE, Hirschhorn JN, Hoover R, Hunter DJ, Kaaks R, Kolonel LN, Kraft P, Ma J, Le Marchand L, Linseisen J, Lund E, Navarro C, Overvad K, **Palli D**, Peeters PH, Pike MC, Riboli E, Stampfer MJ, Thun MJ, Travis RC, Trichopoulos D, Yeager M, Ziegler RG, Feigelson HS, Chanock SJ. CYP17 Genetic Variation and Risk of Breast and Prostate Cancer from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3). *Cancer Epidemiol Biomarkers Prev.* 2007 Nov;16(11):2237-46. IF: **4,642**
91. Sinilnikova OM, McKay JD, Tavtigian SV, Canzian F, DeSilva D, Biessy C, Monnier S, Dossus L, Boillot C, Gioia L, Hughes DJ, Jensen MK, Overvad K, Tjonneland A, Olsen A, Clavel-Chapelon F, Chajes V, Joulin V, Linseisen J, Chang-Claude J, Boeing H, Dahm S, Trichopoulou A, Trichopoulos D, Koliava M, Khaw KT, Bingham S, Allen NE, Key T, **Palli D**, Panico S, Berrino F, Tumino R, Vineis P, Bueno-de-Mesquita HB, Peeters PH, van Gils CH, Lund E, Pera G, Quiros JR, Dorronsoro M, Martinez Garcia C, Tormo MJ, Ardanaz E, Hallmans G, Lenner P, Berglund G, Manjer J, Riboli E, Lenoir GM, Kaaks R. Haplotype-based analysis of common variation in the acetyl-coA carboxylase alpha gene and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev.* 2007 Mar;16(3):409-15. IF: **4,642**
92. Tjonneland A, Christensen J, Olsen A, Stripp C, Thomsen BL, Overvad K, Peeters PH, van Gils CH, Bueno-de-Mesquita HB, Ocke MC, Thiebaut A, Fournier A, Clavel-Chapelon F, Berrino F, **Palli D**, Tumino R, Panico S, Vineis P, Agudo A, Ardanaz E, Martinez-Garcia C, Amiano P, Navarro C, Quiros JR, Key TJ, Reeves G, Khaw KT, Bingham S, Trichopoulou A, Trichopoulos D, Naska A, Nagel G, Chang-Claude J, Boeing H, Lahmann PH, Manjer J, Wirfalt E, Hallmans G, Johansson I, Lund E, Skeie G, Hjartaker A, Ferrari P, Slimani N, Kaaks R, Riboli E. Alcohol intake and breast cancer risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes Control.* 2007 May;18(4):361-73. IF: **3,279**
93. Travis RC, Key TJ, Allen NE, Appleby PN, Roddam AW, Rinaldi S, Egevad L, Gann PH, Rohrmann S, Linseisen J, Pischon T, Boeing H, Johnsen NF, Tjonneland A, Overvad K, Kiemeny L, Bueno-de-Mesquita HB, Bingham S, Khaw KT, Tumino R, Sieri S, Vineis P, **Palli D**, Quiros JR, Ardanaz E, Chirlaque MD, Larrañaga N, Gonzalez C, Sanchez MJ, Trichopoulou A, Bikou C, Trichopoulos D, Stattin P, Jenab M, Ferrari P, Slimani N, Riboli E, Kaaks R. Serum androgens and prostate cancer among 643 cases and 643 controls in the European Prospective Investigation into Cancer and Nutrition. *Int J Cancer.* 2007 Sep 15;121(6):1331-8. IF: **4,555**
94. Veglia F, Vineis P, Overvad K, Boeing H, Bergmann MM, Trichopoulou A, Trichopoulos D, **Palli D**, Krogh V, Tumino R, Linseisen J, Steindorf K, Raaschou-Nielsen O,

- Tjønneland A, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Cirera L, Quiros JR, Day NE, Saracci R, Riboli E. Occupational Exposures, Environmental Tobacco Smoke, and Lung Cancer. *Epidemiology*. Nov;18(6):769-775. IF: 5,283
95. Vineis P, Veglia F, Garte S, Malaveille C, Matullo G, Dunning A, Peluso M, Airolidi L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen JP, Kaaks R, Boeing H, Trichopoulou A, **Palli D**, Crosignani P, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Berglund G, Jarvholm B, Day NE, Key TJ, Saracci R, Riboli E, Autrup H. Genetic susceptibility according to three metabolic pathways in cancers of the lung and bladder and in myeloid leukemias in nonsmokers. *Ann Oncol*. 2007 Jul;18(7):1230-42. IF: 4,875
 96. Vollset SE, Igland J, Jenab M, Fredriksen A, Meyer K, Eussen S, Gjessing HK, Ueland PM, Pera G, Sala N, Agudo A, Capella G, Del Giudice G, **Palli D**, Boeing H, Weikert C, Bueno-de-Mesquita HB, Carneiro F, Pala V, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Bingham S, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FL, Peeters PH, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Slimani N, Ferrari P, Riboli E, González CA. The association of gastric cancer risk with plasma folate, cobalamin, and methylenetetrahydrofolate reductase polymorphisms in the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev*. 2007 Nov;16(11):2416-24. IF: 4,642
 97. Allen NE, Appleby PN, Roddam AW, Tjønneland A, Johnsen NF, Overvad K, Boeing H, Weikert S, Kaaks R, Linseisen J, Trichopoulou A, Misirli G, Trichopoulos D, Sacerdote C, Grioni S, **Palli D**, Tumino R, Bueno-de-Mesquita HB, Kiemeny LA, Barricarte A, Larrañaga N, Sánchez MJ, Agudo A, Tormo MJ, Rodriguez L, Stattin P, Hallmans G, Bingham S, Khaw KT, Slimani N, Rinaldi S, Boffetta P, Riboli E, Key TJ; European Prospective Investigation into Cancer and Nutrition. Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). *Am J Clin Nutr*. 2008 Dec;88(6):1567-75. IF: 6,603
 98. Allen NE, Key TJ, Appleby PN, Travis RC, Roddam AW, Tjønneland A, Johnsen NF, Overvad K, Linseisen J, Rohrmann S, Boeing H, Pischon T, Bueno-de-Mesquita HB, Kiemeny L, Tagliabue G, **Palli D**, Vineis P, Tumino R, Trichopoulou A, Kassapa C, Trichopoulos D, Ardanaz E, Larrañaga N, Tormo MJ, González CA, Quirós JR, Sánchez MJ, Bingham S, Khaw KT, Manjer J, Berglund G, Stattin P, Hallmans G, Slimani N, Ferrari P, Rinaldi S, Riboli E. Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. *Br J Cancer*. 2008 May 6;98(9):1574-81. IF: 4,635
 99. Allen NE, Key TJ, Dossus L, Rinaldi S, Cust A, Lukanova A, Peeters PH, Onland-Moret NC, Lahmann PH, Berrino F, Panico S, Larrañaga N, Pera G, Tormo MJ, Sánchez MJ, Ramón Quirós J, Ardanaz E, Tjønneland A, Olsen A, Chang-Claude J, Linseisen J, Schulz M, Boeing H, Lundin E, **Palli D**, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Bingham S, Khaw KT, Bas Bueno-de-Mesquita H, Trichopoulou A, Trichopoulos D, Naska A, Tumino R, Riboli E, Kaaks R. Endogenous sex hormones and endometrial cancer risk in women in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Endocr Relat Cancer*. 2008 Jun;15(2):485-497. IF: 5,193

100. Breast and Prostate Cancer Cohort Consortium, Cox DG, Bretsky P, Kraft P, Pharoah P, Albanes D, Altshuler D, Amiano P, Berglund G, Boeing H, Buring J, Burt N, Calle EE, Canzian F, Chanock S, Clavel-Chapelon F, Colditz GA, Feigelson HS, Haiman CA, Hankinson SE, Hirschhorn J, Henderson BE, Hoover R, Hunter DJ, Kaaks R, Kolonel L, LeMarchand L, Lund E, **Palli D**, Peeters PH, Pike MC, Riboli E, Stram DO, Thun M, Tjønneland A, Travis RC, Trichopoulos D, Yeager M. Haplotypes of the estrogen receptor beta gene and breast cancer risk. *Int J Cancer*. 2008 Jan 15;122(2):387-92. IF: **4,555**
101. Capellá G, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, Plebani M, **Palli D**, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Berrino F, Vineis P, Tumino R, Panico S, Berglund G, Simán H, Nyrén O, Hallmans G, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key T, Bingham S, Caldas C, Linseisen J, Nagel G, Overvad K, Tjønneland A, Boshuizen HC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Kaaks R, Riboli E, González CA. DNA repair polymorphisms and the risk of stomach adenocarcinoma and severe chronic gastritis in the EPIC-EURGAST study. *Int J Epidemiol*. 2008 Dec;37(6):1316-25. IF: **5,151**
102. Crowe FL, Allen NE, Appleby PN, Overvad K, Aardestrup IV, Johnsen NF, Tjønneland A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Zavitsanou A, Trichopoulos D, Sacerdote C, **Palli D**, Tumino R, Agnoli C, Kiemeny LA, Bueno-de-Mesquita HB, Chirlaque MD, Ardanaz E, Larrañaga N, Quirós JR, Sánchez MJ, González CA, Stattin P, Hallmans G, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ. Fatty acid composition of plasma phospholipids and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr*. 2008 Nov;88(5):1353-63. IF: **6,603**
103. Crowe FL, Key TJ, Appleby PN, Travis RC, Overvad K, Jakobsen MU, Johnsen NF, Tjønneland A, Linseisen J, Rohrmann S, Boeing H, Pischon T, Trichopoulou A, Lagiou P, Trichopoulos D, Sacerdote C, **Palli D**, Tumino R, Krogh V, Bueno-de-Mesquita HB, Kiemeny LA, Chirlaque MD, Ardanaz E, Sánchez MJ, Larrañaga N, González CA, Quirós JR, Manjer J, Wirfält E, Stattin P, Hallmans G, Khaw KT, Bingham S, Ferrari P, Slimani N, Jenab M, Riboli E. Dietary fat intake and risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr*. 2008 May;87(5):1405-13. IF: **6,603**
104. Crusius JB, Canzian F, Capellá G, Peña AS, Pera G, Sala N, Agudo A, Rico F, Del Giudice G, **Palli D**, Plebani M, Boeing H, Bueno-de-Mesquita HB, Carneiro F, Pala V, Save VE, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen N, Key TJ, Bingham S, Caldas C, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Büchner FC, Peeters PH, Numans ME, Clavel-Chapelon F, Trichopoulou A, Lund E, Jenab M, Rinaldi S, Ferrari P, Riboli E, González CA. Cytokine gene polymorphisms and the risk of adenocarcinoma of the stomach in the European prospective investigation into cancer and nutrition (EPIC-EURGAST). *Ann Oncol*. 2008 Nov;19(11):1894-902. IF: **4,875**
105. Dossus L, McKay JD, Canzian F, Wilkening S, Rinaldi S, Biessy C, Olsen A, Tjønneland A, Jakobsen MU, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Fournier A, Linseisen J, Lukanova A, Boeing H, Fisher E, Trichopoulou A, Georgila C, Trichopoulos D, **Palli D**, Krogh V, Tumino R, Vineis P, Quirós JR, Sala N, Martínez-

- García C, Dorronsoro M, Chirlaque MD, Barricarte A, van Duijnhoven FJ, Bueno-de-Mesquita H, van Gils CH, Peeters PH, Hallmans G, Lenner P, Bingham S, Khaw KT, Key TJ, Travis RC, Ferrari P, Jenab M, Riboli E, Kaaks R. Polymorphisms of genes coding for ghrelin and its receptor in relation to anthropometry, circulating levels of IGF-I and IGFBP-3, and breast cancer risk: a case-control study nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). *Carcinogenesis*. 2008 Apr 11. [Epub ahead of print] IF: **5,406**
106. Falchetti M, Lupi R, Rizzolo P, Ceccarelli K, Zanna I, Calò V, Tommasi S, Masala G, Paradiso A, Gulino A, Giannini G, Russo A, **Palli D**, Ottini L. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases. *Breast Cancer Res Treat*. 2008 Jul;110(1):161-7. IF: **4,453**
 107. Falchetti M, Saieva C, Lupi R, Masala G, Rizzolo P, Zanna I, Ceccarelli K, Sera F, Mariani-Costantini R, Nesi G, **Palli D**, Ottini L. Gastric cancer with high-level microsatellite instability: target gene mutations, clinicopathologic features, and long-term survival. *Hum Pathol*. 2008 Jun;39(6):925-32. IF: **3,034**
 108. Gacci M, Lapini A, Serni S, Livi L, Paiar F, Detti B, Simontacchi G, Vittori G, Giubilei G, Mariani M, **Palli D**, Carini M. Predictors of quality of life after radical treatment for prostate cancer. *Urol Int*. 2008;80(3):231-6. IF: **0,82**
 109. Hart AR, Luben R, Olsen A, Tjønneland A, Linseisen J, Nagel G, Berglund G, Lindgren S, Grip O, Key T, Appleby P, Bergmann MM, Boeing H, Hallmans G, Danielsson A, Palmqvist R, Sjödin H, Hagglund G, Overvad K, **Palli D**, Masala G, Riboli E, Kennedy H, Welch A, Khaw KT, Day N, Bingham S. Diet in the aetiology of ulcerative colitis: a European prospective cohort study. *Digestion*. 2008;77(1):57-64. IF: **2,097**
 110. Jenab M, McKay JD, Ferrari P, Biessy C, Laing S, Capella Munar GM, Sala N, Peña S, Crusius JB, Overvad K, Jensen MK, Olsen A, Tjønneland A, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Linseisen J, Boeing H, Bergmann MM, Trichopoulou A, Georgila C, Psaltopoulou T, Mattiello A, Vineis P, Pala V, **Palli D**, Tumino R, Numans ME, Peeters PH, Bueno-de-Mesquita HB, Lund E, Ardanaz E, Sánchez MJ, Dorronsoro M, Navarro Sanchez C, Quirós JR, Hallmans G, Stenling R, Manjer J, Régner S, Key T, Bingham S, Khaw KT, Slimani N, Rinaldi S, Boffetta P, Carneiro F, Riboli E, Gonzalez C. CDH1 gene polymorphisms, smoking, Helicobacter pylori infection and the risk of gastric cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Eur J Cancer*. 2008 Apr;44(6):774-80. IF: **4,454**
 111. Johansson M, Appleby PN, Allen NE, Travis RC, Roddam AW, Egevad L, Jenab M, Rinaldi S, Kiemeny LA, Bueno-de-Mesquita HB, Vollset SE, Ueland PM, Sánchez MJ, Quirós JR, González CA, Larrañaga N, Chirlaque MD, Ardanaz E, Sieri S, **Palli D**, Vineis P, Tumino R, Linseisen J, Kaaks R, Boeing H, Pischon T, Psaltopoulou T, Trichopoulou A, Trichopoulos D, Khaw KT, Bingham S, Hallmans G, Riboli E, Stattin P, Key TJ. Circulating concentrations of folate and vitamin B12 in relation to prostate cancer risk: results from the European prospective investigation into cancer and nutrition study. *Cancer Epidemiol Biomarkers Prev*. 2008 Feb;17(2):279-85. IF: **4,642**
 112. Lumbreras B, Garte S, Overvad K, Tjønneland A, Clavel-Chapelon F, Linseisen JP, Boeing H, Trichopoulou A, **Palli D**, Peluso M, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Martinez C, Dorronsoro M, Barricarte A,

- Chirlaque MD, Quiros JR, Berglund G, Hallmans G, Day NE, Key TJ, Saracci R, Kaaks R, Malaveille C, Ferrari P, Boffetta P, Norat T, Riboli E, Gonzalez CA, Vineis P. Meat intake and bladder cancer in a prospective study: a role for heterocyclic aromatic amines? *Cancer Causes Control*. 2008 Aug;19(6):649-56. IF: **3,279**
113. Masala G, Bendinelli B, Versari D, Saieva C, Ceroti M, Santagiuliana F, Caini S, Salvini S, Sera F, Taddei S, Ghiadoni L, **Palli D**. Anthropometric and dietary determinants of blood pressure in over 7000 Mediterranean women: the European Prospective Investigation into Cancer and Nutrition-Florence cohort. *J Hypertens*. 2008 Nov;26(11):2112-20. IF: **4,364**
114. McKay JD, Hung RJ, Gaborieau V, Boffetta P, Chabrier A, Byrnes G, Zaridze D, Mukeria A, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D, Bencko V, Foretova L, Janout V, McLaughlin J, Shepherd F, Montpetit A, Narod S, Krokan HE, Skorpén F, Elvestad MB, Vatten L, Njølstad I, Axelsson T, Chen C, Goodman G, Barnett M, Loomis MM, Lubinski J, Matyjasik J, Lener M, Oszutowska D, Field J, Liloglou T, Xinarianos G, Cassidy A; EPIC Study, Vineis P, Clavel-Chapelon F, **Palli D**, Tumino R, Krogh V, Panico S, González CA, Ramón Quirós J, Martínez C, Navarro C, Ardanaz E, Larrañaga N, Kham KT, Key T, Bueno-de-Mesquita HB, Peeters PH, Trichopoulou A, Linseisen J, Boeing H, Hallmans G, Overvad K, Tjønneland A, Kumle M, Riboli E, Zelenika D, Boland A, Delepine M, Foglio M, Lechner D, Matsuda F, Blanche H, Gut I, Heath S, Lathrop M, Brennan P. Lung cancer susceptibility locus at 5p15.33. *Nat Genet*. 2008 Dec;40(12):1404-6. IF: **25,556**
115. Neasham D, Gallo V, Guarrera S, Dunning A, Overvad K, Tjønneland A, Clavel-Chapelon F, Linseisen JP, Malaveille C, Ferrari P, Boeing H, Benetou V, Trichopoulou A, **Palli D**, Crosignani P, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, van Gib CH, Lund E, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Berglund G, Jarvholm B, Khaw KT, Key TJ, Bingham S, Diaz TM, Riboli E, Matullo G, Vineis P. Double-strand break DNA repair genotype predictive of later mortality and cancer incidence in a cohort of non-smokers. *DNA Repair (Amst)*. 2009 Jan 1;8(1):60-71. IF: **4,018**
116. Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Gulino A, Giannini G, Bianchi S, Sera F, **Palli D**. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. *Breast Cancer Res Treat*. 2008 Sep 26. [Epub ahead of print] IF: **4,453**
117. **Palli D**, Saieva C, Munnia A, Peluso M, Grechi D, Zanna I, Caini S, Decarli A, Sera F, Masala G. DNA adducts and PM(10) exposure in traffic-exposed workers and urban residents from the EPIC-Florence City study. *Sci Total Environ*. 2008 Sep 15;403(1-3):105-12. IF: **2,182**
118. Peluso M, Airoidi L, Munnia A, Colombi A, Veglia F, Autrup H, Dunning A, Garte S, Gormally E, Malaveille C, Matullo G, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen J, Boeing H, Trichopoulou A, **Palli D**, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita BH, Peeters PH, Kumle M, Agudo A, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros JR, Berglund G, Jarvholm B, Day NE, Key TJ, Saracci R, Kaaks R, Riboli E, Bingham S, Vineis P. Bulky DNA adducts, 4-

aminobiphenyl-haemoglobin adducts and diet in the European Prospective Investigation into Cancer and Nutrition (EPIC) prospective study. *Br J Nutr.* 2008 Sep;100(3):489-95. IF: 2,339

119. Pischon T, Boeing H, Hoffmann K, Bergmann M, Schulze MB, Overvad K, van der Schouw YT, Spencer E, Moons KG, Tjønneland A, Halkjaer J, Jensen MK, Stegger J, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Linseisen J, Kaaks R, Trichopoulou A, Trichopoulos D, Bamia C, Sieri S, **Palli D**, Tumino R, Vineis P, Panico S, Peeters PH, May AM, Bueno-de-Mesquita HB, van Duijnhoven FJ, Hallmans G, Weinehall L, Manjer J, Hedblad B, Lund E, Agudo A, Arriola L, Barricarte A, Navarro C, Martinez C, Quirós JR, Key T, Bingham S, Khaw KT, Boffetta P, Jenab M, Ferrari P, Riboli E. General and abdominal adiposity and risk of death in Europe. *N Engl J Med.* 2008 Nov 13;359(20):2105-20. IF: 52,589
120. Pischon T, Boeing H, Weikert S, Allen N, Key T, Johnsen NF, Tjønneland A, Severinsen MT, Overvad K, Rohrmann S, Kaaks R, Trichopoulou A, Zoi G, Trichopoulos D, Pala V, **Palli D**, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, May A, Manjer J, Wallström P, Stattin P, Hallmans G, Buckland G, Larrañaga N, Chirlaque MD, Martínez C, Redondo Cornejo ML, Ardanaz E, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev.* 2008 Nov;17(11):3252-61. IF: 4,642
121. Rinaldi S, Rohrmann S, Jenab M, Biessy C, Sieri S, **Palli D**, Tumino R, Mattiello A, Vineis P, Nieters A, Linseisen J, Pischon T, Boeing H, Hallmans G, Palmqvist R, Manjer J, Wirfält E, Crowe FL, Khaw KT, Bingham S, Tjønneland A, Olsen A, Overvad K, Lund E, Skeie G, Clavel-Chapelon F, Boutron-Ruault MC, de Lauzon-Guillain B, Ardanaz E, Jakszyn P, Ramon Quiros J, Chirlaque MD, Sanchez MJ, Dorronsoro M, Trichopoulou A, Lagiou P, Trichopoulos D, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, Slimani N, Ferrari P, Byrnes GB, Riboli E, Kaaks R. Glycosylated hemoglobin and risk of colorectal cancer in men and women, the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev.* 2008 Nov;17(11):3108-15. IF: 4,642
122. Rohrmann S, Linseisen J, Key TJ, Jensen MK, Overvad K, Johnsen NF, Tjønneland A, Kaaks R, Bergmann MM, Weikert C, Naska A, Trichopoulou A, Trichopoulos D, Pala V, Sacerdote C, **Palli D**, Tumino R, Bueno-de-Mesquita HB, Vrieling A, González CA, Larrañaga N, Navarro C, Barricarte A, Quiros JR, Martínez-García C, Hallmans G, Stattin P, Manjer J, Wirfält E, Bingham S, Khaw KT, Egevad L, Ferrari P, Jenab M, Riboli E. Alcohol consumption and the risk for prostate cancer in the European prospective investigation into cancer and nutrition. *Cancer Epidemiol Biomarkers Prev.* 2008 May;17(5):1282-7. IF: 4,642
123. Rubio CA, Orrego A, Höög A, Porwitz A, Petersson F, Elmberger G, Glaessgen A, Eriksson E, Kanter L, Jaremko G, Egevad L, Laforga J, Liljefors M, Löfdahl B, Norman P, Larsson O, Wanat R, Wejde J, Zickert P, Björk J, Caini S, **Palli D**, Nesi G. Quantitative assessment of the subepithelial collagen band does not increase the accuracy of diagnosis of collagenous colitis. *Am J Clin Pathol.* 2008 Sep;130(3):375-81. IF: 2,629
124. Sieri S, Krogh V, Ferrari P, Berrino F, Pala V, Thiébaud AC, Tjønneland A, Olsen

- A, Overvad K, Jakobsen MU, Clavel-Chapelon F, Chajes V, Boutron-Ruault MC, Kaaks R, Linseisen J, Boeing H, Nöthlings U, Trichopoulou A, Naska A, Lagiou P, Panico S, **Palli D**, Vineis P, Tumino R, Lund E, Kumle M, Skeie G, González CA, Ardanaz E, Amiano P, Tormo MJ, Martínez-García C, Quirós JR, Berglund G, Gullberg B, Hallmans G, Lenner P, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, van Gils CH, Key TJ, Crowe FL, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Norat T, Riboli E. Dietary fat and breast cancer risk in the European Prospective Investigation into Cancer and Nutrition. *Am J Clin Nutr*. 2008 Nov;88(5):1304-12. IF: **6,603**
125. Vesper HW, Slimani N, Hallmans G, Tjønneland A, Agudo A, Benetou V, Bingham S, Boeing H, Boutron-Ruault MC, Bueno-de-Mesquita HB, Chirlaque D, Clavel-Chapelon F, Crowe F, Drogan D, Ferrari P, Johansson I, Kaaks R, Linseisen J, Lund E, Manjer J, Mattiello A, **Palli D**, Peeters PH, Rinaldi S, Skeie G, Trichopoulou A, Vineis P, Wirfalt E, Overvad K, Strömberg U. Cross-Sectional Study on Acrylamide Hemoglobin Adducts in Subpopulations from the European Prospective Investigation into Cancer and Nutrition (EPIC) Study. *J Agric Food Chem*. 2008 Aug 13;56(15):6046-53. IF: **2,532**
126. Weikert S, Boeing H, Pischon T, Weikert C, Olsen A, Tjønneland A, Overvad K, Becker N, Linseisen J, Trichopoulou A, Mountokalakis T, Trichopoulos D, Sieri S, **Palli D**, Vineis P, Panico S, Peeters PH, Bueno-de-Mesquita HB, Verschuren WM, Ljungberg B, Hallmans G, Berglund G, González CA, Dorronsoro M, Barricarte A, Tormo MJ, Allen N, Roddam A, Bingham S, Khaw KT, Rinaldi S, Ferrari P, Norat T, Riboli E. Blood Pressure and Risk of Renal Cell Carcinoma in the European Prospective Investigation into Cancer and Nutrition. *Am J Epidemiol*. 2007 Nov 29; [Epub ahead of print] IF: **5,285**
127. Ahn J, Schumacher F, Berndt SI, Pfeiffer R, Albanes D, Andriole GL, Ardanaz E, Boeing H, Bueno-de-Mesquita HB, Chanock SJ, Clavel-Chapelon F, Diver WR, Spencer Feigelson H, Graziano JM, Giovannucci E, Haiman CA, Henderson BE, Hoover RN, Kolonel LN, Kraft P, Ma J, Le Marchand L, Overvad K, **Palli D**, Stattin P, Stampfer M, Stram DO, Thomas G, Thun MJ, Travis RC, Trichopoulos D, Virtamo J, Weinstein SJ, Yeager M, Kaaks R, Hunter DJ, Hayes RB. Quantitative trait loci predicting circulating sex steroid hormones in men from the NCI-Breast and Prostate Cancer Cohort Consortium (BPC3). *Human Molecular Genetics*, 18: 3749-3757, 2009. (E-pub 02-07-09) IF: **7.806**
128. Allen NE, Roddam AW, Sieri S, Boeing H, Uhre Jakobsen M, Overvad K, Tjønneland A, Halkjaer J, Vineis P, Contiero P, **Palli D**, Tumino R, Mattiello A, Kaaks R, Rohrmann S, Trichopoulou A, Zilis D, Koumantaki Y, Peeters PH, Bueno-de-Mesquita HB, Barricarte A, Rodríguez L, Dorronsoro M, Sánchez MJ, Chirlaque MD, Esquius L, Manjer J, Wallström P, Ljungberg B, Hallmans G, Bingham S, Khaw KT, Boffetta P, Norat T, Mouw T, Riboli E. A prospective analysis of the association between macronutrient intake and Renal cell Carcinoma in the European Investigation into Cancer and Nutrition (EPIC). *International Journal of Cancer*, 125: 982-987, 2009. (E-pub 25-03-09) IF: **4.555**
129. Besson H, Ekelund U, Luan J, May AM, Sharp S, Travier N, Agudo A, Slimani N, Rinaldi S, Jenab M, Norat T, Mouw T, Rohrmann S, Kaaks R, Bergmann M, Boeing H,

- Clavel-Chapelon F, Boutron-Ruault MC, Overvad K, Andreasen EL, Johnsen NF, Halkjaer J, Gonzalez C, Rodriguez L, Sanchez MJ, Arriola L, Barricarte A, Navarro C, Key TJ, Spencer EA, Orfanos P, Naska A, Trichopoulou A, Manjer J, Wirfalt E, Lund E, **Palli D**, Agnoli C, Vineis P, Panico S, Tumino R, Bueno-de-Mesquita HB, van den Berg SW, Odysseos AD, Riboli E, Wareham NJ, Peeters PH. A cross-sectional analysis of physical activity and obesity indicators in European participants of the EPIC-PANACEA study. *International Journal of Obesity*, 33: 497-506, 2009. (E-pub 17-02-09) IF:3.56
130. Bianchi S, Caini S, Cattani MG, Vezzosi V, Biancalani M, **Palli D**. Diagnostic concordance in reporting breast needle core biopsies using the B classification: a panel in Italy. *Pathology and Oncology Research*, 15: 725-732, 2009. (E-pub 17-05-09) IF:1.272
131. Büchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, Raaschou-Nielsen O, Tjønneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Chang-Claude J, Kaaks R, Boeing H, Weikert S, Trichopoulou A, Lagiou P, Trichopoulos D, **Palli D**, Sieri S, Vineis P, Tumino R, Panico S, Vrieling A, Peeters PH, van Gils CH, Lund E, Gram IT, Engeset D, Martinez C, Gonzalez CA, Larrañaga N, Ardanaz E, Navarro C, Rodríguez L, Manjer J, Ehrnström RA, Hallmans G, Ljungberg B, Allen NE, Roddam AW, Bingham S, Khaw KT, Slimani N, Boffetta P, Jenab M, Mouw T, Michaud DS, Kiemeny LA, Riboli E. Consumption of vegetables and fruit and the risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. *International Journal of Cancer*, 125: 2643-2651, 2009. (E-pub 18-05-09) IF: 4.555
132. Buljse B, Feskens EJM, Forouhi NG, Wareham NJ, Sharp S, **Palli D**, Tognon G, Halkjaer J, Tjønneland A, Jakobsen MU, Overvad K, van der A D, Du H, Sørensen TIA, Boeing H. Fruit and vegetable intake and subsequent change in body weight in European populations: results from the project on Diet, Obesity, and Genes (DiOGenes). *American Journal of Clinical Nutrition*, 90: 202-209, 2009. (E-pub 20-05-09) IF:6.603
133. Campa D, McKay J, Sinilnikova O, Hüsing A, Vogel U, Hansen RD, Overvad K, Witt PM, Clavel-Chapelon F, Boutron-Ruault MC, Chajes V, Rohrmann S, Chang-Claude J, Boeing H, Fisher E, Trichopoulou A, Trichopoulos D, **Palli D**, Villarini A, Sacerdote C, Mattiello A, Tumino R, Peeters PH, van Gils CH, Bas Bueno-de-Mesquita H, Lund E, Chirlaque MD, Sala N, Suarez LR, Barricarte A, Dorronsoro M, Sánchez MJ, Lenner P, Hallmans G, Tsilidis K, Bingham S, Khaw KT, Gallo V, Norat T, Riboli E, Rinaldi S, Lenoir G, Tavtigian SV, Canzian F, Kaaks R. Genetic variation in genes of the fatty acid synthesis pathway and breast cancer risk. *Breast Cancer Research and Treatment*, 118: 565-573, 2009. (E-pub 29-02-09) IF:4.453
134. Canzian F, Kaaks R, Cox DG, Henderson KD, Henderson BE, Berg C, Bingham S, Boeing H, Buring J, Calle EE, Chanock SJ, Clavel-Chapelon F, Dossus L, Spencer Feigelson H, Haiman CA, Hankinson SE, Hoover R, Hunter DJ, Isaacs C, Lenner P, Lund E, Overvad K, **Palli D**, Pearce CL, Quiros JR, Riboli E, Stram DO, Thomas G, Thun MJ, Trichopoulos D, van Gils CH, Ziegler RG. Genetic polymorphisms of the GNRH1 and GNRHR genes and risk of breast cancer in the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3) *BMC Cancer* 2009, IF:9.257

135. Chiarugi A, Ceroti M, **Palli D**, Cevenini G, Guarrera M, Carli P. Sensitivity to UVB is a major risk factor for cutaneous melanoma in a Mediterranean population: results from an Italian case-control study. *Clinical and Experimental Dermatology*, 34:8-15, 2009. IF:1.522
136. Corre T, Schuettler J, Bione S, Marozzi A, Persani L, Rossetti R, Torricelli F, Giotti I, Vogt P, Toniolo D; Italian Network for the study of Ovarian Dysfunctions (Biondi M, Bruni V, Brigante C, Cisternino M, Colombo I, Crosignani PG, D'Avanzo MG, Dalprà L, Danesino C, Di Prospero F, Donti E, Falorni A, Fusi F, Lanzi R, Larizza D, Locatelli N, Madaschi S, Maghnie M, Marzotti S, Migone N, Nappi R, **Palli D**, Patricelli MG, Pisani C, Prontera P, Petraglia F, Renieri A, Ricca I, Ripamonti A, Russo G, Russo S, Tibiletti MG, Tonacchera M, Vegetti W, Villa N, Vineis P, Zuffardi O). A large-scale association study to assess the impact of known variants of the human INHA gene on premature ovarian failure. *Human Reproduction*, 24(8):2023-2028, 2009. (E-pub 29-04-09) IF:3.543
137. Crowe FL, Key TJ, Allen NE, Appleby PN, Roddam A, Overvad K, Grønbæk H, Tjønneland A, Halkjær J, Dossus L, Boeing H, Kröger J, Trichopolou A, Dillis V, Trichopoulos D, Butron-Ruault MC, De Lauzon B, Clavel-Chapelon F, **Palli D**, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Vrieling A, van Gils CH, Peeters PHM, Gram IT, Skeie G, Lund E, Suárez L, Jakšzyn P, Molina-Montes E, Tormo Díaz MJ, Barricarte Gurrea A, Larrañaga N, Khaw KT, Bingham S, Rinaldi S, Slimani N, Norat T, Gallo V, Riboli E, Kaaks R. The association between diet, BMI and serum concentrations of IGF-I and IGF-BPs in the European Prospective Investigation of Cancer and Nutrition (EPIC). *Cancer Epidemiology Biomarkers and Prevention*, 18: 1333-1340, 2009. IF: 4.642
138. De Marco L, Gillio-Tos A, Fiano V, Ronco G, Krogh V, **Palli D**, Panico S, Tumino R, Vineis P, Merletti F, Richiardi L, Sacerdote C. Occult HCV infection: an unexpected finding in a population unselected for hepatic disease. *PloS One*, 4(12): e8128, 2009. IF:5.91
139. D'Errico M, de Rinaldis E, Blasi MF, Viti V, Falchetti M, Calcagnile A, Sera F, Saieva C, Ottini L, **Palli D**, Palombo F, Giuliani A, Dogliotti E. Genome-wide expression profile of sporadic gastric cancers with microsatellite instability. *European Journal of Cancer*, 45: 461-469, 2009. (E-pub 08-12-08) IF: 4.454
140. Du H, van der A DL, van Bakel ME, Slimani N, Forouhi NG, Wareham NJ, Halkjær J, Tjønneland A, Jakobsen MU, Overvad K, Schulze MB, Buijsse B, Boeing H, **Palli D**, Masala G, Sørensen TIA, Saris WH, Feskens EJM. Dietary glycemic index, glycemic load and subsequent weight and waist gain in European men and women. *International Journal of Obesity*, 33: 1280-1208, 2009. (E-pub 25-08-09) IF:3.56
141. Forouhi NG, Sharp SJ, Du H, van der A DL, Halkjær J, Schulze MB, Tjønneland A, Overvad K, Jakobsen MU, Boeing H, Buijsse B, **Palli D**, Masala G, Feskens EJM, Sørensen TIA, Wareham NJ. Dietary fat intake and subsequent weight change in adults: results from the European Prospective Investigation of Cancer and Nutrition cohorts. *American Journal of Clinical Nutrition*, 90: 1632-1641, 2009. (E-pub 14-10-09)

142. Gacci M, Serni S, Lapini A, Vittori G, Nesi G, **Palli D**, Carini M. CXCR3-B Expression correlates with tumor necrosis extension in Renal Cell Carcinoma. *Journal of Urology*, 181: 843-848, 2009. (E-pub 17-12-08) IF: **4.053**
143. Gallo V, Bueno-de-Mesquita HB, Vermeulen R, Andersen P, Kyrozis A, Linseisen J, Kaaks R, Allen NE, Roddam AW, Boshuizen HC, Peeters PHM, **Palli D**, Mattiello A, Sieri S, Tumino R, Jiménez-Martín JM, Tormo Díaz MJ, Rodríguez Suarez L, Trichopoulou A, Agudo A, Arriola L, Barricante-Gurrea A, Bingham S, Khaw KT, Manjer J, Lindkvist B, Overvad K, Winther Bach F, Tjønneland A, Olsen A, Bergmann MM, Boeing H, Clavel-Chapelon F, Lund E, Hallmans G, Middleton L, Vineis P, Riboli E. Smoking and risk of Amyotrophic Lateral Sclerosis: analysis of the EPIC cohort. *Annals of Neurology*, 65: 378-385, 2009. IF:**8.813**
144. IBD in EPIC Study Investigators, Tjønneland A, Overvad K, Bergmann MM, Nagel G, Linseisen J, Hallmans G, Palmqvist R, Sjödin H, Hagglund G, Berglund G, Lindgren S, Grip O, **Palli D**, Day NE, Khaw KT, Bingham S, Riboli E, Kennedy H, Hart A. Linoleic acid, a dietary n-6 polyunsaturated fatty acid, and the aetiology of ulcerative colitis: a nested case-control study within a European prospective cohort study. *Gut*, 58:1606-1611, 2009. (E-pub 23-07-09) IF:**10.015**
145. Lahmann PH, Friedenreich C, Schulz M, Cust AE, Lukanova A, Kaaks R, Tjønneland A, Føns Johnsen N, Overvad K, Fournier A, Boutron Ruault MC, Clavel Chapelon F, Boeing H, Linseisen J, Rohrmann S, Trichopoulou A, Lagiou P, Trichopoulos D, **Palli D**, Mattiello A, Sacerdote C, Agnoli C, Tumino R, Quiros JR, Larrañaga N, Agudo AT, Sánchez MJ, Berglund G, Manjer J, Monninkhof EM, Peeters PHM, Bueno- de-Mesquita HB, Key TJ, Kaw KT, Bingham S, Rinaldi S, Ferrari P, Riboli E. Physical Activity and Ovarian Cancer Risk: the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Epidemiology Biomarkers and Prevention*, 18: 351-354, 2009. IF: **4.642**
146. Lynch SM, Vrieling A, Lubin JH, Kraft P, Mendelsohn JB, Hartge P, Canzian F, Steplowski E, Arslan AA, Gross M, Helzlsouer K, Jacobs EJ, Lacroix A, Petersen G, Zheng W, Albanes D, Amundadottir L, Bingham SA, Boffetta P, Boutron-Ruault MC, Chanock SJ, Clipp S, Hoover RN, Jacobs K, Johnson KC, Kooperberg C, Luo J, Messina C, **Palli D**, Patel AV, Riboli E, Shu XO, Rodríguez Suarez L, Thomas G, Tjønneland A, Tobias GS, Tong E, Trichopoulos D, Virtamo J, Ye W, Yu K, Zeleniuch-Jacquette A, Bueno-de-Mesquita HB, Stolzenberg-Solomon RZ. Cigarette Smoking and Pancreatic Cancer: A Pooled Analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *American Journal of Epidemiology*, 170: 403-413, 2009. (E-pub 26-06-09) IF:**5.285**
147. Marcon F, **Palli D**, Mazzoli E, Siniscalchi, Sera F, Saieva C, Crebelli R. Evaluation of radiation-induced chromosome instability in subjects with family history of gastric cancer. *Biomarkers*, 14: 226-234, 2009. IF:**1.978**
148. Masala G, Assedi M, Ambrogetti D, Sera F, Salvini S, Bendinelli B, Ermini I, Giorgi D, Rosselli del Turco M, **Palli D**. Physical activity and mammographic breast density in a Mediterranean population: the EPIC Florence Longitudinal Study. *International Journal of Cancer*, 124: 1654-1661, 2009. (E-pub 22-10-08) IF:**4.555**

149. Menvielle G, Boshuizen H, Kunst AE, Dalton SO, Vineis P, Bergmann MM, Hermann S, Ferrari P, Raaschou-Nielsen O, Tjønneland A, Kaaks R, Linseisen J, Costi M, Trichopoulou A, Vardis D, **Palli D**, Krogh V, Panico S, Tumino R, Büchner FL, van Gils C, Peeters PHM, Braaten T, Gram I, Lund E, Agudo A, Sanchez MJ, Tormo M, Ardanaz E, Manjer J, Wirfalt E, Hallmans G, Rasmusson T, Bingham S, Khaw KT, Allen N, Key T, Boffetta P, Duell E, Slimani N, Gallo V, Riboli E, Bueno-de-Mesquita HB. Educational inequalities in lung cancer incidence: does tobacco consumption explain them all? *Journal of the National Cancer Institute*, 101: 321-330, 2009. IF:15.678
150. Neasham D, Gallo V, Guarrera S, Dunning A, Overvad K, Tjønneland A, Clavel-Chapelon F, Linseisen JP, Malaveille C, Ferrari P, Boeing H, Benetou V, Trichopoulou A, **Palli D**, Crosignani P, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, van Gib CH, Lund E, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Navarro C, Quiros JR, Berglund G, Jarvholm B, Khaw KT, Key TJ, Bingham S, Diaz TM, Riboli E, Matullo G, Vineis P. Double-strand break DNA repair genotype predictive of later mortality and cancer incidence in a cohort of non-smokers. *DNA Repair*, 8: 60-71, 2009. (E-pub 27-09-08) IF:4.018
151. Ottini L, Rizzolo P, Zanna I, Falchetti M, Masala G, Ceccarelli K, Vezzosi V, Lupi R, Gulino A, Giannini G, Bianchi S, Sera F, **Palli D**. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in Central Italy. *Breast Cancer Research and Treatment*, 16: 577-586, 2009. (E-pub 26-09-08) IF:4.453
152. **Palli D**, Sera F, Giovannelli L, Masala G, Grechi D, Bendinelli B, Caini S, Dolara P, Saieva C. Environmental ozone exposure and oxidative DNA damage in adult residents of Florence, Italy. *Environmental Pollution*, 157 : 1521-1525, 2009. (E-pub 26-10-08) IF:3.135
153. Papi L, **Palli D**, Putignano AL, Congregati C, Zanna I, Marini F, Giusti F, Luzi E, Tonelli F, Genuardi M, Brandi ML, Falchetti A. Germline mutations in MEN1 and BRCA1 genes in a woman with familial Multiple Endocrine Neoplasia type 1 and inherited breast/ovarian cancer syndromes: a case report. *Cancer Genetics and Cytogenetics*, 195: 75-79, 2009. IF: 1.559
154. Papi L, Putignano AL, Congregati C, Zanna I, Sera F, Morrone D, Falchetti M, Ottini L, Rosselli del Turco M, **Palli D**, Genuardi M. Founder mutations account for the majority of BRCA1-attributable hereditary breast/ovarian cancer cases in a population from Tuscany, Central Italy. *Breast Cancer Research and Treatment*, 117: 497-504, 2009. (E-pub 27-09-08) IF: 4.453
155. Rohrmann S, Linseisen J, Vrieling A, Boffetta P, Stolzenberg-Solomon RZ, Lowenfels AB, Jensen MK, Overvad K, Olsen A, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Fagherazzi G, Gesthimani M, Pagona L, Trichopoulou A, Kaaks R, Bergmann MM, Boeing H, Bingham S, Khaw KT, Allen N, Roddam A, **Palli D**, Pala V, Panico S, Tumino R, Vineis P, Peeters PH, Hjartåker A, Lund E, Cornejo ML, Agudo A, Arriola L, Sánchez MJ, Tormo MJ, Barricarte Gurrea A, Lindkvist B, Manjer J,

- Johansson I, Ye W, Slimani N, Duell EJ, Jenab M, Michaud DS, Mouw T, Riboli E, Bueno-de-Mesquita HB. Ethanol intake and the risk of pancreatic cancer in the European prospective investigation into cancer and nutrition (EPIC). *Cancer Causes and Control*, 20:785-794, 2009. (E-pub 16-01-09) IF: **3.279**
156. Romaguera D, Norat T, Mouw T, May AM, Bamia C, Slimani N, Travier N, Besson H, Luan J, Wareham N, Rinaldi S, Couto E, Clavel-Chapelon F, Boutron-Ruault MC, Cottet V, **Palli D**, Agnoli C, Panico S, Tumino R, Vineis P, Agudo A, Rodriguez L, Sanchez MJ, Amiano P, Barricarte A, Huerta JM, Key T, Spencer EA, Bueno de Mesquita HB, Büchner FL, Orfanos P, Naska A, Trichopoulou A, Rohrmann S, Kaaks R, Bergmann M, Boeing H, Johansson I, Hellstrom V, Manjer J, Wirfält E, Uhre Jacobsen M, Overvad K, Tjønneland A, Halkjaer J, Lund E, Braaten T, Engeset D, Odysseos A, Riboli E, Peeters PHM. Adherence to the Mediterranean diet is associated with lower abdominal adiposity in European men and women. *Journal of Nutrition*, 139: 1728-1737, 2009. (E-pub 01-07-09) IF: **3.771**
157. Rubio CA, Höög CM, Broström O, Gustavsson J, Karlsson M, Moritz P, Stig R, Wikman O, Mattsson L, **Palli D**. Assessing the size of polyp phantoms in tandem colonoscopies. *Anticancer Research*, 29(5):1539-1545, 2009. IF: **1.414**
158. Saadatian-Elahi M, Slimani N, Chajès V, Jenab M, Goudable J, Biessy C, Ferrari P, Byrnes G, Autier P, Peeters PH, Ocké M, Bueno de Mesquita B, Johansson I, Hallmans G, Manjer J, Wirfält E, González CA, Navarro C, Martinez C, Amiano P, Suárez LR, Ardanaz E, Tjønneland A, Halkjaer J, Overvad K, Jakobsen MU, Berrino F, Pala V, **Palli D**, Tumino R, Vineis P, de Magistris MS, Spencer EA, Crowe FL, Bingham S, Khaw KT, Linseisen J, Rohrmann S, Boeing H, Noethlings U, Olsen KS, Skeie G, Lund E, Trichopoulou A, Oustoglou E, Clavel-Chapelon F, Riboli E. Plasma phospholipid fatty acid profiles and their association with food intakes: results from a cross-sectional study within the European Prospective Investigation into Cancer and Nutrition. *American Journal of Clinical Nutrition*, 8: 331-346, 2009. (E-pub 03-12-08) IF: **6.603**
159. Simonelli V, D'Errico M, **Palli D**, Prasad R, Wilson SH, Dogliotti E. Characterization of DNA polymerase β splicing variants in gastric cancer: the most frequent exon 2-deleted isoform is a non coding RNA. *Mutation Research*, 670: 79-87, 2009. (E-pub 24-07-09) *Fundamental and Molecular Mechanisms of Mutagenesis* IF: **4.159**
160. Steffen A, Schulze MB, Pischon T, Dietrich T, Molina E, Chirlaque MD, Barricarte A, Amiano P, Quirós JR, Tumino R, Mattiello A, **Palli D**, Vineis P, Agnoli C, Misirli G, Boffetta P, Kaaks R, Rohrmann S, Bueno-de-Mesquita HB, Peeters PHM, May AM, Spencer E, Allen NE, Bingham S, Tjønneland A, Halkjaer J, Overvad K, Stegger J, Manjer J, Lindkvist B, Hallmans G, Stenling R, Lund E, Riboli E, Gonzalez CA, Boeing H. Anthropometry and esophageal cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Epidemiology Biomarkers and Prevention*, 18: 2079-2089, 2009. (E-pub 30-06-09) IF: **4.642**
161. Suzuki R, Allen NE, Key TJ, Appleby PN, Tjønneland A, Johnsen NF, Jensen MK, Overvad K, Boeing H, Pischon T, Kaaks R, Rohrmann S, Trichopoulou A, Misirli G, Trichopoulos D, Bueno-de-Mesquita HB, van Duijnhoven F, Sacerdote C, Pala V, **Palli D**, Tumino R, Ardanaz E, Quirós JR, Larrañaga N, Sánchez MJ, Tormo MJ, Jakszyn P,

- Johansson I, Stattin P, Berglund G, Manjer J, Bingham S, Khaw KT, Egevad L, Ferrari P, Jenab M, Riboli E. A prospective analysis of the association between dietary fiber intake and prostate cancer risk in EPIC. *International Journal of Cancer*, 124: 245-249, 2009. (E-pub 23-09-08) IF: **4.555**
162. Suzuki R, Allen NE, Appleby PN, Key TJ, Dossus L, Tjønneland A, Føns Johnsen N, Overvad K, Sacerdote C, **Palli D**, Krogh V, Tumino R, Rohrmann S, Linseisen J, Boeing H, Trichopoulou A, Makrygiannis G, Misirli G, Bueno-de-Mesquita HB, May AM, Díaz MJ, Sánchez MJ, Barricarte Gurrea A, Rodríguez Suárez L, Buckland G, Larrañaga N, Bingham S, Khaw KT, Rinaldi S, Slimani N, Jenab M, Riboli E, Kaaks R. Lifestyle factors and serum androgens among 636 middle aged men from seven countries in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes and Control*, 20:811-812, 2009. (E-pub 21-03-09) IF:**3.279**
163. Travier N, Agudo A, May AM, Gonzalez C, Luan J, Besson H, Wareham NJ, Slimani N, Rinaldi S, Clavel-Chapelon F, Boutron-Ruault MC, **Palli D**, Agnoli C, Mattiello A, Tumino R, Vineis P, Rodriguez L, Sanchez MJ, Dorronsoro M, Barricarte A, Tormo MJ, Norat T, Mouw T, Key TJ, Spencer EA, Bueno-de-Mesquita B, Vrieling A, Orfanos P, Naska A, Trichopoulou A, Rohrmann S, Kaaks R, Bergmann M, Boeing H, Hallmans G, Johansson I, Manjer J, Lindkvist B, Jakobsen MU, Overvad K, Tjønneland A, Halkjaer J, Lund E, Braaten T, Odysseos A, Riboli E, Peeters PH. Smoking and body fatness measurements: A cross sectional analysis in the EPIC-PANACEA study. *Preventive Medicine*, 49: 365-373, 2009. (E-pub 26-08-09) IF:**2.314**
164. Travis RC, Crowe FL, Allen NE, Appleby PN, Roddam AW, Tjønneland A, Olsen A, Linseisen J, Kaaks R, Boeing H, Kröger J, Trichopoulou A, Dilis V, Trichopoulos D, Vineis P, **Palli D**, Tumino R, Sieri S, Bueno-de-Mesquita HB, van Duijnhoven FJ, Chirlaque MD, Barricarte A, Larrañaga N, González CA, Argüelles MV, Sánchez MJ, Stattin P, Hallmans G, Khaw KT, Bingham S, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ. Serum Vitamin D and Risk of Prostate Cancer in a Case-Control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). *American Journal of Epidemiology*, 69:1223-1232, 2009. (E-pub 09-04-2009) IF:**5.285**
165. Travis RC, Spencer EA, Allen NE, Appleby PN, Roddam AW, Overvad K, Johnsen NF, Olsen A, Kaaks R, Linseisen J, Boeing H, Nöthlings U, Bueno-de-Mesquita HB, Ros MM, Sacerdote C, **Palli D**, Tumino R, Berrino F, Trichopoulou A, Dilis V, Trichopoulos D, Chirlaque MD, Ardanaz E, Larranaga N, Gonzalez C, Suárez LR, Sánchez MJ, Bingham S, Khaw KT, Hallmans G, Stattin P, Rinaldi S, Slimani N, Jenab M, Riboli E, Key TJ. Plasma phyto-oestrogens and prostate cancer in the European Prospective Investigation into Cancer and Nutrition. *British Journal of Cancer*, 100: 1817-1823, 2009. (E-pub 12-05-09) IF:**4.635**
166. van Duijnhoven FJ, Bueno-De-Mesquita HB, Ferrari P, Jenab M, Boshuizen HC, Ros MM, Casagrande C, Tjønneland A, Olsen A, Overvad K, Thorlacius-Ussing O, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Kaaks R, Linseisen J, Boeing H, Nöthlings U, Trichopoulou A, Trichopoulos D, Misirli G, **Palli D**, Sieri S, Panico S, Tumino R, Vineis P, Peeters PH, van Gils CH, Ocké MC, Lund E, Engeset D, Skeie G, Suárez LR, González CA, Sánchez MJ, Dorronsoro M, Navarro C, Barricarte A, Berglund G, Manjer J, Hallmans G, Palmqvist R, Bingham SA, Khaw KT, Key TJ, Allen NE, Boffetta P, Slimani N, Rinaldi S, Gallo V, Norat T, Riboli E. Fruit, vegetables and

colorectal cancer risk: the European Prospective Investigation into Cancer and Nutrition. American Journal of Clinical Nutrition, 89:1441-52, 2009.(E-pub 01-04-09) IF:6.603

167. Vannucchi AM, Masala G, Antonioli E, Susini MC, Guglielmelli P, Pieri L, Maggi L, Caini S, **Palli D**, Bogani C, Ponziani V, Pancrazzi A, Annunziato F, Bosi A. Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. Cancer Epidemiology Biomarkers and Prevention, , 18: 2068-2073, 2009. (E-pub16-06-09) IF:4.642
168. Vrieling A, Verhag BAJ, van Duijnhoven FJB, Jenab M, Overvad K, Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Rohrmann S, Boeing H, Nöthlings U, Trichopoulou A, Tountas J, Zilis D, **Palli D**, Sieri S, Mattiello A, Tumino R, Vineis P, van Gils CH, Peeters PHM, Engeset D, Lund E, Rodríguez Suárez L, Jakszyn P, Larrañaga N, Sánchez MJ, Chirlaque MD, Ardanaz E, Manjer J, Lindkvist B, Hallmans G, Ye W, Bingham S, Khaw KT, Roddam A, Key T, Boffetta P, Duell EJ, Michaud DS, Riboli E, Bueno-de-Mesquita HB. Fruit and vegetable consumption and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC). International Journal of Cancer, 124: 1926-1934, 2009.(E-pub 07-11-08) IF:4.555
169. Weikert C, Dietrich T, Boeing H, Bergmann MM, Boutron-Ruault MC, Clavel-Chapelon F, Allen N, Key T, Lund E, Olsen A, Tjønneland A, Overvad K, Rohrmann S, Linseisen J, Pischon T, Trichopoulou A, Weinehall L, Johansson I, Sánchez MJ, Agudo A, Barricarte A, Amiano P, Chirlaque MD, Quirós JR, Wirfalt E, Peeters PH, Bueno-de-Mesquita HB, Vrieling A, Pala V, **Palli D**, Vineis P, Tumino R, Panico S, Bingham S, Khaw KT, Norat T, Jenab M, Ferrari P, Slimani N, Riboli E. Lifetime and baseline alcohol intake and risk of cancer of the Upper Aero-Digestive Tract in the European Investigation into Cancer and Nutrition (EPIC) study. International Journal of Cancer, 125:406-412, 2009. (E-pub 23-02-09) IF: 4.555
170. Aleksandrova K, Jenab M, Boeing H, Jansen E, Bueno-de-Mesquita HB, Rinaldi S, Riboli E, Overvad K, Dahm CC, Olsen A, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, **Palli D**, Krogh V, Tumino R, Vineis P, Panico S, Kaaks R, Rohrmann S, Trichopoulou A, Lagiou P, Trichopoulos D, van Duijnhoven FJ, Leufkens AM, Peeters PH, Rodríguez L, Bonet C, Sánchez MJ, Dorronsoro M, Navarro C, Barricarte A, Palmqvist R, Hallmans G, Khaw KT, Wareham N, Allen NE, Spencer E, Romaguera D, Norat T, Pischon T. Circulating C-Reactive Protein Concentrations and Risks of Colon and Rectal Cancer: A Nested Case-Control Study Within the European Prospective Investigation into Cancer and Nutrition. American Journal of Epidemiology, 172: 407-418, 2010. (E-pub 15-07-10) IF:5.285
171. Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, Fuchs CS, Gross MD, Jacobs EJ, Lacroix AZ, Petersen GM, Stolzenberg-Solomon RZ, Zheng W, Albanes D, Amundadottir L, Bamlet WR, Barricarte A, Bingham SA, Boeing H, Boutron-Ruault MC, Buring JE, Chanock SJ, Clipp S, Gaziano JM, Giovannucci EL, Hankinson SE, Hartge P, Hoover RN, Hunter DJ, Hutchinson A, Jacobs KB, Kraft P, Lynch SM, Manjer J, Manson JE, McTiernan A, McWilliams RR, Mendelsohn JB, Michaud DS, **Palli D**, Rohan TE, Slimani N, Thomas G, Tjønneland A, Tobias GS, Trichopoulos D, Virtamo J, Wolpin BM, Yu K, Zeleniuch-Jacquotte A, Patel AV; Pancreatic Cancer Cohort Consortium (PanScan). Anthropometric measures, body

- mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *Archives of Internal Medicine*, 170:791-802, 2010. IF:8.391
172. Boffetta P, Couto E, Wichmann J, Ferrari P, Trichopoulos D, Bueno-de-Mesquita HB, van Duynhoven FJ, Büchner FL, Key T, Boeing H, Nöthlings U, Linseisen J, Gonzalez CA, Overvad K, Nielsen MR, Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Laggiou P, Naska A, Benetou V, Kaaks R, Rohrmann S, Panico S, Sieri S, Vineis P, **Palli D**, van Gils CH, Peeters PH, Lund E, Brustad M, Engeset D, Huerta JM, Rodríguez L, Sánchez MJ, Dorronsoro M, Barricarte A, Hallmans G, Johansson I, Manjer J, Sonestedt E, Allen NE, Bingham S, Khaw KT, Slimani N, Jenab M, Mouw T, Norat T, Riboli E, Trichopoulou A. Fruit and Vegetable Intake and Overall Cancer Risk in the European Prospective Investigation Into Cancer and Nutrition (EPIC). *Journal of National Cancer Institute*, 102: 529-537, 2010. (E-pub 06-04-2010) IF:15.678
 173. Büchner FL, Bueno-de-Mesquita HB, Linseisen J, Boshuizen HC, Kiemeny LA, Ros MM, Overvad K, Hansen L, Tjønneland A, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Kaaks R, Rohrmann S, Boeing H, Nöthlings U, Trichopoulou A, Zylis D, Dilis V, **Palli D**, Sieri S, Vineis P, Tumino R, Panico S, Peeters PH, van Gils CH, Lund E, Gram IT, Braaten T, Martinez C, Agudo A, Arriola L, Ardanaz E, Navarro C, Rodríguez L, Manjer J, Wirfält E, Hallmans G, Rasmuson T, Key TJ, Roddam AW, Bingham S, Khaw KT, Slimani N, Boffetta P, Byrnes G, Norat T, Michaud D, Riboli E. Fruits and vegetables consumption and the risk of histological subtypes of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Causes and Control*, 21: 357-371, 2010. (E-pub 19-11-09) IF:3.279
 174. Büchner FL, Bueno-de-Mesquita HB, Ros MM, Overvad K, Dahm CC, Hansen L, Tjønneland A, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Kaaks R, Rohrmann S, Boeing H, Nöthlings U, Trichopoulou A, Zylis D, Dilis V, **Palli D**, Sieri S, Vineis P, Tumino R, Panico S, Peeters PH, van Gils CH, Lund E, Gram IT, Braaten T, Sánchez MJ, Agudo A, Larrañaga N, Ardanaz E, Navarro C, Argüelles MV, Manjer J, Wirfält E, Hallmans G, Rasmuson T, Key TJ, Khaw KT, Wareham N, Slimani N, Vergnaud AC, Xun WW, Kiemeny LA, Riboli E. Variety in fruit and vegetable consumption and the risk of lung cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Epidemiology Biomarkers and Prevention*, 19:2278-2286, 2010. (E-pub 31-08-10) IF:4.642
 175. Buckland G, Agudo A, Luján L, Jakszyn P, Bueno-de-Mesquita HB, **Palli D**, Boeing H, Carneiro F, Krogh V, Sacerdote C, Tumino R, Panico S, Nesi G, Manjer J, Regnér S, Johansson I, Stenling R, Sanchez MJ, Dorronsoro M, Barricarte A, Navarro C, Quirós JR, Allen NE, Key TJ, Bingham S, Kaaks R, Overvad K, Jensen M, Olsen A, Tjønneland A, Peeters PH, Numans ME, Ocké MC, Clavel-Chapelon F, Morois S, Boutron-Ruault MC, Trichopoulou A, Laggiou P, Trichopoulos D, Lund E, Couto E, Boffetta P, Jenab M, Riboli E, Romaguera D, Mouw T, González CA. Adherence to a Mediterranean diet and risk of gastric adenocarcinoma within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort study. *American Journal of Clinical Nutrition*, 91: 381-390, 2010. (E-pub 17-12-09) IF:6.603
 176. Cammarota G, Masala G, Cianci R, **Palli D**, Bendinelli B, Galli J, Pandolfi F,

Gasbarrini A, Landolfi R. Reflux symptoms in wind instrument players. *Alimentary Pharmacology & Therapeutics*, 31: 593-600, 2010. (E-pub 2-12-09) IF:3.201

177. Dossus L, Allen N, Kaaks R, Bakken K, Lund E, Tjønneland A, Olsen A, Overvad K, Clavel-Chapelon F, Fournier A, Chabbert-Buffet N, Boeing H, Schütze M, Trichopoulou A, Trichopoulos D, Lagiou P, **Palli D**, Krogh V, Tumino R, Vineis P, Mattiello A, Bueno-de-Mesquita HB, Onland-Moret NC, Peeters PHM, Dumeaux V, Redondo ML, Duell E, Sanchez-Cantalejo E, Arriola L, Chirlaque MD, Ardanaz E, Manjer J, Borgquist S, Lukanova A, Lundin E, Khaw KT, Wareham N, Key T, Chajes V, Rinaldi S, Slimani N, Mouw T, Gallo V, Riboli E. Reproductive risk factors and endometrial cancer: The European Prospective Investigation into Cancer and nutrition. *International Journal of Cancer*, 127: 442-451, 2010. (E-pub 18-11-09) IF:4.555
178. Dossus L, Rinaldi S, Becker S, Lukanova A, Tjønneland A, Olsen A, Stegger J, Overvad K, Chabbert-Buffet N, Jimenez-Corona A, Clavel-Chapelon F, Rohrmann S, Teucher B, Boeing H, Schütze M, Trichopoulou A, Benetou V, Lagiou P, **Palli D**, Berrino F, Panico S, Tumino R, Sacerdote C, Redondo ML, Travier N, Sanchez MJ, Altzibar JM, Chirlaque MD, Ardanaz E, Bueno-de-Mesquita HB, van Duijnhoven FJ, Onland-Moret NC, Peeters PH, Hallmans G, Lundin E, Khaw KT, Wareham N, Allen N, Key T, Slimani N, Hainaut P, Romaguera D, Norat T, Riboli E, Kaaks R. Obesity, inflammatory markers and endometrial cancer risk: a prospective case-control study. *Endocrine Related Cancer*, 17: 1007-1019, 2010. (E-pub 15-09-10) IF:5.193
179. Du H, van der A DL, Boshuizen HC, Forouhi NG, Wareham NJ, Halkjær J, Tjønneland A, Overvad K, Jakobsen MU, Boeing H, Buijsse B, Masala G, **Palli D**, Sørensen TI, Saris WH, Feskens EJ. Dietary fiber and subsequent changes in body weight and waist circumference in European men and women. *American Journal of Clinical Nutrition*, 91:329-336, 2010. (E-pub 16-12-09)) IF:6.603
180. Duell EJ, Travier N, Lujan-Barroso L, Boutron-Ruault MC, Clavel-Chapelon F, **Palli D**, Krogh V, Mattiello A, Tumino R, Sacerdote C, Rodriguez L, Sanchez-Cantalejo E, Navarro C, Barricarte A, Dorronsoro M, Khaw KT, Wareham N, Allen NE, Tsilidis KK, Bueno-de-Mesquita HB, Jeurnink SM, Numans ME, Peeters PH, Lagiou P, Valanou E, Trichopoulou A, Kaaks R, Lukanova-McGregor A, Bergman MM, Boeing H, Manjer J, Lindkvist B, Stenling R, Hallmans G, Dahm CC, Overvad K, Olsen A, Tjønneland A, Bakken K, Lund E, Jenab M, McCormack V, Rinaldi S, Michaud D, Mouw T, Nesi G, Carneiro F, Riboli E, González CA. Menstrual and Reproductive Factors, Exogenous Hormone Use, and Gastric Cancer Risk in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition. *American Journal of Epidemiology*, 172: 1384-1393, 2010. (E-pub 04-11-10) IF:5.285
181. Eussen SJPM, Vollset SE, Hustad S, Midttun Ø, Meyer K, Fredriksen Å, Ueland PM, Jenab M, Slimani N, Ferrari P, Pera G, Agudo A, Sala N, Capellá G, Del Giudice G, **Palli D**, Boeing H, Weikert C, Bueno-de-Mesquita HB, Büchner FL, Carneiro F, Berrino F, Vineis P, Tumino R, Panico S, Berglund G, Manjer J, Stenling R, Hallmans G, Martínez C, Arriola L, Barricarte A, Navarro C, Quirós JR, Allen NE, Key TJ, Bingham S, Linseisen J, Kaaks R, Overvad K, Tjønneland A, Peeters PHM, Numans ME, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Lund E, Plebani M, Riboli E, González CA. Vitamin B2 and B6 species and genetic polymorphisms related to one-carbon metabolism as risk of gastric adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EurGast). *Cancer Epidemiology*.

182. Eussen SJ, Vollset SE, Igland J, Meyer K, Fredriksen A, Ueland PM, Jenab M, Slimani N, Boffetta P, Overvad K, Tjønneland A, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Weikert C, Pischon T, Linseisen J, Kaaks R, Trichopoulou A, Zilis D, Katsoulis M, **Palli D**, Berrino F, Vineis P, Tumino R, Panico S, Peeters PH, Bueno-de-Mesquita HB, van Duijnhoven FJ, Gram IT, Skeie G, Lund E, González CA, Martínez C, Dorronsoro M, Ardanaz E, Navarro C, Rodríguez L, Van Guelpen B, Palmqvist R, Manjer J, Ericson U, Bingham S, Khaw KT, Norat T, Riboli E. Plasma folate, related genetic variants, and colorectal cancer risk in EPIC. *Cancer Epidemiology, Biomarkers and Prevention*, 19:1328-1340, 2010. IF:4.642
183. Eussen SJ, Vollset SE, Hustad S, Midttun O, Meyer K, Fredriksen A, Ueland PM, Jenab M, Slimani N, Boffetta P, Overvad K, Thorlacius-Ussing O, Tjønneland AM, Olsen A, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Weikert C, Pishon T, Linseisen J, Kaaks R, Trichopoulou A, Zilis D, Katsoulis M, **Palli D**, Pala V, Vineis PP, Tumino R, Panico S, Peeters PH, Bueno-de-Mesquita HB, van Duijnhoven F, Skeie G, Muñoz X, Martínez-García C, Dorronsoro M, Ardanaz E, Navarro C, Rodríguez L, Van Guelpen B, Palmqvist R, Manjer J, Ericson UC, Bingham SA, Khaw KT, Norat T, Riboli E. Plasma vitamins B2, B6, B12, and related genetic variants as predictors of colorectal cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, 19: 2549-2561, 2010. (E-pub 02-09-10) IF:4.642
184. Gallo V, Neasham D, Airoidi L, Ferrari P, Jenab M, Boffetta P, Overvad K, Tjønneland A, Clavel-Chapelon F, Boeing H, Pala V, **Palli D**, Panico S, Tumino R, Arriola L, Lund E, Bueno-de-Mesquita HB, Peeters PHM, Berglund G, Melander O, Hallmans, Riboli E, Saracci R, Vineis P. Second-hand smoke, cotinine levels and risk of circulatory mortality in a large cohort study of never smokers. *Epidemiology*, 21:207-214, 2010. (E-pub 14-01-2010) IF:5.283
185. Hoefft B, Linseisen J, Beckmann L, Müller-Decker K, Canzian F, Hüsing A, Kaaks R, Vogel U, Jakobsen MU, Overvad K, Hansen RD, Knüppel S, Boeing H, Trichopoulou A, Yvoni K, Trichopoulos D, Berrino F, **Palli D**, Panico S, Tumino R, Bueno-de-Mesquita HB, van Duijnhoven FJ, van Gils CH, Peeters PH, Dumeaux V, Lund E, Huerta Castaño JM, Muñoz X, Rodríguez L, Barricarte A, Manjer J, Jirström K, Van Guelpen B, Hallmans G, Spencer EA, Crowe FL, Khaw KT, Wareham N, Morois S, Boutron-Ruault MC, Clavel-Chapelon F, Chajes V, Jenab M, Boffetta P, Vineis P, Mouw T, Norat T, Riboli E, Nieters A. Polymorphisms in fatty acid metabolism-related genes are associated with colorectal cancer risk. *Carcinogenesis*, 31:466-472, 2010. (E-pub 30-12-2009) IF:5.406
186. Hosnijeh FS, Krop EJ, Scoccianti C, Krogh V, **Palli D**, Panico S, Tumino R, Sacerdote C, Nawroly N, Portengen L, Linseisen J, Vineis P, Vermeulen R. Plasma Cytokines and Future Risk of Non-Hodgkin Lymphoma (NHL): A Case-Control Study Nested in the Italian European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiology, Biomarkers and Prevention*, 19: 1577-1584, 2010. (E-pub 25-05-10). IF:4.642
187. Huerta JM, Navarro C, Chirlaque MD, Tormo MJ, Steindorf K, Buckland G, Carneiro F, Johnsen NF, Overvad K, Stegger J, Tjønneland A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, Boeing H, Kaaks R, Rohrmann S, Vigl M, Lagiou P,

- Trichopoulos D, Trichopoulou A, Bas Bueno-de-Mesquita H, Monninkhof EM, Numans ME, Peeters PH, Mattiello A, Pala V, **Palli D**, Tumino R, Vineis P, Agudo A, Ardanaz E, Arriola L, Molina-Montes E, Rodríguez L, Lindkvist B, Manjer J, Stenling R, Lund E, Crowe FL, Key TJ, Khaw KT, Wareham NJ, Jenab M, Norat T, Romaguera D, Riboli E, González CA. Prospective study of physical activity and risk of primary adenocarcinomas of the oesophagus and stomach in the EPIC (European Prospective Investigation into Cancer and nutrition) cohort. *Cancer Causes and Control*, 21: 657-669, 2010. (E-pub 06-01-10) IF:3.279
188. Jacobs EJ, Chanock SJ, Fuchs CS, Lacroix A, McWilliams RR, Steplowski E, Stolzenberg-Solomon RZ, Arslan AA, Bas Bueno-de-Mesquita H, Gross M, Helzlsouer K, Petersen G, Zheng W, Agalliu I, Allen NE, Amundadottir L, Boutron-Ruault MC, Buring JE, Canzian F, Clipp S, Dorronsoro M, Gaziano JM, Giovannucci EL, Hankinson SE, Hartge P, Hoover RN, Hunter DJ, Jacobs KB, Jenab M, Kraft P, Kooperberg C, Lynch SM, Sund M, Mendelsohn JB, Mouw T, Newton CC, Overvad K, **Palli D**, Peeters PH, Rajkovic A, Shu XO, Thomas G, Tobias GS, Trichopoulos D, Virtamo J, Wactawski-Wende J, Wolpin BM, Yu K, Zeleniuch-Jacquotte A. Family history of cancer and risk of pancreatic cancer: A pooled analysis from the pancreatic cancer cohort consortium (PANSCAN). *International Journal of Cancer*, 127: 421-428, 2010. (E-pub 04-01-10) IF:4.555
189. Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJB, Norat T, Pischon T, Jansen EHJM, Slimani N, Byrnes G, Rinaldi S, Tjønneland A, Olsen A, Overvad K, Boutron Ruault MC, Clavel-Chapelon F, Morois S, Kaaks R, Linseisen J, Boeing H, Bergmann M, Trichopoulou A, Misirli G, Trichopoulos D, Berrino F, Vineis P, Panico S, **Palli D**, Tumino R, Ros M, van Gils CH, Peeters PH, Brustad M, Lund E, Tormo MJ, Ardanaz E, Rodríguez Suárez L, Sánchez MJ, Dorronsoro M, Gonzalez CA, Hallmans G, Palmqvist R, Roddam A, Key TJ, Khaw KT, Bingham S, Boffetta P, Autier P, Hainaut P, Riboli E. Pre-diagnostic Circulating Vitamin D Concentration, Dietary Vitamin D and Calcium and Risk of Colorectal Cancer in European Populations. *British Medical Journal*, 340: b5500, 2010. IF:9.723
190. Lahmann PH, Cust AE, Friedenreich CM, Schulz M, Lukanova A, Kaaks R, Lundin E, Tjønneland A, Halkjær J, Tang Severinsen M, Overvad K, Fournier A, Chabbert-Buffet N, Clavel-Chapelon F, Dossus L, Pischon T, Boeing H, Trichopoulou A, Lagiou P, Naska A, **Palli D**, Grioni S, Mattiello A, Tumino R, Sacerdote C, Redondo Cornejo ML, Jakszyn P, Sánchez MJ, Tormo MJ, Ardanaz E, Larraitz Arriola, Manjer J, Jirström K, Bueno-de-Mesquita HB, May AM, Peeters PHM, Onland-Moret NC, Bingham S, Khaw KT, Allen NE, Spencer E, Rinaldi S, Slimani N, Chajes V, Riboli E. Anthropometric Measures and Epithelial Ovarian Cancer Risk in the European Prospective Investigation into Cancer and Nutrition. *International Journal of Cancer*, 126:2404-2415, 2010. (E-pub 09-10-09) IF:4.555
191. Menvielle G, Boshuizen H, Kunst AE, Vineis P, Dalton SO, Bergmann MM, Hermann S, Veglia F, Ferrari P, Raaschou-Nielsen O, Tjønneland A, Kaaks R, Linseisen J, **Palli D**, Krogh V, Tumino R, Rodriguez L, Agudo A, Sánchez MJ, Tormo MJ, Ardanaz, Bingham, Khaw KT, Boffetta P, Duell E, Slimani N, Gallo V, Riboli E, Bueno-de-Mesquita HB. Occupational exposures contribute to educational inequalities in lung cancer incidence among men. Evidence from the EPIC prospective cohort study. *International Journal of Cancer*, 126:1928-35, 2010. (E-pub 06-10-09) IF:4.555

192. Michaud DS, Gallo V, Schlehofer B, Tjønneland AM, Olsen A, Overvad K, Dahm CC, Kaaks R, Lukanova A, Boeing H, Schutze M, Trichopoulou A, Bamia C, Kyrozi A, Sacerdote C, Agnoli C, **Palli D**, Tumino R, Mattiello A, Bueno-de-Mesquita B, Ros M, Peeters PH, van Gils C, Lund E, Bakken K, Gram I, Barricarte A, Navarro C, Dorronsoro M, Sanchez Perez M, Rodriguez L, Duell E, Hallmans G, Melin B, Manjer J, Borgquist S, Khaw KT, Wareham NJ, Allen NE, Tsilidis K, Romieu I, Rinaldi S, Vineis P, Riboli E. Reproductive factors and exogenous hormone use in relation to risk of glioma and meningioma in a large European cohort study. *Cancer Epidemiology Biomarkers and Prevention*, 19: 2562- 2569, 2010. (*E-pub* 27-08-10) IF:4.642
193. Ottini L, **Palli D**, Rizzo S, Federico M, Bazan V, Russo A. Male breast cancer. *Critical Reviews in Oncology/Hematology*, 73:141-155, 2010. (*E-pub* 06-05-09) IF:4.632
194. **Palli D**, Polidoro S, D'Errico M, Saieva C, Guarrera S, Calcagnile A, Sera F, Allione A, Gemma S, Zanna I, Filomena A, Testai E, Caini S, Moretti R, Gomez-Miguel MJ, Nesi G, Luzzi I, Ottini L, Masala G, Matullo G, Dogliotti E. Polymorphic DNA Repair and Metabolic Genes: a Multigenic Study on Gastric Cancer. *Mutagenesis*, 25: 569-575, 2010. (*E-pub* 03-09-10) IF:2.382
195. Papi L, Putignano AL, Congregati C, Piaceri I, Zanna I, Sera F, Morrone D, Genuardi M, **Palli D**. A PALB2 germline mutation associated with hereditary breast cancer in Italy. *Familial Cancer*, 9(2):181-185, 2010. (*E-pub* 18-09-09) IF:2.247
196. Price AJ, Allen NE, Appleby PN, Crowe FL, Jenab M, Rinaldi S, Slimani N, Kaaks R, Rohrmann S, Boeing H, Pischon T, Benetou V, Naska A, Trichopoulou A, **Palli D**, Sieri S, Tumino R, Vineis P, Bueno de mesquita HB, Donate I, Gonzalez CA, Sanchez MJ, Chirlaque MD, Ardanaz E, Larranaga N, Khaw KT, Rodwell S, Gallo V, Michaud DS, Riboli E, Key TJ. Plasma phytanic acid concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition. *American Journal of Clinical Nutrition*, 91: 1769-1776. 2010. (*E-pub* 28-04-10) IF:6.603
197. Ragin C, Minor A, Agudo A, Farmer P, Garte S, Gonzales CA, Kalina I, Matullo G, Popov T, **Palli D**, Peluso M, Riccieri F, Sram R, Vineis P, Taioli E. Pooled analysis of studies on DNA adducts and dietary vitamins. *Mutation Research-Reviews*, 705: 77-82, 2010. (*E-pub* 15-04-10) IF:4.353
198. Riccieri F, Godschalk RW, Peluso M, Phillips D, Agudo A, Georgiadis PA, Loft S, Tjønneland AM, Raaschou-Nielsen O, **Palli D**, Perera F, Vermeulen R, Taioli E, Sram RJ, Munnia A, Rosa F, Allione A, Matullo G, Vineis P. Bulky DNA adducts in white-blood cells: a pooled analysis of 3600 subjects. *Cancer Epidemiology Biomarkers and Prevention*, 19: 3174-3181, 2010. (*E-pub* 04-10-10) IF:4.642
199. Richiardi L, De Marco L, Gillio Tos A, Merletti F, Fiano V, **Palli D**, Masala G, Agnoli C, Tagliabue G, Panico S, Mattiello A, Tumino R, Frasca G, Vineis P, Sacerdote C. Persistent infection by HCV and EBV in peripheral blood mononuclear cells and risk of non-Hodgkin's lymphoma. *Cancer Epidemiology*, 34:709-712, 2010. (*E-pub* 13-08-10) IF:1.6
200. Rinaldi S, Cleveland R, Norat T, Biessy C, Rohrmann S, Linseisen J, Boeing H, Pischon T, Panico S, Agnoli C, **Palli D**, Tumino R, Vineis P, Peeters PHM, van Gils C, Bueno-de-Mesquita HB, Vrieling A, Allen NE, Roddam A, Bingham S, Khaw KT, Manjer

- J, Borgquist S, Dumeaux V, Gram IT, Lund E, Trichopoulou A, Makrygiannis G, Benetou V, Molina E, Suárez ID, Barricarte Gurrea A, Gonzalez CA, Tormo MJ, Altzibar JM, Olsen A, Tjønneland A, Grønbaek H, Overvad K, Clavel-Chapelon F, Boutron-Ruault MC, Morois S, Slimani N, Boffetta P, Jenab M, Riboli E, Kaaks R. Serum levels of IGF-I, IGFBP-3 and colorectal cancer risk: results from the EPIC cohort, plus a meta-analysis of prospective studies. *International Journal of Cancer*, 126: 1702-1715, 2010 (*E-pub* 06-10-09) IF: **4.555**
201. Romaguera D, Angquist L, Du H, Jakobsen MU, Forouhi NG, Halkjær J, Feskens EJ, van der A DL, Masala G, Steffen A, **Palli D**, Wareham NJ, Overvad K, Tjønneland A, Boeing H, Riboli E, Sørensen TI. Dietary Determinants of Changes in Waist Circumference Adjusted for Body Mass Index - a Proxy Measure of Visceral Adiposity. *PLoS One*, 5(7):e11588, 2010. IF:**4.4**
202. Romaguera D, Norat T, Vergnaud AC, Mouw T, May AM, Agudo A, Buckland G, Slimani N, Rinaldi S, Couto E, Clavel-Chapelon F, Boutron-Ruault MC, Cottet V, Rohrmann S, Teucher B, Bergmann M, Boeing H, Tjønneland A, Halkjaer J, Jakobsen MU, Dahm CC, Travier N, Rodriguez L, Sanchez MJ, Amiano P, Barricarte A, Huerta JM, Luan J, Wareham N, Key TJ, Spencer EA, Orfanos P, Naska A, Trichopoulou A, **Palli D**, Agnoli C, Mattiello A, Tumino R, Vineis P, Bueno-de-Mesquita HB, Büchner FL, Manjer J, Wirfält E, Johansson I, Hellstrom V, Lund E, Braaten T, Engeset D, Odysseos A, Riboli E, Peeters PH. Mediterranean dietary patterns and prospective weight change in participants of the EPIC-PANACEA project. *American Journal of Clinical Nutrition*, 92: 912-921, 2010. (*E-pub* 01-09-10) IF:**6.603**
203. Rundle A, Richie J, Steindorf K, Peluso M, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Linseisen JP, Boeing H, Trichopoulou A, **Palli D**, Krogh V, Tumino R, Panico S, Bueno-De-Mesquita HB, Peeters PH, Lund E, Gonzalez CA, Martinez C, Dorronsoro M, Barricarte A, Tormo MJ, Quiros J, Agudo A, Berglund G, Jarvholm B, Bingham S, Key TJ, Gormally E, Saracci R, Kaaks R, Riboli E, Vineis P. Physical activity and lung cancer among non-smokers: a pilot molecular epidemiological study within EPIC. *Biomarkers*, 15: 20-30, 2010. (*E-pub* 06-01-2010) IF:**1.978**
204. Schumacher FR, Cheng I, Freedman ML, Mucci L, Allen NE, Pollak MN, Hayes RB, Stram DO, Canzian F, Henderson BE, Hunter DJ, Virtamo J, Manjer J, Gaziano JM, Kolone LN, Tjønneland A, Albanes D, Calle EE, Giovannucci E, Crawford ED, Haiman CA, Kraft P, Willett WC, Thun MJ, Le Marchand L, Kaaks R, Feigelson HS, Bueno-de-Mesquita HB, **Palli D**, Riboli E, Lund E, Amiano P, Andriole G, Dunning AM, Trichopoulos D, Stampfer MJ, Key TJ, Ma J on behalf of the NCI Breast & Prostate Cancer Cohort Consortium. A Comprehensive Analysis of Common IGF1, IGFBP1 and IGFBP3 Genetic Variation with Prospective IGF-I and IGFBP-3 Blood Levels and Prostate Cancer Risk Among Caucasians. *Human Molecular Genetics*, 19: 3089-3101, 2010. (*E-pub* 19-05-10) IF:**7.806**
205. Sieri S, Krogh V, Berrino F, Evangelista A, Agnoli C, Brighenti F, Pellegrini N, **Palli D**, Masala G, Sacerdote C, Veglia F, Tumino R, Frasca G, Grioni S, Pala V, Mattiello A, Chiodini P, Panico S. Dietary glycemic load and index and risk of coronary heart disease in a large Italian cohort. The EPICOR study. *Archives of Internal Medicine*, 170: 640-647, 2010. IF: **8.391**

206. Silvestri V, Rizzolo P, Zanna I, Falchetti M, Masala G, Bianchi S, Papi L, Giannini G, **Palli D**, Ottini L. *PALB2* mutations in male breast cancer: a population-based study in Central Italy. *Breast Cancer Research and Treatment*, 122: 299-301, 2010. (E-pub 24-02-10) IF: **4.453**
207. Truong T, Sauter W, McKay JD, Hosgood HD 3rd, Gallagher C, Amos CI, Spitz M, Muscat J, Lazarus P, Illig T, Wichmann HE, Bickeböller H, Risch A, Dienemann H, Zhang ZF, Naeim BP, Yang P, Zienolddiny S, Haugen A, Le Marchand L, Hong YC, Kim JH, Duell EJ, Andrew AS, Kiyohara C, Shen H, Matsuo K, Suzuki T, Seow A, Ng DP, Lan Q, Zaridze D, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Constantinescu V, Bencko V, Foretova L, Janout V, Caporaso NE, Albanes D, Thun M, Landi MT, Trubicka J, Lener M, Lubinski J; EPIC-lung, Wang Y, Chabrier A, Boffetta P, Brennan P, Hung RJ. EPIC Collaborators: Vineis P, Clavel-Chapelon F, **Palli D**, Tumino R, Krogh V, González CA, Quirós JR, Martínez C, Navarro C, Ardanaz E, Larrañaga N, Khaw KT, Key T, Bueno-de-Mesquita HB, Peeters PH, Trichopoulou A, Kaaks R, Boeing H, Hallmans G, Overvad K, Tjønneland A, Kumle M, Riboli E. International Lung Cancer Consortium: coordinated association study of 10 potential lung cancer susceptibility variants. *Carcinogenesis*, 31:625-633, 2010. (E-pub 27-01-2010) IF: **5.406**
208. Tsilidis KK, Allen NE, Key TJ, Bakken K, Lund E, Berrino F, Fournier A, Olsen A, Tjønneland A, Overvad K, Boutron-Ruault MC, Clavel-Chapelon F, Byrnes G, Chajes V, Rinaldi S, Chang-Claude J, Kaaks R, Bergmann M, Boeing H, Koumantaki Y, Stasinopoulou G, Trichopoulou A, **Palli D**, Tagliabue G, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, van Duijnhoven FJ, van Gils CH, Peeters PH, Rodríguez L, González CA, Sánchez MJ, Chirlaque MD, Barricarte A, Dorronsoro M, Borgquist S, Manjer J, van Guepen B, Hallmans G, Rodwell SA, Khaw KT, Norat T, Romaguera D, Riboli E. Oral contraceptives, reproductive history and risk of colorectal cancer in the European Prospective Investigation into Cancer and Nutrition. *British Journal of Cancer*, 103: 1755-1759, 2010. (E-pub 02-11-10) IF: **4.635**
209. Vergnaud AC, Norat T, Romaguera D, Mouw T, May AM, Travier N, Luan J, Wareham N, Slimani N, Rinaldi S, Couto E, Clavel-Chapelon F, Boutron-Ruault MC, Cottet V, **Palli D**, Agnoli C, Panico S, Tumino R, Vineis P, Agudo A, Rodriguez L, Sanchez MJ, Amiano P, Barricarte A, Huerta JM, Key TJ, Spencer EA, Bueno-de-Mesquita B, Büchner FL, Orfanos P, Naska A, Trichopoulou A, Rohrmann S, Hermann S, Boeing H, Buijsse B, Johansson I, Hellstrom V, Manjer J, Wirfält E, Jakobsen MU, Overvad K, Tjønneland A, Halkjaer J, Lund E, Braaten T, Engeset D, Odysseos A, Riboli E, Peeters PH. Meat consumption and prospective weight change in participants of the EPIC-PANACEA study. *American Journal of Clinical Nutrition*, 92: 398-407, 2010. (E-pub 30-06-10) IF: **6.603**
210. Villari D, Nesi G, Della Melina A, **Palli D**, Ceroti M, Castigli M, Filocamo MT, Li Marzi V, Nicita G. Radical retropubic prostatectomy for prostate cancer with microscopic bladder neck involvement: survival and prognostic implications. *British Journal of Urology International*, 105: 946-950, 2010. (E-pub 05-10-09) IF: **2.751**
211. Vrieling A, Bueno-de-Mesquita HB, Boshuizen HC, Michaud DS, Severinsen MT, Overvad K, Olsen A, Tjønneland A, Clavel-Chapelon F, Boutron-Ruault MC, Kaaks R, Rohrmann S, Boeing H, Nöthlings U, Trichopoulou A, Moutsiou E, Dilis V, **Palli D**, Krogh V, Panico S, Tumino R, Vineis P, van Gils CH, Peeters PH, Lund E, Gram IT,

- Rodríguez L, Agudo A, Larrañaga N, Sánchez MJ, Navarro C, Barricarte A, Manjer J, Lindkvist B, Sund M, Ye W, Bingham S, Khaw KT, Roddam A, Key T, Boffetta P, Duell EJ, Jenab M, Gallo V, Riboli E. Cigarette smoking, environmental tobacco smoke exposure and pancreatic cancer risk in the European Prospective Investigation into Cancer and Nutrition International Journal of Cancer, 2394- 2403, 2010. (*E-pub* 29-09-09) IF: **4.555**
212. Zanna I, Rizzolo P, Sera F, Falchetti M, Aretini P, Giannini G, Masala G, Gulino A, **Palli D**, Ottini L. BRCAPRO 5 model is a useful tool in genetic counselling and clinical management of male breast cancer cases. *European Journal of Human Genetics*, 18: 856-858, 2010. (*E-pub* 17-03-10) IF: **4.003**
213. Büchner FL, Bueno-de-Mesquita HB, Ros MM, Kampman E, Egevad L, Overvad K, Tjønneland A, Roswall N, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud M, Kaaks R, Chang-Claude J, Boeing H, Weikert S, Trichopoulou A, Naska A, Benetou V, **Palli D**, Sieri S, Vineis P, Tumino R, Panico S, van Duijnhoven FJ, Peeters PH, van Gils CH, Lund E, Gram IT, Sánchez MJ, Jakszyn P, Larrañaga N, Ardanaz E, Navarro C, Rodríguez L, Manjer J, Ehrnström R, Hallmans G, Ljungberg B, Key TJ, Allen NE, Khaw KT, Wareham N, Slimani N, Jenab M, Boffetta P, Kiemenev LA, Riboli E. Variety in vegetable and fruit consumption and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition. *International Journal of Cancer*, 2011. (*E-pub* 31-08-10) IF: **4.693**
214. Campa D, Claus R, Dostal L, Stein A, Chang-Claude J, Meidtner K, Boeing H, Olsen A, Tjønneland A, Overvad K, Rodríguez L, Bonet C, Sánchez MJ, Amiano P, Huerta JM, Barricarte A, Khaw KT, Wareham N, Travis RC, Allen NE, Trichopoulou A, Bamia C, Benetou V, **Palli D**, Agnoli C, Panico S, Tumino R, Sacerdote C, van Kranen H, Bas Bueno-de-Mesquita H, Peeters PH, van Gils CH, Lenner P, Sund M, Lund E, Gram IT, Rinaldi S, Chajes V, Romieu I, Engel P, Boutron-Ruault MC, Clavel-Chapelon F, Siddiq A, Riboli E, Canzian F, Kaaks R. Variation in genes coding for AMP-activated protein kinase (AMPK) and breast cancer risk in the European Prospective Investigation on Cancer (EPIC). *Breast Cancer Research and Treatment*, 2010. (*E-pub* 30-11-10) IF: **4.453**
215. Chuang SC, Gallo V, Michaud D, Overvad K, Tjønneland A, Clavel-Chapelon F, Romieu I, Straif K, **Palli D**, Pala V, Tumino R, Sacerdote C, Panico S, Peeters PH, Lund E, Gram IT, Manjer J, Borgquist S, Riboli E, Vineis P. Exposure to environmental tobacco smoke in childhood and incidence of cancer in adulthood in never smokers in the European prospective investigation into cancer and nutrition. *Cancer Causes and Control*, 2011. (*E-pub* 30-01-11) IF: **3.279**
216. Crowe FL, Roddam AW, Key TJ, Appleby PN, Overvad K, Jakobsen MU, Tjønneland A, Hansen L, Boeing H, Weikert C, Linseisen J, Kaaks R, Trichopoulou A, Misirli G, Lagiou P, Sacerdote C, Pala V, **Palli D**, Tumino R, Panico S, Bueno-de-Mesquita HB, Boer J, van Gils CH, Beulens JW, Barricarte A, Rodríguez L, Larrañaga N, Sánchez MJ, Tormo MJ, Buckland G, Lund E, Hedblad B, Melander O, Jansson JH, Wennberg P, Wareham NJ, Slimani N, Romieu I, Jenab M, Danesh J, Gallo V, Norat T, Riboli E; European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart Study Collaborators. Fruit and vegetable intake and mortality from ischaemic heart disease: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Heart study. *European Heart Journal*, 2011. (*E-pub* 18-01-11) IF: **7.924**

217. Dossus L, Becker S, Rinaldi S, Lukanova A, Tjønneland A, Olsen A, Overvad K, Chabbert-Buffet N, Boutron-Ruault MC, Clavel-Chapelon F, Teucher B, Chang-Claude J, Pischon T, Boeing H, Trichopoulou A, Benetou V, Valanou E, **Palli D**, Sieri S, Tumino R, Sacerdote C, Galasso R, Redondo ML, Bonet Bonet C, Molina-Montes E, Altzibar JM, Chirlaque MD, Ardanaz E, Bueno-de-Mesquita HB, van Duijnhoven FJ, Peeters PH, Onland-Moret NC, Lundin E, Idahl A, Khaw KT, Wareham N, Allen N, Romieu I, Fedirko V, Hainaut P, Romaguera D, Norat T, Riboli E, Kaaks R. Tumor necrosis factor (TNF)- α , soluble TNF receptors and endometrial cancer risk: The EPIC study. *International Journal of Cancer*. 2010. (E-pub 10-12-10) IF:4.693
218. González CA, Travier N, Lujan L, Castellsagué X, Bosch FX, Roura E, Bueno-de-Mesquita HB, **Palli D**, Boeing H, Pala V, Sacerdote C, Tumino R, Panico S, Manjer J, Dillner J, Hallmans G, Kjellberg L, Sanchez MJ, Altzibar JM, Barricarte A, Navarro C, Rodriguez L, Allen N, Key TJ, Kaaks R, Rohrmann S, Overvad K, Olsen A, Tjønneland A, Munk C, Krüger Kjaer S, Peeters PH, van Duijnhoven FJ, Clavel-Chapelon F, Boutron-Ruault MC, Trichopoulou A, Benetou V, Naska A, Lund E, Engeset D, Skeie G, Franceschi S, Slimani N, Rinaldi S, Riboli E. Dietary factors and in-situ and invasive cervical cancer risk in the European Prospective Investigation into Cancer and Nutrition (EPIC) study. *International Journal of Cancer*, 2010. (E-pub 17-09-10) IF:4.555
219. Halkjær J, Olsen A, Overvad K, Jakobsen MU, Boeing H, Buijsse B, **Palli D**, Tognon G, Du H, van der A DL, Forouhi NG, Wareham NJ, Feskens EJ, Sørensen TI, Tjønneland A. Intake of total, animal and plant protein and subsequent changes in weight or waist circumference in European men and women: the Diogenes project. *International Journal of Obesity*, 2010. (E-pub 07-12-10) IF:3.56
220. Jakszyn PG, Gonzalez CA, Lujan Barroso L, Ros MM, Bueno-de-Mesquita HB, Roswall N, Tjønneland AM, Buchner FL, Egevad L, Overvad K, Raaschou-Nielsen O, Clavel-Chapelon F, Boutron-Ruault MC, Touillaud MS, Chang-Claude J, Allen NE, Kiemeny LA, Key TJ, Kaaks R, Boeing H, Weikert S, Trichopoulou A, Oikonomou E, Zylis D, **Palli D**, Berrino F, Vineis P, Tumino R, Mattiello A, Peeters PH, Parr CL, Gram IT, Skeie G, Sanchez MJ, Larranaga N, Ardanaz E, Navarro C, Rodriguez L, Ulmert D, Ehrnstrom R, Hallmans G, Ljungberg B, Roddam AW, Bingham SA, Khaw KT, Slimani N, Boffetta PA, Jenab M, Mouw T, Michaud DS, Riboli E. Red meat, dietary nitrosamines and heme iron and risk of bladder cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). *Cancer Epidemiology, Biomarkers and Prevention*, 2011. (E-pub 14-01-11) IF:4.642
221. Marcon F, Silvestrini F, Siniscalchi E, **Palli D**, Saieva C, Crebelli R. Gene expression in response to ionizing radiation and family history of gastric cancer. *Familial Cancer*, 10: 107-..., 2011. (E-pub 09-11-10) IF:2.247
222. Palmirotta R, Guadagni F, Savonarola A, Ludovici G, Nesi G, **Palli D**, Falchetti M, Ottini L. PAI-1 4G/5G repeat is a target in gastric carcinomas with microsatellite instability. *Digestive and Liver Disease*, 2011. (E-pub 07-01-11) IF:1.982
223. Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, Bianchi S, **Palli D**, Ottini L. Mutation analysis of BRIP1 in male breast cancer cases: a population-based study in

Central Italy. Breast Cancer Research and Treatment, 2010. (E-pub 17-12-10)
IF:4.453

224. Tsilidis KK, Allen NE, Key TJ, Sanjoaquin MA, Bakken K, Berrino F, Fournier A, Lund E, Overvad K, Olsen A, Tjønneland A, Byrnes G, Chajes V, Rinaldi S, Boutron-Ruault MC, Clavel-Chapelon F, Chang-Claude J, Kaaks R, Bergmann M, Boeing H, Koumantaki Y, **Palli D**, Pala V, Panico S, Tumino R, Vineis P, Bueno-de-Mesquita HB, van Duijnhoven FJ, van Gils CH, Peeters PH, Rodríguez L, González CA, Sánchez MJ, Chirlaque MD, Barricarte A, Dorronsoro M, Khaw KT, Rodwell SA, Norat T, Romaguera D, Riboli E. Menopausal hormone therapy and risk of colorectal cancer in the European prospective investigation into cancer and nutrition. International Journal of Cancer, 2010. (E-pub 09-06-10) IF:4.693
225. Bendinelli B, Masala G, Saieva C, Salvini S, Calonico C, Sacerdote C, Agnoli C, Grioni S, Frasca G, Mattiello A, Chiodini P, Tumino R, Vineis P, **Palli D**, Panico S. Fruit, vegetables, olive oil and risk of coronary heart disease in Italian women: the EPICOR study. American Journal of Clinical Nutrition, 93:275-283, 2011. (E-pub 22-12-10)
IF:6.603
226. Campa D, Hüsing A, Chang-Claude J, Dostal L, Boeing H, Kröger J, Tjønneland A, Roswall N, Overvad K, Dahm CC, Rodríguez L, Sala N, Pérez MJ, Larrañaga N, Chirlaque MD, Ardanaz E, Khaw KT, Wareham N, Allen NE, Travis RC, Trichopoulou A, Naska A, Bamia C, **Palli D**, Sieri S, Tumino R, Sacerdote C, van Kranen HJ, Bas Bueno-de-Mesquita H, Stattin P, Johansson M, Chajes V, Rinaldi S, Romieu I, Siddiq A, Norat T, Riboli E, Kaaks R, Canzian F. Genetic variability of the fatty acid synthase pathway is not associated with prostate cancer risk in the European Prospective Investigation on Cancer (EPIC). European Journal of Cancer, 47: 420-427, 2011. (E-pub 19-10-10) IF:4.454
227. Crowe FL, Key TJ, Allen NE, Appleby PN, Overvad K, Grønbaek H, Tjønneland A, Halkjaer J, Dossus L, Boeing H, Kröger J, Trichopoulou A, Zylis D, Trichopoulos D, Boutron-Ruault MC, de Lauzon-Guillain B, Clavel-Chapelon F, **Palli D**, Berrino F, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, van Gils CH, Peeters PH, Gram IT, Rodríguez L, Jakszyn P, Molina-Montes E, Navarro C, Barricarte A, Larrañaga N, Khaw KT, Rodwell S, Rinaldi S, Slimani N, Norat T, Gallo V, Riboli E, Kaaks R. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1 -2 and -3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Annals of Human Biology, 38:194-202, 2011. (E-pub 23-08-10) IF:1.06
228. Franceschi S, Lise M, Trepo C, Berthillon P, Chuang SC, Nieters A, Travis RC, Vermeulen R, Overvad K, Tjønneland AM, Olsen A, Bergmann M, Boeing H, Kaaks R, Becker N, Trichopoulou A, Lagiou P, Bamia C, **Palli D**, Sieri SA, Panico S, Tumino R, Sacerdote C, Bueno-de-Mesquita HB, Peeters PH, Rodríguez L, Lujan Barroso L, Dorronsoro M, Sanchez MJ, Navarro C, Barricarte Gurrea A, Regner S, Borgquist S, Melin B, Hallmans G, Khaw KT, Wareham NJ, Rinaldi S, Hainaut P, Riboli E, Vineis P. Infection with hepatitis B and C viruses and risk of lymphoid malignancies in the European Prospective Investigation into Cancer and Nutrition (EPIC). Cancer Epidemiology, Biomarkers and Prevention, 20: 208-214, 2011. (E-pub 23-11-10)
IF:4.642

229. Giovannelli L, Pitozzi V, Luceri C, Giannini L, Toti S, Salvini S, Sera F, Souquet JM, Cheynier V, Sofi F, Mannini L, Gori AM, Abbate R, **Palli D**, Dolara P. Effects of de-alcoholised wines with different polyphenol content on DNA oxidative damage, gene expression of peripheral lymphocytes, and haemorheology: an intervention study in post-menopausal women. *European Journal of Nutrition*, 50: 19-29, 2011. (E-pub 27-04-10) IF:2.098
230. Leufkens AM, van Duijnhoven FJ, Siersema PD, Boshuizen HC, Vrieling A, Agudo A, Gram IT, Weiderpass E, Dahm C, Overvad K, Tjønneland A, Olsen A, Boutron-Ruault MC, Clavel-Chapelon F, Morois S, **Palli D**, Grioni S, Tumino R, Sacerdote C, Mattiello A, Herman S, Kaaks R, Steffen A, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Peeters PH, van Gils CH, van Kranen H, Lund E, Dumeaux V, Engeset D, Rodríguez L, Sánchez MJ, Chirlaque MD, Barricarte A, Manjer J, Almquist M, van Guelpen B, Hallmans G, Khaw KT, Wareham N, Tsilidis KK, Straif K, Leon-Roux M, Vineis P, Norat T, Riboli E, Bueno-de-Mesquita HB. Cigarette smoking and colorectal cancer risk in the EPIC study. *Clinical Gastroenterology and Hepatology*, 9:137-144, 2011. (E-pub25-10-10) IF:5.465
231. Menvielle G, Kunst AE, van Gils CH, Peeters PH, Boshuizen H, Overvad K, Olsen A, Tjønneland A, Hermann S, Kaaks R, Bergmann MM, Illner AK, Lagiou P, Trichopoulos D, Trichopoulou A, **Palli D**, Berrino F, Mattiello A, Tumino R, Sacerdote C, May A, Monninkhof E, Braaten T, Lund E, Quirós JR, Duell EJ, Sánchez MJ, Navarro C, Ardanaz E, Borgquist S, Manjer J, Khaw KT, Allen NE, Reeves GK, Chajes V, Rinaldi S, Slimani N, Gallo V, Vineis P, Riboli E, Bueno-de-Mesquita HB. The contribution of risk factors to the higher incidence of invasive and *in situ* breast cancers among women with higher levels of education in the European Prospective Investigation into Cancer and nutrition. *American Journal of Epidemiology*, 2010. (E-pub 17-11-10) IF:5.285
232. Purdue MP, Johansson M, Zelenika D, Toro JR, Scelo G, Moore LE, Prokhorchouk E, Wu X, Kiemeny LA, Gaborieau V, Jacobs KB, Chow WH, Zaridze D, Matveev V, Lubinski J, Trubicka J, Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Bucur A, Bencko V, Foretova L, Janout V, Boffetta P, Colt JS, Davis FG, Schwartz KL, Banks RE, Selby PJ, Harnden P, Berg CD, Hsing AW, Grubb RL 3rd, Boeing H, Vineis P, Clavel-Chapelon F, **Palli D**, Tumino R, Krogh V, Panico S, Duell EJ, Quirós JR, Sanchez MJ, Navarro C, Ardanaz E, Dorronsoro M, Khaw KT, Allen NE, Bueno-de-Mesquita HB, Peeters PH, Trichopoulos D, Linseisen J, Ljungberg B, Overvad K, Tjønneland A, Romieu I, Riboli E, Mukeria A, Shangina O, Stevens VL, Thun MJ, Diver WR, Gapstur SM, Pharoah PD, Easton DF, Albanes D, Weinstein SJ, Virtamo J, Vatten L, Hveem K, Njølstad I, Tell GS, Stoltenberg C, Kumar R, Koppova K, Cussenot O, Benhamou S, Oosterwijk E, Vermeulen SH, Aben KK, van der Marel SL, Ye Y, Wood CG, Pu X, Mazur AM, Boulygina ES, Chekanov NN, Foglio M, Lechner D, Gut I, Heath S, Blanche H, Hutchinson A, Thomas G, Wang Z, Yeager M, Fraumeni JF Jr, Skryabin KG, McKay JD, Rothman N, Chanock SJ, Lathrop M, Brennan P. Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. *Nature Genetics*, 43: 60-65, 2011. (E-pub 05-12-10) IF:25.556
233. Silvestri V, Rizzolo P, Falchetti M, Zanna I, Masala G, **Palli D**, Ottini L. Mutation screening of RAD51C in male breast cancer patients. *Breast Cancer Research*, 13: 304, 2011. IF: 4.371

**15.2 LIST OF PAPERS WITH IF (FROM JANUARY 2005) OF THE SCIENTIFIC COORDINATOR(S) OF
ADDITIONAL RESEARCH UNIT(S) DR.SSA MARIA ADELAIDE CALIGO (UNIVERSITY OF PISA)**

1. Ramus SJ, Karsonaki C, Gayther SA,**Caligo MA**, Easton DF, Antoniou AC; on behalf of Consortium of Investigators of Modifiers of BRCA1/2. Genetic Variation at 9p22.2 and Ovarian Cancer Risk for BRCA1 and BRCA2 Mutation Carriers. *J Natl Cancer Inst.* 2011 Jan 19;103(2):105-116, (IF 14.069).
2. Antoniou AC, Beesley J, McGuffog L,**Caligo M**, Platte R, Chenevix-Trench G, Easton DF; CIMBA. Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Res.* 2010 Dec 1;70(23):9742-54, (IF 7.543).
3. Walker LC, Fredericksen ZS, Wang X, **Caligo MA**, Antoniou AC, Chenevix-Trench G, Spurdle AB, Couch FJ. Evidence for SMAD3 as a modifier of breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Res.* 2010 Nov 29;12(6), IF 5.326.
4. Balia C, Sensi E, Lombardi G, Roncella M, Bevilacqua G, **Caligo MA**. PALB2: a novel inactivating mutation in a Italian breast cancer family. *Fam Cancer.* 2010 Dec; 9(4):531-6, IF 2.189.
5. Antoniou AC, Wang X, Fredericksen ZS.....**Caligo MA**, Chenevix-Trench G, Easton DF, Couch FJ. A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nat Genet.* 2010 Oct;42(10):885-92, IF 34.284.
6. Guidugli L, Rugani C, Lombardi G, Aretini P, Galli A, **Caligo MA**. A recombination-based method to characterize human BRCA1 missense variants. *Breast Cancer Res Treat.* 2011 Jan;125(1):265-72, IF 4.696.
7. Osorio A, Milne RL, Pita G, G, **Caligo MA**,..... Evaluation of a candidate breast cancer associated SNP in ERCC4 as a risk modifier in BRCA1 and BRCA2 mutation carriers. Results from the Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA). *Br J Cancer.* 2009 Dec 15;101(12):2048-54, IF 4.346.
8. Vannucci L, Chiuppesi F, di Martino F, **Caligo MA**, Bevilacqua G, Pistello Feline immunodeficiency virus vector as a tool for preventative strategies against human breast cancer. *Vet Immunol Immunopathol.* 2010 Mar 15;134(1-2):132-7.
9. Michelucci A, Di Cristofano C, Lami A, Collecchi P, **Caligo MA**, Decarli N, Leopizzi M, Aretini P, Bertacca G, Porta RP, Ricci S, Della Rocca C, Stanta G, Bevilacqua G, Cavazzana A. PIK3CA in breast carcinoma: a mutational analysis of sporadic and hereditary cases. *Diagn Mol Pathol.* 2009 Dec;18(4):200-5.
10. De Nicolo A, Parisini E, Zhong Q, Dalla Palma M, Stoeckert KA, Domchek SM, Nathanson KL, **Caligo MA**, Vidal M, Cusick ME, Garber JE. Multimodal assessment of protein functional deficiency supports pathogenicity of BRCA1 p.V1688del. *Cancer Res.* 2009 Sep 1;69(17):7030-7, IF 7.543.
11. Antoniou AC, Sinilnikova OM, **Caligo MA**, Common variants in LSP1, 2q35 and

- 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Hum Mol Genet.* 2009 Nov 15;18(22):4442-56, IF 7.386.
12. Di Cecco L, Melissari E, Mariotti V, Iofrida C, Galli A, Guidugli L, Lombardi G, **Caligo MA**, Iacopetti P, Pellegrini S. Characterisation of gene expression profiles of yeast cells expressing BRCA1 missense variants. *Eur J Cancer.* 2009 Aug;45(12):2187-96, IF 4.121.
 13. Pensabene M, Spagnoletti I, Capuano I, Condello C, Pepe S, Contegiacomo A, Lombardi G, Bevilacqua G, **Caligo MA**. Two mutations of BRCA2 gene at exon and splicing site in a woman who underwent oncogenetic counseling. *Ann Oncol.* 2009 May;20(5):874-8, IF 5.647.
 14. Johnatty SE, Couch FJ, , **Caligo MA**, No evidence that GATA3 rs570613 SNP modifies breast cancer risk. *Breast Cancer Res Treat.* 2009 Sep;117(2):371-9, IF 4.696.
 15. **Caligo MA**, Bonatti F, Guidugli L, Aretini P, Galli A yeast recombination assay to characterize human BRCA1 missense variants of "unknown pathological significance" *Hum Mutat.* 2009 Jan;30(1):123-33, IF 6.887.
 16. De Nicro A, Tancredi M, Lombardi G, Flemma CC, Barbuti S, Di Cristofano C, Sobhian B, Bevilacqua G Drapkin R, and **Caligo MA**. A novel breast cancer-associated BRIP1(FANCI/BACH1) germline mutation impairs protein stability and function. *Clinical Cancer Res.* 2008, July 15; 14(14): 4672-79, IF 6.747.
 17. Antoniou AC, Spurdle AB, **Caligo MA**, DF; CIMBA. Common breast cancer predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers" *Amer Jour of Human Genetics.* 2008, April 82: 937-48, IF 12.303.
 18. Fabio Marroni, Giovanna Cipollini, Bernard Peissel, Emma D'Andrea, Matilde Pensabene, Paolo Radice, **Maria Adelaide Caligo**, Silvano Presciuttini and Generoso Bevilacqua. Reconstructing the genealogy of a *BRCA1* founder mutation by phylogenetic analysis. *Ann Hum Genet.* 2008, May;72: 310-318, IF 2.145.
 19. Del Chiaro M, Zerbi A, Falconi M, Bertacca L, Polese M, Sartori N, Boggi U, Casari G, Longoni BM, Salvia R, **Caligo MA**, Di Carlo V, Pederzoli P, Presciuttini S, Mosca F. Cancer risk among the relatives of patients with pancreatic ductal adenocarcinoma *Pancreatology.* 2007, Oct 1 ;7(5-6):459-69.
 20. Palli D, Falchetti M, Masala G, Lupi R, Sera F, Saieva C, D'Amico C, Ceroti M, Rizzolo P, **Caligo MA**, Zanna I, Ottini L. Association between the BRCA2 N372H variant and male breast cancer risk: a population-based case-control study in Tuscany, Central Italy. *BMC Cancer.* 2007, Sep 3;7(1):170, IF 2.736.
 21. Lombardi G, Di Cristofano C, Capodanno A, Iorio MC, Aretini P, Isola P, Tancredi M, Collecchi P, Naccarato AG, Porta RP, Bevilacqua G, **Caligo MA**. High level of messenger RNA for BRMS1 in primary breast carcinomas is associated with poor prognosis. *Int J Cancer.* 2007, Mar 15;120(6):1169-78, IF 4.722.
 22. Lombardi G, Falaschi E, Di Cristofano C, Naccarato AG, Sensi E, Aretini P, Roncella M,

- Bevilacqua G, Caligo MA. Identification of novel alternatively spliced BRCA1-associated RING domain (BARD1) messenger RNAs in human peripheral blood lymphocytes and in sporadic breast cancer tissues. *Genes Chromosomes Cancer*. 2007, Sep;46(9):791-5, IF 3.858.
23. Bonatti F, Pepe C, Tancredi M, Lombardi G, Aretini P, Sensi E, Falaschi E, Cipollini G, Bevilacqua G, Caligo MA. RNA-based analysis of BRCA1 and BRCA2 gene alterations. *Cancer Genet Cytogenet*. 2006, Oct 15;170(2):93-101, IF 1.537.
24. Pepe C, Guidugli L, Sensi E, Aretini P, D'Andrea E, Montagna M, Manoukian S, Ottini L, Radice P, Viel A, Bevilacqua G, Caligo MA. Methyl group metabolism gene polymorphisms as modifier of breast cancer risk in Italian BRCA1/2 carriers. *Breast Cancer Res Treat*. 2007, May;103(1):29-36, IF 4.696.
25. Wu JY, Vlastos AT, Pelte MF, Caligo MA, Bianco A, Krause KH, Laurent GJ, Irminger-Finger I. Aberrant expression of BARD1 in breast and ovarian cancers with poor prognosis. *Int J Cancer*. 2006, Mar 1;118(5):1215-26, IF 4.722.

15.3 LIST OF PAPERS WITH IF (FROM JANUARY 2005) OF THE SCIENTIFIC COORDINATOR(S) OF
ADDITIONAL RESEARCH UNIT(S) PROF.SSA SIMONETTA BIANCHI (UNIVERSITY OF FLORENCE)

1. CSERNI G, **BIANCHI S**, BOECKER W et al. Improving the reproducibility of diagnosing micrometastases and isolated tumor cells. *CANCER* 103: 358-367, 2005. [I.F. 4.800]
2. LIVI L, PAIAR F, MELDOLESI E, TALAMONTI C, SIMONTACCHI G, DETTI B, SALERNO S, **BIANCHI S** et al. Tubular carcinoma of the breast: outcome and loco-regional recurrence in 307 patients. *EUROPEAN JOURNAL OF SURGICAL ONCOLOGY* 31: 9-12, 2005. [I.F.: 3.184]
3. SALVADORI B, PINZANI P, DISTANTE V, CASELLA D, **BIANCHI S** et al. Comparison of pre- and postsurgical concentration of blood HER-2 mRNA and Her-2 extracellular domain reflects HER-2 status in early breast cancer. *CLINICAL CHEMISTRY AND LABORATORY MEDICINE* 51: 254-256, 2005. [I.F.: 1.918]
4. PACI E, PONTI A, ZAPPA M, PATRIARCA S, FALINI P, DELMASTRO G, **BIANCHI S** et al. Early diagnosis, not differential treatment, explains better survival in service screening. *EUROPEAN JOURNAL OF CANCER* 41: 2728-2734, 2005. [I.F.: 3.706]
5. LIVI L, PAIAR F, MELDOLESI E, **BIANCHI S** et al. The management of elderly patients with T1-T2 breast cancer treated with or without radiotherapy. *EUROPEAN JOURNAL OF SURGICAL ONCOLOGY* 31: 473-478, 2005. [I.F.: 3.184]
6. ITALIAN NETWORK FOR QUALITY ASSURANCE OF TUMOR BIOMARKERS (INQAT) GROUP. Pathologists participating in the grading quality control program: ALDI M, ANDREINI L, **BIANCHI S** et al. Quality control for histological grading in breast cancer: an Italian experience. *PATHOLOGICA* 97: 1-6, 2005.
7. DISTANTE V, ORZALESI L, CASELLA D, SIMONCINI R, VAGGELLI L, **BIANCHI S** et al. Sentinel node biopsy for nonpalpable breast lesions. *OSPEDALI D' ITALIA CHIRURGIA* 11: 186-189, 2005.
8. **BIANCHI S**, PALLI D, FALCHETTI M et al. ErbB-receptors expression and survival in breast carcinoma: a 15-year follow-up study. *JOURNAL OF CELLULAR PHYSIOLOGY* 206: 702-708, 2006. [I.F.: 3.638]
9. CSERNI G, **BIANCHI S**, VEZZOSI V et al. The value of cytokeratin immunohistochemistry in the evaluation of axillary sentinel nodes in patients with lobular breast carcinoma. *JOURNAL OF CLINICAL PATHOLOGY* 59: 518-522, 2006. [I.F.: 2.245]
10. LIVI L, PAIAR F, SAIEVA C, SIMONTACCHI G, NORI J, SANCHEZ L, SANTINI R, MANGONI M, FONDELLI S, DISTANTE V, **BIANCHI S** et al. Breast cancer in elderly: treatment of 1500 patients. *BREAST JOURNAL* 12: 353-359, 2006. [I.F.: 1.677]
11. LIVI L, PAIAR F, SIMONTACCHI G, BARCA R, DETTI B, FONDELLI S, BASTIANI P, SANTINI R, SCOTTI V, **BIANCHI S** et al. Loco regional failure pattern after lumpectomy

- and breast irradiation in 4185 patients with t1 and t2 breast cancer. Implications for nodal irradiation. ACTA ONCOLOGICA 45: 564-570, 2006. [I.F.: 1.856]
12. PARENTI G, NASSI R, SILVESTRI S, **BIANCHI S** et al. Multi-step approach in a complex case of Cushing's syndrome and medullary thyroid carcinoma. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION 29: 177-181, 2006. [I.F.: 1.496]
 13. PINZANI P, SALVADORI B, SIMI L, **BIANCHI S** et al. Isolation by size of epithelial tumor cells in peripheral blood of patients with breast cancer: correlation with real-time reverse transcriptase-polymerase chain reaction results and feasibility of molecular analysis by laser microdissection. HUMAN PATHOLOGY 37: 711-718, 2006. [I.F.: 2.810]
 14. SUSINI T, NORI J, OLIVIERI S, LIVI L, **BIANCHI S** et al. Radiofrequency ablation for minimally invasive treatment of breast carcinoma. A pilot study in elderly inoperable patients. GYNECOLOGIC ONCOLOGY 104: 304-310, 2007. [I.F.: 2.319]
 15. CIATTO S, HOUSSAMI N, AMBROGETTI D, **BIANCHI S** et al. Accuracy and underestimation of malignancy of breast core needle biopsy: the Florence experience of over 4000 consecutive biopsies. BREAST CANCER RESEARCH AND TREATMENT 101: 291-297, 2007. [I.F.: 4.671]
 16. HOUSSAMI N, CIATTO S, BILOUS M, VEZZOSI V, **BIANCHI S** Borderline breast core needle histology: predictive values for malignancy in lesions of uncertain malignant potential (B3). BRITISH JOURNAL OF CANCER: 96: 1253-1257, 2007. [I.F.: 4.459]
 17. CSERNI G, **BIANCHI S**, VEZZOSI V et al. Validation of clinical prediction rules for a low probability of nonsentinel and extensive lymph node involvement in breast cancer patients. THE AMERICAN JOURNAL OF SURGERY 194: 288-293, 2007. [I.F.: 2.101]
 18. CSERNI G, **BIANCHI S**, VEZZOSI V et al. Sentinel lymph node biopsy in staging small (up to 15 mm) breast carcinomas. Results from a European multi-institutional study. PATHOLOGY ONCOLOGY RESEARCH 13: 5-14, 2007. [I.F.: 1.241]
 19. CSERNI G, **BIANCHI S**, VEZZOSI V, et al. Sentinel lymph node biopsy and non-sentinel node involvement in special type breast carcinomas with a good prognosis. EUROPEAN JOURNAL OF CANCER 43: 1407-1414, 2007. [I.F.: 4.167]
 20. BRANCATO B, HOUSSAMI N, FRANCESCA D, **BIANCHI S** et al. Does computer-aided detection (CAD) contribute to the performance of digital mammography in a self-referred population? BREAST CANCER RESEARCH AND TREATMENT 2007 (in press) (Epub 2007 Oct 16). [I.F.: 4.671]
 21. **BIANCHI S**, VEZZOSI V Microinvasive carcinoma of the breast. PATHOLOGY AND ONCOLOGY RESEARCH. 2008; 14: 105-111. [I.F.: 1.272]
 22. OTTINI L, RIZZOLO P, ZANNA I, FALCHETTI M, MASALA G, CECCARELLI K, VEZZOSI V, GULINO A, GIANNINI G, **BIANCHI S**, SERA F, PALLI D. BRCA1/BRCA2 mutation status and clinical-pathologic features of 108 male breast cancer cases from Tuscany: a population-based study in central Italy. BREAST CANCER RES TREAT 2009; 116:577-586. [I. F.: 5.684]

23. LIVI L, BORGHESI S, SAIEVA C, FAMBRINI M, IANNALFI A, GRETO D, PAIAR F, SCOCCIANI S, SIMONTACCHI G, **BIANCHI S**, CATALIOTTI L, BITI G. Benefit of radiation boost after whole-breast radiotherapy. *INT J RADIAT ONCOL BIOL PHYS* 2009; 75:1029-1034. [I. F.: 4.639]
24. SUSINI T, NORI J, OLIVIERI S, MOLINO C, MARINI G, **BIANCHI S**, VEZZOSI V, LIVI L, MASCALCHI M, SCARSELLI G. Predicting the status of axillary lymph nodes in breast cancer: a multiparameter approach including axillary ultrasound scanning. *BREAST* 2009; 18:103-108. [I. F.: 2.087]
25. LIVI L, BORGHESI S, SAIEVA C, MEATTINI I, RAMPINI A, PETRUCCI A, DETTI B, BRUNI A, PAIAR F, MANGONI M, MARRAZZO L, AGRESTI B, CATALIOTTI L, **BIANCHI S**, BITI G. Radiotherapy timing in 4,820 patients with breast cancer: University of Florence experience. *INT J RADIAT ONCOL BIOL PHYS*. 2009; 73:365-369. [I. F.: 4.639]
26. GÖKÖZ O, PRESENTI L, GAMBACORTA G, ZOLFANELLI F, TRICARICO R, NISTRI R, BARONI G, **BIANCHI S**, MASSI D. Skin-Type Adnexal Tumor With Trichoblastic Germinative Differentiation in the Breast: A Case Report. *INT J SURG PATHOL* 2009. [I. F.: 1.275]
27. **BIANCHI S**, CAINI S, CATTANI MG, VEZZOSI V, BIANCALANI M, PALLI D. Diagnostic concordance in reporting breast needle core biopsies using the B classification-A panel in Italy. *PATHOL ONCOL RES*. 2009;15:725-732. [I. F.: 1.260]
28. SCHRÖDER FH, HUGOSSON J, ROOBOL MJ, TAMMELA TL, CIATTO S, NELEN V, KWIATKOWSKI M, LUJAN M, LILJA H, ZAPPA M, DENIS LJ, RECKER F, BERENGUER A, MÄÄTTÄNEN L, BANGMA CH, AUS G, VILLERS A, REBILLARD X, VAN DER KWAST T, BLIJENBERG BG, MOSS SM, DE KONING HJ, AUVINEN A; **ERSPC Investigators (Bianchi S. et al.)**. Screening and prostate-cancer mortality in a randomized European study. *N ENGL J MED* 2009; 360:1320-1328. [I. F.: 50.017]
29. LIVI L, BUONAMICI FB, SIMONTACCHI G, SCOTTI V, FAMBRINI M, COMPAGNUCCI A, PAIAR F, SCOCCIANI S, PALLOTTA S, DETTI B, AGRESTI B, TALAMONTI C, MANGONI M, **BIANCHI S**, CATALIOTTI L, MARRAZZO L, BUCCIOLINI M, BITI G. Accelerated Partial Breast Irradiation with IMRT: New Technical Approach and Interim Analysis of Acute Toxicity in a Phase III Randomized Clinical Trial. *INT J RADIAT ONCOL BIOL PHYS* 2010; 77: 509-515. [I. F.: 4.639]
30. SUSINI T, BUSSANI C, MARINI G, NORI J, OLIVIERI S, MOLINO C, **BIANCHI S**, VEZZOSI V, PAGLIERANI M, GIACHI M, BORRANI E, SCARSELLI G. Preoperative assessment of HER-2/neu status in breast carcinoma: The role of quantitative real-time PCR on core-biopsy specimens. *GYNECOL ONCOL*. 2010; 118: 234- 239. [I. F.: 2.919]
31. CASTELLANO I, MARCHIÒ C, TOMATIS M, PONTI A, CASELLA D, **BIANCHI S**, VEZZOSI V, ARISIO R, PIETRIBIASI F, FRIGERIO A, MANO MP, RICARDI U, ALLIA E, ACCORTANZO V, DURANDO A, BUSSOLATI G, TOT T, SAPINO A. Micropapillary

ductal carcinoma in situ of the breast: an inter-institutional study. MOD PATHOL 2010; 23: 260-269. [I. F.: 4.678]

32. BLAMEY RW, HORNMARK-STENSTAM B, BALL G ET AL. **ONCOPOOL CONTRIBUTORS (BIANCHI S ET AL)** ONCOPOOL- A European database for 16,944 cases of breast cancer. EUR J CANCER 2010; 46: 56-71. [I. F.: 4.671]
33. SUSINI T, BUSSANI C, MARINI G, NORI J, OLIVIERI S, MOLINO C, **BIANCHI S**, ET AL. Preoperative assessment of HER-2/neu status in breast carcinoma: the role of quantitative real-time PCR on core-biopsy specimens. GYNECOLOGIC ONCOLOGY 2010; 116: 234-239. [I. F.: 2.919]
34. ZITO FA, VERDERIO P, SIMONE G, ANGIONE V, APICELLA P, **BIANCHI S** ET AL. Reproducibility in the diagnosis of needle core biopsies of non-palpable breast lesions: an international study using virtual slides published on the world-wide web. HISTOPATHOLOGY 2010; 56: 720-726. [I. F.: 4.131]
35. VAN DEURZEN CH, CSERNI G, **BIANCHI S** ET AL. Nodal-stage classification in invasive lobular breast carcinoma: influence of different interpretations of the pTNM classification. J CLIN ONCOL 2010; 28: 999-1004. [I. F.: 17.157]
36. HOUSSAMI N, AMBROGETTI D, MARINOVICH L, **BIANCHI S**. ET AL. Accuracy of preoperative model for predicting invasive breast cancer in women with ductal carcinoma in situ on vacuum assisted core needle biopsy. ANN SURG ONCOL (2010), doi: 10.1245/s10434-010-1438-9. [I. F.: 4.130]
37. CSERNI G, AMENDOEIRA I, **BIANCHI S** ET AL. Distinction of isolated tumour cells and micrometastasis in lymph nodes of breast cancer patients according to the new Tumour Node Metastasis (TNM) definitions. EUR J CANCER (2010), doi: 10.1016/j.ejca.2010.11.011. [I. F.: 4.671]
38. **BIANCHI S**, CAINI S, RENNE G ET AL. Positive predictive value for malignancy on surgical excision of breast lesions of uncertain malignant potential (B3) diagnosed by stereotactic vacuum-assisted needle core biopsy (VANCB): a large multi-institutional study in Italy. BREAST 2011 Jan 3 Epub ahead of print. [I. F.: 2.087]

16. FINANCIAL REQUEST

16.1 PRINCIPAL INVESTIGATOR'S UNIT (S)

	Year 1	Year 2	Year 3	Total
A) NON-STAFF PERSONNEL (CONTRACTS, FELLOWSHIPS, ETC). SPECIFY: CONTRACTS	35.000	35.000	35.000	105.000
B) CONSUMABLES SUPPLIES: (TIPS, DISPOSABLE MATERIALS)	3.000	3.000	3.000	9.000
C) SMALL EQUIPMENT(S) SPECIFY:	0	0	0	0
D) TRAVEL EXPENSES (MEETINGS, COURSES, ETC.)	2000	2000	2000	6.000
E) PUBLICATION COSTS. SPECIFY:	0	0	0	0
F) OVERHEAD (DI CUI 50% PER L'ENTE RICEVENTE)	4000	4000	4000	12.000
TOTAL COSTS	44.000	44.000	44.000	132.000

16.2 JUSTIFICATION OF EACH ITEM BUDGET (except for overhead)

A) NON-STAFF PERSONNEL

2 PhD contracts for 3 years (identification of male breast cancer cases, personal interviews; dietary, life-style and family history data collection; collection of snap-frozen tissue samples, medical records, diagnostic confirmation, collection of blood samples, retrieval of histological specimens)

B) CONSUMABLE SUPPLIES

Questionnaires, Tips, Disposable materials,

c) Small Equipment(s)

d) Travel Expenses (Meetings, Courses, etc.)

Dissemination of results (meetings/workshops etc.)

e) Publication Costs

16.3 ADDITIONAL UNIT(S) WITHIN REGIONE TOSCANA Dr.ssa MARIA ADELAIDE CALIGO

	Year 1	Year 2	Year 3	Total
A) NON-STAFF PERSONNEL (CONTRACTS, FELLOWSHIPS, ETC). SPECIFY: CONTRACT	16000	16000	16000	48000
B) CONSUMABLES SUPPLIES: (REAGENTS, ENZYMES, TAQ, TIPS, PRIMERS ETC)	9000	9000	9000	27000
C) SMALL EQUIPMENT(S) (MAX 20.000 EUROS). SPECIFY:				
D) TRAVEL EXPENSES (MEETINGS, COURSES, ETC.)	1000	1000	1000	3000
E) PUBLICATION COSTS. SPECIFY:				
F) OVERHEAD.				
TOTAL COSTS	26000	26000	26000	78000

16.4 ADDITIONAL UNIT(S) - JUSTIFICATION OF EACH ITEM BUDGET (except for overhead)

A) NON-STAFF PERSONNEL

1 PhD contracts for 3 years (DETECTION OF GERMLINE MUTATIONS IN BRCA GENES AND MODERATE GENES, GENOTYPING OF SNPs)

B) CONSUMABLE SUPPLIES

REAGENTS, ENZYMES, TAQ, TIPS, PRIMERS ETC

c) Small Equipment(s)

d) Travel Expenses (Meetings, Courses, etc.)

Dissemination of results (meetings/workshops etc.)

e) Publication Costs

16.3 ADDITIONAL UNIT(S) WITHIN REGIONE TOSCANA Prof.ssa SIMONETTA BIANCHI

	Year 1	Year 2	Year 3	Total
A) NON-STAFF PERSONNEL (CONTRACTS, FELLOWSHIPS, ETC). SPECIFY:				
B) CONSUMABLES SUPPLIES: ANTIBODIES AND DISPOSABLE MATERIAL FOR TISSUE MICROARRAY	10000	10000	10000	30000
C) SMALL EQUIPMENT(S) (MAX 20.000 EUROS). SPECIFY:				
D) TRAVEL EXPENSES (MEETINGS, COURSES, ETC.)				
E) PUBLICATION COSTS. SPECIFY:				
F) OVERHEAD.				
TOTAL COSTS	10000	10000	10000	30000

16.4 ADDITIONAL UNIT(S) - JUSTIFICATION OF EACH ITEM BUDGET (except for overhead)

A) NON-STAFF PERSONNEL

B) CONSUMABLE SUPPLIES

ANTIBODIES AND DISPOSABLE MATERIAL FOR TISSUE MICROARRAY

c) Small Equipment(s)

d) Travel Expenses (Meetings, Courses, etc.)

e) Publication Costs

16.5 TOTAL

	Year 1	Year 2	Year 3	Total
TOTAL COSTS	80000	80000	80000	240000

17. AVAILABLE GRANT(S) CO-FINANCING THE PROPOSAL (Principal Investigator)

Project Title	
Principal Investigator	
Granting Agency	
Amount Granted (Euros)	
Amount Available for Co-Financing (Euros)	

17.1 AVAILABLE GRANT(S) CO-FINANCING THE PROPOSAL (Additional Research Units)

Project Title	
Principal Investigator	
Granting Agency	
Amount Granted (Euros)	
Amount Available for Co-Financing (Euros)	

18. SUGGESTED REVIEWERS (MAX 3).

FIRST AND LAST NAME : LOUISE A. BRINTON
POSITION: PHD MPH Chief Hormonal and Reproductive Epidemiology Branch
INSTITUTION : Division of Cancer Epidemiology and Genetics, National Cancer Institute.
ADDRESS: 6120 Executive Blvd, Suite 550, Rm 5018
CITY: Rockville, MD 20852-7234
PHONE: 301-496-1691
E-MAIL: brinton@nih.gov

FIRST AND LAST NAME : PAOLO BRUZZI
POSITION: HEAD EPIDEMIOLOGIA CLINICA
INSTITUTION: DIPARTIMENTO EPIDEMIOLOGIA, PREVENZIONE E FUNZIONI SPECIALI, IST GENOVA
ADDRESS : LARGO R. BENZI, 10 -
CITY: 16132 GENOVA
PHONE: 010 5737476-7
E-MAIL: paolo.bruzzi@istge.it

FIRST AND LAST NAME
POSITION
INSTITUTION
ADDRESS
CITY
PHONE
E-MAIL

19. BIO-ETHICAL REQUIREMENTS

Does the proposed research involve:

19.1 HUMAN EXPERIMENTATION

~~YES~~

NO

Human experimentation includes involvement of human subjects and other issues with ethical implications.

If **YES**, include approval from the competent Ethical Committee (as addendum A). If this is not yet available at time of submission, please sign the statement below. ITT will not allocate funds until the Ethical Committee approval has been obtained.

Date P.I. Signature.....

19.2 ANIMAL EXPERIMENTATION

YES

~~NO~~

The Committee for animal use in cancer research has evaluated the proposal.

If **YES**, include approval from the competent Committee (as addendum A). If this is not yet available at time of submission, please sign the statement below. ITT will not allocate funds until the Committee approval has been obtained.

Date P.I. Signature

19.3 STATEMENT (fill in only if you have signed YES (n.19.1 and/or 19.2))

Ihereby declare that I will pledge to obtain the approval of the "Ethical Committee" (for Human Experimentation) and /or the approval of the "competent Committee" (for animal experimentation) for the present Proposal (title)..... before commencing research.

Date..... P.I. Signature

20. DECLARATION AND PRIVACY STATEMENT

I hereby certify that all information submitted in the application form is accurate and complete.

I agree that, in accordance with law 196/2003, the processing of my personal data shall be performed for the following purposes:

1. administrative management of the dossiers;
2. evaluation of the value of the research projects with transmission of the data to the *Italian and non-Italian referees/evaluators*;
3. activities ancillary and/or pursuant to the above;

The communication of personal data for these purposes is not compulsory although refusal to do so, owing to the peculiarity of the relationship between the data and the aim for which it is requested, will render the candidate ineligible for selection/award.

Date P.I. Signature

ispo ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA
Direz. U.O. Epidemiologia Molecolare e Nutrizionale
Dr. Domenico Palli



ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA



Al Direttore Generale ISPO
Prof. G. Amunni

Firenze, 7 Giugno 2013

Oggetto: Relazione progettuale del progetto ITT *"Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors"*.

Il progetto con durata triennale si propone di:

- 1) Espandere la serie di popolazione di casi di carcinoma della mammella maschile già disponibili presso la SC di Epidemiologia Molecolare e Nutrizionale, reclutando i casi incidenti in Toscana nel periodo 2009-2013 per un totale previsto di 220 casi. Questa serie rappresenta la più importante a livello nazionale e si colloca tra le più importanti a livello internazionale.
- 2) Valutare nella suddetta serie la prevalenza di mutazioni *germline* nei geni di predisposizione ad alta penetranza BRCA1 e BRCA2 e le possibili alterazioni nella loro espressione genica.
- 3) Identificare altri geni, a bassa e media penetranza, possibilmente coinvolti nello sviluppo del carcinoma della mammella maschile.
- 4) Descrivere il profilo istologico ed immunoistochimico dei tumori mammari maschili esaminati al fine di identificare associazioni con caratteristiche biomolecolari.
- 5) Valutare le possibili interazioni tra i geni mutati e polimorfici identificati e l'esposizione ambientale e fattori di stile di vita.

Il progetto verrà svolto in collaborazione con le additional unit di seguito riportate, indicate nel progetto approvato dall'Istituto Toscano Tumori:

- GROUP- Gruppo di Ricerca Oncologica dell'Università di Pisa – Responsabile e Referente per il progetto Dott.ssa M.A. Caligo - che si occuperà dell'analisi mutazionale
- Università degli Studi di Firenze - Dipartimento di Chirurgia e Medicina Traslazionale, Sezione di Anatomia Patologica, - Responsabile e Referente per il progetto Prof.ssa S. Bianchi- per l'identificazione, allestimento e recupero campioni tissutali.

Il progetto sopra descritto è stato finanziato dall'Istituto Toscano Tumori con un finanziamento annuo di € 50.000,00 per un totale di € 150.000,00.

Le voci di spesa, così come descritto nel budget approvato dall'ITT per il triennio del finanziamento, sono le seguenti:



ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA



Personale: € 76.500,00 per Ricercatore con Laurea in Scienze Biologiche (identificazione nuovi casi, ricostruzione storia familiare, analisi dati) e per un'Assistente Sanitaria (prelievo di sangue, raccolta informazioni su alimentazione e stile di vita)

Beni di consumo: € 1.500,00 per acquisto materiale di cancelleria e spedizioni postali (€ 500,00/anno)

Rimborsi per partecipazioni a Convegni nazionali e missioni per riunioni del gruppo di lavoro in sedi nazionali: € 1.092,00 (€ 364,00/anno)

Spese generali di gestione (overheads): € 7.908,00 (€ 2.636,00/anno)

Trasferimenti/ finanziamenti ad altri enti:

- GROUP- Gruppo di Ricerca Oncologica dell'Università di Pisa per un totale di € 45.000,00.
- Università degli Studi di Firenze - Dipartimento di Chirurgia e Medicina Traslazionale, Sezione di Anatomia Patologica per un totale di € 18.000,00.

Cordiali saluti

ispo ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA
Direttore U.O. Epidemiologia Molecolare e Nutrizionale
Dr. Domenico Palli

Visto
Il Referente Scientifico
Dr. Eugenio Paci



ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA



**PIANO ECONOMICO-FINANZIARIO
PROGETTI FINALIZZATI**

Struttura organizzativa proponente: S.C. Epidemiologia Molecolare e Nutrizionale

Responsabile del progetto: Dr. Domenico Palli

Titolo del progetto: "Molecular epidemiology of male breast cancer in Tuscany: genetic alterations and environmental factors"

Ente finanziatore: ITT - Regione Toscana

Importo finanziamento: € 150.000,00

Delibera numero:

Codice Autorizzazione: 83/13

Centro di Costo: 696

Data inizio progetto: comunicazione avvio progetto

Data conclusione progetto: tre anni dalla data di comunicazione avvio progetto

Modalità di pagamento: € 50.000,00 dopo comunicazione avvio progetto; € 50.000,00 alla fine del primo anno; € 35.000,00 alla fine del secondo anno; € 15.000,00 alla scadenza del progetto.

	2013/14	2014/2015	2015/2016	Totale	VOCE DI CORRISPONDENTE EROGATORE	SPESA ENTE
Beni di consumo:	500,00	500,00	500,00	1.500,00	Consumables supplies	
- cancelleria ed altri beni economici (es. stampati, mouse, ...)						
- farmaci						
- presidi (es. guanti, sonde, ...)						
- diagnostici (es. reagenti di laboratorio, test HPV, ...)						
- acquisto libri e riviste (anche su supporto informatico; riviste on line)						
- altro (specificare)						
Beni di tipo strumentale:						
- attrezzature sanitarie						
- attrezzature informatiche e altro non sanitario (es. computer, stampanti, ... importi > 516,00 euro; per importi < 516,00 euro riferirsi a beni di consumo)						
Beni immateriali:						
- software, opere di ingegno, brevetti						
Servizi:						
- Acquisto prestazioni sanitarie (es. prestazioni di laboratorio)						
- Acquisto prestazioni non sanitarie (es. servizio elabor. dati)						
- Spese per pubblicazioni						
- Spese per organizzazione convegni e congressi (es. cene, coffee break, ...)						
- Spese postali						
- Spese telefoniche						
Trasferimenti/ finanziamenti ad altri enti (Convenzioni con: Gruppo di Ricerca Università di Pisa per € 45.000,00 e Univ. Firenze - Sezione Anatomia Patologica per € 18.000,00)	21.000,00	21.000,00	21.000,00	63.000,00	Additional unit	
Personale	25.500,00	25.500,00	25.500,00	76.500,00	Non-staff personnel	
- collaborazioni, consulenze ed incarichi professionali	25.500,00	25.500,00	25.500,00	76.500,00		
- personale dipendente, tempo determinato						
- personale dipendente, tempo indeterminato						
Rimborsi	364,00	364,00	364,00	1.092,00	Travel expenses	
- missioni/rimborsi spese collaborazioni, consulenze ed incarichi professionali						
- missioni/rimborsi spese dipendenti, tempo determinato						
- missioni/rimborso spese tempo indeterminato (incluso PI)						
Altro (specificare)						
Progetti del personale						
Spese generali di gestione (overheads)	2.636,00	2.636,00	2.636,00	7.908,00	Overhead	
Totale	50.000,00	50.000,00	50.000,00	150.000,00		

Firma Responsabile del progetto

ispO ISTITUTO PER LO STUDIO
E LA PREVENZIONE ONCOLOGICA
Direttore U.O. Epidemiologia Molecolare e Nutrizionale
Dr. Domenico Palli

Firenze 7 Giugno 2013

Firma Resp. Struttura Org.

[Signature]